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Abstract
Liquid biopsies, using analytes such as circulating tumour DNA (ctDNA), can detect and
quantify cancer in a minimally invasive way and can provide information on tumour hetero-
geneity. Current limitations in the liquid biopsy field are centred around the general sensitivity
of the present assays and the input and logistical requirements for sensitive detection.
While detection rates from liquid biopsy platforms are good when ctDNA levels and
tumour burden are high, they are lacking the required sensitivity to detect cancer in the early
stage and minimal residual disease setting. Here I present the INtegration of VAriant Reads
(INVAR) pipeline, which can greatly enhance the sensitivity of ctDNA detection by utilising
large patient specific mutation lists on sequencing data. The methodology can be applied
to (custom) capture and (shallow) whole genome sequencing data and detects ctDNA down
to parts per million, proving more sensitive than previously published methods. INVAR
was applied to samples from 90 treatment naïve patients with early stage non-small cell
lung cancer to characterise the ctDNA levels and could provide a better sensitivity than
comparable cohorts. In addition, I outsourced samples from 27 patients to be analysed with
the InVisionSeq™ assay, which does not require a priori tumour information but proved to
be less sensitive than INVAR.
I also assessed the potential for reducing the logistical burden in ctDNA analysis by
sampling minimal blood volumes that do not require immediate processing. I interrogated if
ctDNA can be detected from as little as a blood spot and show ctDNA detection using this
approach in both, xenograft and human samples. ctDNA detection from blood spots provides
a means to sample xenograft models without having to sacrifice the animal, allowing for
longitudinal monitoring in this setting. It may also present an opportunity to frequently
sample blood from patients and could reduce the logistical burden on sample collection
and processing. In the future, after optimising the protocol, this could serve to reduce the
complexity of clinical/translational studies. The removal of large DNA fragments using this
protocol may also facilitate the analysis of ctDNA from archival cohorts where samples were
collected under suboptimal conditions.

Lay Abstract
Cells can release DNA into the blood, either passively when they die or actively when alive.
In cancer patients, the cancerous cells also release DNA into the circulation, called circulating
tumour DNA (ctDNA). By obtaining a blood sample from a cancer patient, researchers can
obtain information on the cancer from this ctDNA, without the need to analyse a surgical
specimen or a biopsy collected from the tumour by a large needle. While this minimally
invasive method is very promising for the analysis of cancer, the sensitivity of currently used
analysis methods is limited especially for the detection of early cancer or of low disease
burden potentially remaining after initial treatment. Additionally, the current best practices
for plasma collection require prompt processing or the use of cell-preserving materials and
restrict the broad application and study of ctDNA.
The level of ctDNA in the circulation correlate with the tumour size of the patient. Patients
with late stage disease and larger tumour volumes tend to have a higher concentration of
ctDNA, making its detection easier, while patients with early stage disease or patients after
treatment have smaller tumour volumes and lower levels of ctDNA, making its detection
more difficult. The currently popular methods in the field target a fixed number of genes
known to be related to cancer or few cancer specific mutations and have been effective
in detecting high levels of ctDNA. However, they lack sensitivity in detecting low ctDNA
levels. Here, I aim to improve sensitivity by targeting more point mutations and developed a
method called INtegration of VAriant Reads (INVAR). INVAR is generalisable to a variety
of sequencing data and can detect ctDNA at levels up to 100 times lower than other methods.
When applied to 90 patients with early stage lung cancer, INVAR could detect ctDNA in the
majority of patients, showing the potential of the INVAR method.
In this work I also present a method for sample processing that requires minimal process-
ing of samples at the time of collection. This can simplify protocols and allow more extensive
collection of samples for analysis. In this case a drop of blood is applied to a filter paper and
left to dry. DNA can then be extracted from the dried blood spot and analysed for the presence
of ctDNA. In the first application ctDNA was detected in both, a human blood sample and
blood from a mouse that had an implanted human tumour. Detection from a dried blood
spot opens opportunities to collect samples at high frequency from animals with implanted
xii
human tumours, which was previously difficult due to their lower blood volume. It also
offers the possibility to collect patient samples more frequently and potentially even allows
for sample collection at home. In the future, once the method has been optimised further,
ctDNA analysis from dried blood spots could reduce the complexity of studies. Additionally,
the same method could also be used to analyse older samples that were collected under
suboptimal conditions and are not suitable for analysis with current methods, and may be
‘rescued’ for study using this new method.
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Chapter 1
Introduction
1.1 Attribution
Section 1.3 in this chapter is adapted from the book chapter ”Overview of selected approaches
for cell free DNA library preparation and sequencing”, which was submitted in January 2018
as part of the book “Circulating Tumour DNA – Purification and Analysis Techniques”:
“Overview of selected approaches for cell free DNA library preparation and sequencing”
K. Heider§, F. Mouliere, C. G. Smith§
§ Corresponding author
Part of section 1.2 in this chapter was previously included in my first year report.
1.1.1 Author contributions
The book chapter and its associated figures were prepared by me. I have received feedback
from both Florent Mouliere and Chris Smith along the way. The first year report was written
by me, with feedback from Charlie Massie. It was initially written and submitted in July
2016 and was part of the first year evaluation process.
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1.2 The biology of cell free DNA
Circulating cell free DNA (cfDNA) was first described in 1948 by Mandel and Metais [1]
and has been of interest in many different areas of research such as prenatal diagnostics [2],
athletics [3], transplantation patients [4], and acute trauma patients [5]. cfDNA and its
possible importance for cancer patients was first described in 1977 by Leon et al. [6].
cfDNA has a multi-modal size distribution and is found as short 70 – 200bp fragments
but also as long 21kb fragments [7]. The difference in fragment length is believed to be due
to the mechanism of its release by the cells of origin. The shorter fragments are likely to
be released through apoptosis, while the long fragments are thought to be associated with
exosomes or cells undergoing necrosis (see Fig. 1.1A) [3, 8]. The length of plasma cfDNA
fragments centres at 166bp, representing the length of DNA wrapped around the nucleosome
and a linker histone (see Fig. 1.1B) [9]. This mode of distribution is usually complemented
by additional peaks at multiples of 166bp, representing di- and trinucleosomes, typical of
an apoptotic ladder [10, 11]. Additionally, cfDNA shows a 10bp oscillatory pattern below
fragment lengths of 150bp, likely related to the length of individual helical turns as the DNA
winds around the histone (Fig. 1.1B) [9, 12].
In cancer research, scientists are interested in cfDNA that is released specifically by
tumour cells (called circulating tumour DNA, or ctDNA) [13, 8]. Compared to cfDNA,
ctDNA has been shown to be even more fragmented, exhibiting a mode of distribution
between 133-145bp (or smaller) in length [14, 15]. The tumour derived ctDNA carries
information on the genetic changes of the tumour and can guide treatment decisions [16].
ctDNA has been demonstrated to represent most of the cellular populations that make
up a given tumour. As such it allows a global ‘snap-shot’ of the disease at a given time.
Conversely, conventional biopsy techniques might not capture this global representation [17–
19]. This is especially important for late stage disease where the assessment of metastasis via
biopsy becomes technically challenging. Additionally, the ease of sampling and minimally
invasive nature of cfDNA collection allow for serial monitoring of patients, which would
otherwise be harmful using biopsies or computed tomography (CT) scans [20, 21]. In the
long run, the aim is to broaden the clinical applications of ctDNA as a biomarker, helping to
diagnose cancer patients earlier, monitor treatment response more effectively, and stratify
patients according to risk groups or specific treatments [22, 23].
Our understanding of cfDNA in the cancer setting, and ways to analyse it, have improved
greatly since it was first described [6, 24]. The first diagnostic test using plasma ctDNA to
identify non-small cell lung cancer (NSCLC) patients with an EGFR exon19 deletion has
already been FDA-approved for the clinic. This alteration is important as patients carrying
this mutation can be effectively treated with the tyrosine kinase inhibitor gefitinib (Iressa) [16].
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More recently, the COBAS® EGFR mutation test v2 was FDA approved for using plasma
samples of NSCLC patients to detect alterations that allow treatment with the tyrosine kinase
inhibitors erlotinib (Tarceva) and osimertinib (Tagrisso) [25]. Multiple studies have also
shown the utility of ctDNA as a means of identifying recurrence sooner than conventional
methods, with important clinical implications [19, 26]. Finally, with the development of
easy-to-use kits and the continuous reduction in sequencing costs, the analysis of ctDNA
in the clinic represents an increasingly viable and attractive option. Recent developments
that tailor sequencing to the biology of ctDNA, innovative sequencing solutions, as well as
integration of machine learning analysis of large scale cohorts will also lead to intriguing
new avenues for implementation of liquid biopsy in the clinic.
1.2.1 Challenges associated with circulating tumour DNA analysis
The concentration of cfDNA in the blood varies between 5 and 10 ng/mL of plasma [28, 29].
However, only a small proportion of this will be ctDNA released by the tumour. Depending
on the cancer stage and subtype, this proportion can vary quite substantially. Bettegowda and
colleagues showed increased levels of ctDNA at later disease stages: patients with stage IV
disease showed a median ctDNA concentration of around 10% while patients with early stage
disease showed only a few copies of mutant ctDNA in the circulation [30]. Overall, levels of
ctDNA in the circulation correlate with tumour burden; patients with a larger tumour size
tend to also have higher levels of ctDNA [19, 31, 32]. The more cancerous cells present in the
body, the more cancerous DNA can be released into the circulation. Interestingly, they also
observed great variability with regards to ctDNA concentration within each stage, indicating
that stage alone is not the only factor affecting ctDNA concentration in the circulation.
The same study also analysed ctDNA detection rates in different cancer types and could
show that the detectability of ctDNA with a PCR-based assay or Safe-SeqS, a massively
parallel sequencing method, was close to 100% in the plasma of advanced bladder, colorectal,
gastroesophageal, and ovarian cancer patients [30]. However, for advanced glioma or kidney
cancer patients, the average rate of detection was only around 10%, highlighting the effect of
cancer type on the ability to detect ctDNA [30]. Therefore, both disease stage and cancer
type are affecting the ability of detecting ctDNA. Later studies could also identify differences
in detection rates with respect to cancer subtypes [19].
The majority of ctDNA analysis assays have focused on identification of tumour specific
single nucleotide variants (SNVs) but efforts have also been made by exploring methylation
profiling [33] and structural rearrangement assays [34]. When focusing on SNVs, the field
has been using both, PCR and sequencing based methods.
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Fig. 1.1 Cell free DNA characteristics.
(A) Mechanisms of cfDNA release. cfDNA is thought to be released via a variety of
mechanisms such as apoptosis, necrosis or active secretion. Taken from Wan et al. [8]. (B)
Size profile of cfDNA. A characteristic peak around 166bp fragment length corresponds
to the DNA wrapped around the histone and its linker. An oscillatory pattern is observed
for fragments below 150bp and corresponds to individual DNA turns around the histone.
Adapted from Mouliere et al. [27].
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Once sequencing became cheaper, efforts have been made to increase the number of
interrogated loci in a given sample, thereby increasing the overall sensitivity and chance of
detection. Fig. 1.2 depicts this concept: If one were to target only a single mutant locus, the
maximum sensitivity of a perfect assay is equivalent to the total number of cfDNA input
genomes (G). The total number of input genomes (G) is limited by the volume of blood
realistically obtainable from a cancer patient (usually between 2 and 10mL). As a result,
the potential sensitivity from a single locus assay is limited and can never be better than
a few molecules per G. If one were to interrogate multiple mutated loci (N) one can now
interrogate the G input genomes across the N mutations (NxG). This improves the sensitivity
of the assay and becomes a few molecules per NxG. This concept of targeting multiple
mutations has proven especially useful when disease burden and ctDNA concentrations are
low [8, 19, 31, 35, 36].
The main challenges in the ctDNA field is the low proportion of ctDNA in the circulation.
Depending on the stage and tumour type of the patient, the detection of ctDNA can become
quite difficult. As illustrated in Fig. 1.2, the detection of ctDNA is directly related to the total
number of available molecules for the analysis. This in turn can be understood as the product
of the total number of mutated loci targeted and the amount of genetic material available for
the analysis. Therefore, one can optimise the chances to detect ctDNA in any given setting
by trying to maximise one or both of these parameters.
1.3 Sequencing based methods for cfDNA analysis
There are multiple sequencing-based methods that can be used to analyse cfDNA. The
techniques differ in the way the library is prepared, the size of the genome that will be
analysed, and the mean sequencing depth per sample. In the following sections, I will
compare different methods for cfDNA library preparation and sequencing. I will also
highlight the advantages and disadvantages associated with each.
1.3.1 Preparing next-generation sequencing libraries from cfDNA
Multiple strategies are currently available to prepare a DNA sample for next-generation
sequencing. Both digital polymerase chain reaction (dPCR) and library preparation methods
are commonly used in ctDNA analysis; however, this chapter will mostly focus on library
preparation methods. A library preparation for cfDNA usually entails end repair, appending
sequencer-specific ‘adapters’ to the sequence of interest, and amplification of the fragments
(see Fig. 1.3) [37–39]. This final step is necessary due to the low concentrations of input
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locus 1 locus 3locus 2 locus 5locus 4 locus N...
Plasma sample with
limited input:
G copies of
the genome
N mutations in tumour sequencing
Sensitivity: few molecules per NxG
Reference genome
Tumor mutations ACGGATACGCGATGGACTAGTCAACTCAATGCGTAGCTACCACTCAATGAGTAGGTATC
ACGGCTACGCGATCGACTAGTCGACTCAATGAGTAGCTACGACTCAATGAGTAGCTATC
Total molecules sampled ~ N mutations targetd x G copies of the genome
Fig. 1.2 Benefit of multi loci sampling in ctDNA detection.
A given sample contains a limited number of copies of the genome, denoted by G. For plasma
samples the small amount of material, generally on the order of a few thousand genomes
(also referred to as copies), limits the sensitivity that is attainable in detection of individual
mutations to one mutant copy per G copies present in the sample (e.g. 1 copy per 10,000),
even if the assay employed has low background noise and can provide better resolution (e.g.
below 1x10e−5). By analysing in parallel a large number of marker loci (e.g. loci that are
found to be mutated in the patient’s tumour), denoted by N, detection of tumour DNA can be
substantially enhanced to detect one or few mutant molecules per NxG copies. For example,
with N=1000 mutations and G=3000 copies, this provides a total of 3,000,000 reads for
analysis and can achieve detection to parts per million and beyond. The same approach can
be employed for other applications which aim to detect non-background/altered DNA, such
as detection of fetal DNA or DNA from transplanted organs, in limited amounts of material
such as plasma samples or other body fluids.
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DNA that are commonly available from cfDNA [38, 40]. While tissue or germline DNA
library preparation kits require a fragmentation step to generate short fragments (∼200bp)
compatible with the sequencer (a potential source of severe fragment loss [41]), cfDNA
samples do not have to undergo DNA shearing due to its already fragmented nature. One
of the main challenges when sequencing DNA libraries is to mitigate the bias introduced
by PCR amplification [39]. This challenge is particularly important in cancer genomics
when attempting to sensitively detect SNVs targetable by precision medicine [42]. Another
consideration is the maintenance of molecular complexity during library preparation to
increase the chances of finding rare mutations with low allelic frequencies. Current methods
typically vary in the efficiency with which the final output represents the molecules which
went in to the reaction [39, 43]. The two most common library preparation techniques in the
cfDNA field (double and single stranded library preparation) are described in more detail in
the next section.
Fig. 1.3 cfDNA library preparation methods.
Comparison of double stranded and single stranded library preparation methods for cfDNA.
In general samples undergo end repair, appending of sequencer-specific ‘adapters’ to the
sequence of interest, and amplification of the fragments. Unique molecular identifiers can be
added for additional error collapsing. Adapted from Vong et al. [44]
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1.3.2 Library preparation of double-stranded DNA
The most commonly used library preparation protocols in the cfDNA field are aimed at
sequencing double-stranded DNA. Indeed, a multitude of kits and methods are available
that follow a similar workflow. The cfDNA sample first undergoes end-repair, followed
by a phosphorylation of the 5’ ends. The 3’ ends undergo an A-tailing step to allow for
ligation of the sequencer-specific adapters. Upon adapter ligation, samples undergo a few
cycles of PCR to enrich the fragments that are compatible with the sequencer (Fig. 1.3).
This is followed by a final ‘clean up’ of the library to remove excess adapter dimers and
hetero-duplexes [39–41]. Individual DNA samples can be tagged with uniquely barcoded
adapters. These barcodes consist of a short and unique stretch of bases and allow for
multiplexed sequencing. Molecules originating from the same sample will obtain the same
string of unique bases, therefore, each barcoded-DNA fragment in the sequencing pool can
be attributed to its sample of origin [42].
Competition in the market of library preparation kits has helped to lower the prices of
the kits while also improving their quality. The required input for most kits starts at less
than a nanogram of DNA, allowing for sample preparation even when very little material is
available [43].
The most commonly used double-stranded library preparation protocols tend to capture
fragments greater than 100bp in length [45]. It is still unclear why shorter fragments are
not observed but there are different hypotheses. Shorter molecules could be lost during the
extraction or library clean up step, be damaged or be of single stranded nature and thereby
not captured by the double-stranded protocol. This results in the loss of fragments shorter
than 100bp, which may be enriched for ctDNA [14, 15]. Single-stranded library preparation
methods have emerged as an alternative library preparation approach that may overcome this
problem [45, 46].
1.3.3 Single-stranded DNA library preparation
Developed for the analysis of ancient, degraded DNA, current single-stranded DNA library
preparation methods allow for the capture of single-stranded, double-stranded, and damaged
DNA fragments [46]. Therefore, as compared to double-stranded library preparation proto-
cols that capture only double-stranded DNA, single-stranded DNA library preparation allows
for the capture of a broader range of DNA fragments (Fig. 1.3). Indeed, in a study that used
a single-stranded protocol on DNA from a cohort of transplant patients, a greater portion of
50 - 100bp fragments was recovered using this approach as compared to a double-stranded
equivalent [45]. Also, when applied to plasma samples from healthy individuals, a greater
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representation of shorter DNA fragments was recovered as compared to the standard double-
stranded library preparation [47]. An updated version of the Gansauge and Meyer ancient
DNA protocol was published in 2017, showing greater recovery of DNA, and an improved
turn-around time [48]. Previous research suggested an enrichment of ctDNA in shorter
fragments [14, 15, 49, 50]. Therefore, the use of single-stranded DNA library preparation
protocols, that improve the coverage of shorter fragments, might be expected to improve the
recovery, and detection of, ctDNA. However, initial reports seem to indicate that there is no
improvement in ctDNA detection using a single-stranded DNA library [51], raising questions
as to the origin of the additional DNA fragments that are captured by this protocol.
Other single-stranded protocols include the commercially available SMART ChIP-Seq
kit that is based on template switching. This protocol was initially developed for RNA
approaches [52, 53]. Compared to the ancient DNA protocols described above, the SMART
ChIP – Seq protocol involves a simpler, and quicker, workflow. However, a recent publication
indicates that this method preferentially captures fragments with poly dA/dT tracts, which
could induce a bias in cfDNA recovery [54]. Similar comparisons should be performed on
the other library preparation methods to obtain a clearer picture of the sequencing biases
specific to each method.
Here I have introduced different methods to prepare sequencing libraries from cfDNA
samples. Their main advantages and disadvantages are highlighted in table 1.1. One of the
most commonly used approaches in the field is double-stranded DNA library preparation.
There are a variety of high quality and easy to use kits available, making it a robust method
for the preparation of cfDNA samples for sequencing. However, double-stranded library
preparations will capture mostly non-degraded fragments longer than 100bp, thereby not
representing all cfDNA populations. Single-stranded DNA library preparation methods have
partly addressed this problem by allowing the capture of both shorter and degraded DNA
fragments, as well as single- and double-stranded DNA.
1.3.4 Enrichment of circulating tumour DNA using size selection
Single-stranded library preparation protocols aid in capturing shorter DNA fragments, which
might be biased towards a higher proportion of ctDNA, but do not actually enrich for ctDNA.
One means by which one could potentially do so is by carrying out size-selection. As early
as 2010 it was observed that ctDNA fragments are predominantly shorter than 150bp, while
cfDNA of non-cancerous origin is predominantly 166bp in length (Fig. 1.4) [9, 14, 15, 27,
50, 55, 56]. Therefore, focusing the analysis on the shorter fragment lengths could enrich
the sample for ctDNA over cfDNA, making its detection easier. In 2011, Mouliere and
colleagues showed an enrichment for ctDNA relative to cfDNA at the shorter fragment
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lengths in xenograft samples [14]. In 2016, Underhill and colleagues applied this concept to
human samples and could show that mutant alleles of BRAF V600E in melanoma patients
were more commonly observed at shorter fragment lengths compared to wild-type fragments.
Similarly, an enrichment for EGFR T790M was observed in lung cancer patients when
selecting for shorter cfDNA fragments [15]. Mouliere and colleagues confirmed the ctDNA
enrichment in shorter fragment lengths across 344 plasma samples from 200 cancer patients
varying in cancer type and stage [27]. Selecting for the region of 90 - 150bp, the study shows
a more than two-fold median enrichment for ctDNA across all samples after size selection.
Both, in silico and in vitro methods have been used to select for the shorter fragments [15,
27]. In silico methods select for the fragments of interest only after sequencing, allowing the
researcher to apply different size selection windows to the same sample. This is especially
useful if the same sample is used for additional analysis not requiring size selection or if
the best enrichment window is not previously known. However, this approach requires
additional sequencing to ensure sufficient reads are remaining for downstream analysis after
selecting for the fragment length region of choice, resulting in higher sequencing costs. In
vitro methods on the other hand select for the region of interest before the sample undergoes
sequencing, usually using a form of gel-based selection [15, 27]. Only the region of interest
is retained and sequenced, reducing the total required sequencing of the sample as compared
to the in silico selection. While this approach could be cheaper overall, the main drawback is
the sample loss in the process. Not only are any fragments outside the window of interest
lost for downstream analysis but even within the selection window fragment selection is not
100% efficient.
1.3.5 Sequencing error correction using unique molecular identifiers
While selecting for certain fragments may lead to more confident mutation detection, the
general level of background noise remains a challenge in the field. Indeed, with an error rate
of just below 1%, current sequencing methods yield data with high background noise [41, 57].
Additionally, given the low concentration of cfDNA, PCR amplification is usually warranted
during library preparation. This further leads to the induction of PCR errors that may reach
allelic fractions as high or higher than true mutations [58, 59]. Methods have evolved to aid
in the downstream analysis and differentiation of true mutations from noise.
The concept of uniquely tagging individual molecules was first described in 2003 in
the context of determining the unique number of mRNA molecules in a given sample [60].
In 2011, unique molecular identifiers (UMIs) were first used to reduce PCR background
noise and obtain a cleaner sequencing result [61, 62]. UMIs are composed of a string of
entirely random nucleotides that tag each molecule of the initial sample in a unique way [61].
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Fig. 1.4 Potential for size selection on cfDNA.
(A) ctDNA tends to show a shorter fragment length than non cancerous cfDNA, allowing
for sample enrichment by selecting shorter fragment length. Adapted from Mouliere et
al. [27]. (B) A given cfDNA sample can be enriched for tumour derived ctDNA fragments
by size selecting the sample for fragments shorter than 150bp. The generally shorter ctDNA
fragments (shown in purple) will mostly be retained while the longer cfDNA fragments
(shown in green) will be removed. Figure adapted from an initial figure prepared by Irena
Hudecova.
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After sequencing, the UMIs are used to group fragments of the same origin into families
which are then combined into a single consensus sequence [63]. As shown in Fig. 1.5, this
consensus sequence aids in identifying PCR and sequencing errors, which should only be
present in some, but not all, members of a given family. Conversely, true mutations should be
represented in most, if not all, of the members of that family. Thus, the use of UMIs allows
for error suppression and more stringent and confident calling, which improves downstream
analyses. Collapsing reads purely based on start- and end-position is not advised since the
size distribution of cfDNA is too tight and different unique molecules could have the same
start and end position by chance [64].
PCR amplication
and sequencing
Read collapsing using UMIs and positon
real mutation
random error
Fig. 1.5 Schematic representation of background noise reduction through UMIs.
Unique molecules are tagged with different adapters before undergoing PCR amplification
and sequencing. Utilising read position and UMI sequence information, PCR and sequencing
errors are removed and molecules are collapsed into a consensus sequence.
UMIs have started to make an impact within the field of ctDNA research. Recent examples
of their application include the Safe–SeqS approach with an error rate of only 3.5x10−6
mutations/bp (70-fold less than without using UMIs), which was used for the multi-cancer
study by Bettegowda and colleagues [30, 58]. UMIs were also incorporated into the iDES
CAPP-Seq approach used by Newman and colleagues to study early-stage lung cancers.
Using this approach, the authors showed that, together with in-silico background polishing, a
sensitivity of 0.0025% could be achieved [65].
Despite their promise, there are some limitations when using UMIs. For example, it is
possible that PCR errors that occur early in the amplification process may not be filtered out.
Furthermore, sequencing errors in the sequence of the UMI itself may lead to assignment of
fragments to the wrong family [57].
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The widespread development of high-depth sequencing for ctDNA mutation analysis,
as well as the availability of standardised kits, lead to an easier implementation of the
approach without the necessity of prior experience [66]. Tools such as CONNOR, MAGERI,
UMI-tools, and Agilent’s SureCall further aid with the analysis of UMI data [63, 67–69].
Building upon the background noise suppression achieved through the use of UMIs,
Schmitt and colleagues developed a technique called duplex sequencing. They not only
incorporate UMIs into their library preparation but also retain strand directionality and origin
to further reduce background noise [70]. After generating a strand-based consensus sequence,
they identify which two strands came from the same original double-stranded molecule and
combine those two consensus strands into a final duplex consensus sequence. They estimate
their error rate to be at 3.8 × 10−10 or even lower, allowing for very sensitive mutation calling.
However, this degree of read combining warrants a great initial sequencing depth, resulting
in a much increased sequencing cost [70].
Indexing with unique molecular barcodes has been proposed to counteract potential PCR
and sequencing biases that arise during the standard preparation process. While indexing
will remove a great number of PCR and sequencing errors, they might still fail to correct for
early PCR errors or lose data due to PCR and sequencing errors in the barcodes themselves.
A summary of the main options and new developments available for cfDNA library
preparation, ctDNA enrichment, and error rate reduction are compared in table 1.1. I will
now turn towards the different sequencing methods available for cfDNA analysis.
Method Main advantages Main disadvantages
Double-stranded
library preparation
Quick and optimised
protocols
Loss of shorter and
degraded fragments
Low input
Single-stranded library
preparation
Capturing short and
degraded fragments
Bias in fragment recovery
Low input More complex protocols
Unique molecular
identifiers
Reduced noise by read
collapsing into families
Greater sequencing depth
required
Unable to identify early
PCR errors
UMI sequencing errors
result in wrong collapsing
Table 1.1 Comparison of library preparation methods. Highlighted are the major advan-
tages and disadvantages of the library preparation methods discussed in this chapter.
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1.3.6 Tailoring approaches for cell free DNA sequencing
Upon generation of a library, different sequencing methods are available depending on the
required analysis (Fig. 1.6). One can either proceed directly with whole genome sequencing,
or enrich the sample for some part of the genome. In the following sections, different se-
quencing approaches will be explained in more detail and their advantages and disadvantages,
as well as their application to the study of plasma DNA, will be discussed.
Fig. 1.6 Sequencing methods for cfDNA analysis.
cfDNA can be analysed by targeted and untargeted sequencing approaches. Whole genome
sequencing will cover the entire genome while capture based approaches will focus on a
subpart of the genome. This can be accomplished using a commercial kit covering (for
example) the entire exome (whole exome sequencing) or by designing a custom capture
sequencing panel covering specific regions or genes of interest.
Whole genome sequencing
Whole genome sequencing (WGS) of plasma DNA provides researchers with a comprehen-
sive view of the entire genome of the patient [71], facilitating the analysis of somatic copy
number alterations (CNAs), structural variants (SVs), and SNVs. With the development of
digital karyotyping, it has become possible to analyse copy number changes of the genome
in greater detail, even with sufficient sensitivity to observe focal events involving small ge-
nomic regions (<1Mbp) [72]. Digital karyotyping laid the foundation for later copy number
analysis and its implementation to plasma analysis. Whole genome sequencing analysis of
cancerous plasma samples was first employed in 2012 when CNAs were identified, even in
the absence of matched tumour specimens [73]. Using CNAs to detect cancer represents
a useful tool since amplifications and deletions are often an early event in cancer develop-
ment [74]. Additionally, it is possible to infer the copy number status from low-depth data,
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even with a sequencing depth of <1x, in turn allowing simple and cost-effective interrogation
of ctDNA [75, 76]. The ability to detect CNAs even at low depth has led to the use of terms
such as shallow whole genome sequencing (sWGS) or low-pass whole genome sequencing.
For sWGS-based CNA analysis, the genome is apportioned into ‘bins’ of an equally sized
length (ranging from kb-Mb). The sequencing reads that map within each of these bins are
counted and this value is compared to the average bin read count across the entire genome.
Any bins spanning regions that are amplified or deleted will contain greater or fewer reads
than the respective average bin count. Such a ratio is obtained for every bin across the length
of the genome, allowing one to generate a CNA profile. This graphic representation of the
genome allows to quickly visualise amplifications and deletions, as well as compare the
overall pattern between different samples from the same patient, or between different patients.
The chosen bin size is correlated with the sequencing depth where greater sequencing depth
allows for a smaller bin size and, therefore, a more detailed CNA profile.
One can convert the above CNA profiles into quantifiable metrics to estimate ctDNA
levels, for example, using a z-score as described by Heitzer and colleagues [77]. This
method determines a score for each sample based on the deviation in read distribution from a
cohort of control plasma samples [77]. A sequencing depth coverage from 0.1x to 0.2x is
sufficient to determine the z-score of a patient [77]. Similar metrics such as ichorCNA [75]
and t-MAD [27] have since been published, all allowing quantification of copy number
alterations.
One can also identify SNVs from WGS data; however, greater sequencing depth is
required to ensure sufficient confidence in mutation calling. Indeed, the detection limit of
SNVs is directly correlated with the coverage; the more a sample is sequenced, the lower the
mutation frequency detection threshold (i.e. greater sensitivity). At a sequencing depth of 17x,
Chan and colleagues identified both CNAs and SNVs in plasma samples from four cancer
patients [17]. Comparing the copy number data from plasma and matched tumour tissue, the
authors observed a better correlation with increasing tumour size and ctDNA fraction in the
plasma [17]. For one patient with two different cancer types, CNA analysis suggested that
the copy number alterations of both cancers could be detected in the plasma, demonstrating
that plasma analysis has the potential to overcome spatial tumour heterogeneity [17].
When analysing SNVs, the authors could show that mutations shared between different
tumour regions in the same patient were better represented in the plasma, as reflected by
their higher allele fraction [17]. Conversely, sub-clonal tumour mutations were less well-
represented and had a greater chance of being missed [17, 75].
In summary, whole genome sequencing is a powerful tool to obtain genome-wide in-
formation for a sample but becomes increasingly cost prohibitive as the required depth of
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sequencing increases. Indeed, even a modest overall depth of ∼30x (generally used to geno-
type polymorphisms) typically requires a high enough sequencing cost such as to preclude
use in most clinical and research settings.
Capture-based sequencing approaches
While WGS of plasma DNA can provide a comprehensive overview of a patient’s genome,
it lacks sensitivity for the detection of low-frequency mutations due to the current cost of
sequencing. By restricting the size of the region to be analysed, one can reach a greater
depth per sample while maintaining or decreasing the cost of sequencing. This greater
depth results in a greater sensitivity and the ability to reliably detect mutations at lower
frequencies [71]. After library preparation, samples can undergo a ‘hybrid capture’ process.
In this method, regions of interest are selected by the annealing of complementary DNA
or RNA ‘baits’ or primer pairs. Captured regions are amplified while uncaptured regions
are washed away. Depending on the design of the capture baits, the captured regions may
include the entire exome (whole exome sequencing, WES), or some other custom-designed
region (custom capture sequencing). In the case of the latter, current approaches typically
target commonly mutated genes, or already identified mutations. A major limitation of
capture-based approaches can be uneven coverage, due to the fact that some regions lack
complexity and are difficult to target. As a result, they will not be captured and enriched
during the hybridisation [78].
Whole exome sequencing
Assuming that most driver mutations will occur in the actively transcribed part of the genome,
targeting the exome allows researchers to focus their sequencing efforts on this ∼1% of the
genome. Many companies offer exome capture reagents, varying in the capture approach,
complexity of the protocol, and covered regions [79].
WES has been demonstrated to be a useful tool for monitoring tumour evolution. Murtaza
and colleagues applied WES to serial plasma samples with high (>10%) levels of ctDNA.
An input of 2.3ng DNA (690 genome equivalents) and a sequencing depth of 31-160x was
sufficient to call mutations from patient plasma [18]. Using longitudinally obtained samples,
it was possible to track tumour evolution throughout treatment [18].
Furthermore, Girotti and colleagues applied WES to plasma samples from stage III
melanoma patients. They successfully identify resistance mutations, highlighting the potential
for ctDNA as a disease monitoring tool [80]. Dietz and colleagues showed the utility of
WES on low volume serum samples from stage III NSCLC patients. However, due to limited
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sample input and sequencing depth (68x) they validated only 17% of mutations identified
in matched tumour specimens [81]. Nevertheless, they also identified a potential resistance
mutation that was absent in the corresponding tumour sample, highlighting how ctDNA can
overcome spacial tumour heterogeneity [81]. WES was applied to plasma samples from
metastatic cancer patients in a study by Butler and colleagues [82]. They showed good
correlation between tumour and plasma mutations and again identified additional plasma
mutations that were absent in the tumour sample [82]. However, their study focused on only
two patients, utilising 15mL and 25mL of plasma at sequencing depths of 309x and 561x
respectively [82].
While there is a growing number of studies showing the feasibility of WES on plasma and
serum samples, it is important to consider the current limitations. All studies thus far have
focused on late stage cancer patients, in whom levels of ctDNA are generally higher [30, 64].
Additionally, the sequencing depth in these studies is quite high which, whilst allowing for
greater sensitivity in mutation calling, increases the overall cost of this approach. Applied to
a larger cohort or in a clinical setting, WES would generally not be currently feasible.
Custom capture sequencing
As an alternative to ‘off the shelf’ exome capture kits, custom capture methods have emerged,
allowing one to focus sequencing efforts on particular genomic loci of interest. This, in turn,
means that either the same number of samples can be sequenced to a greater depth, allowing
for more sensitive mutation calling, or more samples can be sequenced to the same depth,
enabling application to larger cohorts.
Cancer Personalized Profiling by Deep Sequencing (CAPP – Seq) is one example of
a custom capture sequencing approach that relies on the presence of recurring mutations
across a cancer cohort. Using publicly available WES and structural rearrangement data,
common mutations and rearrangements are identified and used to design a targeted gene
panel [31]. Focusing on NSCLC, a 125kb panel was designed and applied to plasma samples
from stage I – IV patients. The small panel size allowed for deep sequencing (∼10,000x
in this study) at a reasonable cost per sample. For late stage patients, CAPP – Seq showed
100% sensitivity for ctDNA detection and proved advantageous over imaging technology for
disease detection, emphasising the potential of capture-based methods for cancer diagnosis
and monitoring [31]. The same authors further developed the iDES CAPP – Seq approach
described previously (see section 1.3.5), a technique that implements molecular barcodes
and background polishing of sequencing ‘noise’. These developments allow for a sensitivity
of 0.0025%, sufficient for the detection of ctDNA at very low levels [30, 65].
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Phallen and colleagues also used a targeted capture approach to detect ctDNA in patients
with different cancer types and stages of disease. Their targeted error correction sequencing
(TEC – Seq) method utilises an 81kb gene panel containing 58 cancer related genes. Error
suppression of their data is based on the start and end position of the reads, as well as a
small number of dual-index barcode adapters [64]. Using their general gene panel and deep
sequencing with 30,000x coverage, Phallen and colleagues were able to detect ctDNA in
62% of all stage I and II patients and 77% of all stage III and IV patients [64]. Similar to the
analysis of Bettegowda and colleagues, they also found a difference in detection between
different cancer types and an increased detectability with later stage disease [30, 64].
Alternative sequencing based methods
Beyond hybrid capture based approaches, other methods allow for sensitive mutation detec-
tion. For example, tagged amplicon deep sequencing (TAm – Seq) is an amplification-based
approach that combines singleplex and multiplex amplification steps [35]. Regions of interest
are first enriched by amplification in a multiplexed PCR, thereby reducing later sampling
bias. The sample is then split and a singleplex PCR of each of the regions of interest is
carried out [35]. Amplicons are selected based on publicly available data or cohort-specific
knowledge of mutations [35]. The size of the amplicons is around 100bp, accounting for the
majority of cfDNA fragments based on the known distribution of fragment lengths [9, 55].
TAm – Seq has a similar sensitivity to dPCR, and reduces sampling bias through the first
multiplexed amplification step [83].
The recent TRACERx study used patient-specific amplicon sequencing panels for the
enrichment of libraries to improve detection and sensitivity [19]. Based on WES tumour data,
a median of 18 SNVs were identified for each of 96 patients. These regions were enriched
in libraries prepared from plasma samples. While not as sensitive as iDES CAPP – Seq,
the approach used by Abbosh and colleagues was able to detect ctDNA in 94% of stage I
squamous cell carcinoma NSCLC patients. On the other hand, the ctDNA detection rate in
patients with adenocarcinoma NSCLC was only 12.8% at stage I, highlighting the interaction
between ctDNA detection and cancer (sub-)type [19, 30].
When choosing the most appropriate sequencing method, it is important to have a good
estimation of the expected levels of ctDNA in a given sample. Depending on the ctDNA
fraction, more or less sensitive methods will be required for analysis. One potentially useful
practice could be to implement sWGS of a given plasma sample prior to choosing the analysis
approach. This is because sWGS is a comparatively cheap and rapid technique that can
assess likely ctDNA levels. Indeed, the mFast-SeqS and ichorCNA approaches have been
demonstrated to aid in determining ctDNA concentration in the plasma, in-turn identifying
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the best analysis platform [75, 76]. These approaches allow the user to group the samples into
low and high tumour burden ctDNA samples and, based on this classification, one can then
choose an approach for the analysis of the specific alterations in the sample. The only caveat
to this would be the reliance on somatic CNAs – this approach would not be as effective in
cancers known to carry few somatic CNAs [84].
I have presented in this section various methods for sequencing cfDNA from plasma
samples. Fig. 1.7 provides a schematic overview of the preparation process involved in the
described methods. The main difference between these methods is the size of the genome that
will be sequenced and the resulting sensitivity, specificity, and sequencing cost per sample.
The methods also differ in the type of somatic event they can detect. While WGS provides
the broadest and least biased overview of a given sample, it is also the most expensive
method if an appreciable depth of sequencing is required. Using capture-based methods,
one decreases the window of the genome that is being targeted, thereby reducing the total
sequencing cost per sample. Off-the-shelf capture approaches exist that target the whole
exome or a cancer specific gene lists. Alternatively, one can design custom capture panels
to improve the sequencing depth of bespoke regions of interest while maintaining the same
overall cost. Lastly, alternative sequencing approaches such as amplicon sequencing were
presented which can also be used for sensitive detection of ctDNA.
1.4 Lung cancer
Lung cancer is the second most abundant cancer in both, males and females. It is more
common in older age groups and tends to be slightly more common in males than in
females [85]. The single most common cause of lung cancer (close to 90% of all cases) is
smoking [86]. The incidence of lung cancer is related to both, the years of smoking and the
number of cigarettes per day. Other common risk factors include a family history in lung
cancer, exposure to arsenic or asbestos, and living in areas with strong air pollution [87].
Lung cancers from smokers tend to show a larger transversion rate and higher mutation
burden compared to lung tumours of non-smokers [88]. Especially the cytosine to adenine
transversion is associated with tobacco smoking is predominantly seen in adenocarcinomas
of smokers [89].
In 2012, over 44,000 new cases of lung cancer were diagnosed in the UK and accounted
for 13% of all new cancer cases that year, making it the third most common cancer [90].
Due to a decrease in smoking prevalence, lung cancer incidence rates have decreased since
the early 1990s. However, the incidence rate in females is still increasing, due to their later
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Fig. 1.7 Overview of preparation process of different cfDNA sequencing methods de-
scribed in this chapter.
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uptake of smoking [87, 90]. Since the 1990s, incidence in males has decreased by 31%,
while it increased by 28% in females in the UK [90].
The five main histological subtypes of lung cancer are adenocarcinoma, squamous-
cell carcinoma, small-cell carcinoma, large-cell neuroendocrine carcinoma, and pulmonary
carcinoid tumours, with adenocarcinoma, squamous-cell carcinoma, and small-cell carcinoma
being the most common [89, 91]. The majority of the genomic alterations found in the
various subtypes are specific to the given subtype and only few events are shared between
subtypes [89]. During my PhD I was mostly working on patients presenting with non-small
cell lung cancer (NSCLC), which makes up 85 – 90% of all lung cancer cases. The remaining
cases are mostly small cell lung cancer [92]. NSCLC grows and spreads more slowly
than small cell lung cancer and contains three main subclasses, depending on the tumour
morphology (40% adenocarcinoma, 25 – 30% squamous cell carcinoma, and 10 – 15% large
cell carcinoma) [93].
In the UK, lung cancer is mostly diagnosed at the later stages. In 2014, 67% of the
diagnosed cases were stage III or IV [90]:
England Scotland Northern Ireland
Stage of Diagnosis 2014 2014-2015 2010-2014
Stage I 15 18 13
Stage II 7 9 8
Stage III 19 22 22
Stage IV 48 46 43
Stage Unknown 10 5 15
Table 1.2 Stage at diagnosis of lung cancer in the UK. Percentage of cases diagnosed at
the respective stages (%). Data taken from Cancer Research UK [90]
Lung cancer is the leading cause of cancer death, being responsible for more than 20% of
all deaths associated with cancer [94]. The survival of lung cancer is extremely low with only
5% of patients still being alive 10 years after their diagnosis [90]. Over the last 40 years there
have only been marginal improvements in the five and ten year survival rates [90]. However,
patients are now twice as likely to survive for the first year after their diagnosis (table 1.3).
The survival of lung cancer is highest for patients diagnosed at earlier stages. As seen in
Table 1.4, 35% of patients diagnosed with stage I disease will still be alive after five years,
while only 6% of stage III patients will still be alive (see Table 1.4). For patients diagnosed
with stage IV, survival rates past two years are too low to even be calculated [90].
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Period of Diagnosis 1 year 5 year 10 year
1971-1972 15.9 4.6 3.1
1980-1981 18.4 5.6 3.8
1990-1991 20.4 6 3.9
2000-2001 24.2 6.8 3.9
2005-2006 27.8 8 4.3
2010-2011 32.1 9.5 4.9
Table 1.3 Lung cancer survival rates over time. Survival is shown in precent. Data was
taken from Cancer Research UK [90]
Stage at Diagnosis 5 year survival (%)
Stage I 35.33%
Stage II 20.89%
Stage III 6.32%
Stage IV unavailable
Stage Not Known 5.79%
All Stages 9.68%
Table 1.4 Lung cancer 5 year survival by stage. Survival is reported in percent. Data was
taken from Cancer Research UK [90]
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Even though the abundance of lung cancer is quite high, little improvement has been
made with regards to overall survival. After 40 years of active research, the long-term
survival after being diagnosed with lung cancer is still amongst the worst of all cancers [95].
This can be attributed to lung cancer being mostly diagnosed at the later stage of disease. The
symptoms for lung cancer are unfortunately not specific for the disease but also indicative of
other respiratory diseases, They include chest pain, cough, difficulty breathing, fatigue, chest
infection and weight loss [96, 97]. As a result, lung cancer is often only diagnosed at the
advanced stages, considerably reducing the overall survival chances of the patient.
1.4.1 ctDNA in non-small cell lung cancer
Liquid biopsies have been proposed as an alternative of cancer detection and in some cases
have been approved for the clinic [16]. In lung cancer, ctDNA has shown sensitive detection
in the later stages but detection in the early stages has been limited [28]. A recent review
compared the currently published literature on ctDNA detection in early stage NSCLC [28].
Four different studies [19, 36, 64, 98] were highlighted with regards to their detection rates
for different tumour stages as well as the ctDNA levels in the detected cases. The studies
utilise either gene panels and hybridisation technology [36, 64] or multiplex PCR [19, 98]
to detect ctDNA. The CAPP-Seq assay and TRACERx study were aimed at the detection
of MRD, utilising information on the mutations seen in the tumour, while the CancerSEEK
and TEC-Seq assay took an untargeted approach geared towards the detection of cancer [28].
Even though all four studies analysed patients with NSCLC, there was some variability in
the patient cohorts of the studies with regards to stage and tumour subtype. For example, the
cohort used for the CAPP-Seq study mostly contained late stage patients, while the cohort
used for the TEC-Seq application was biased towards early stage patients. The TRACERx
and CancerSEEK studies showed an even representation of all cancer stages (see Table 1.5).
Study I II III IV Total
CAPP-Seq 5 (15.6%) 6 (18.8%) 21 (65.6%) 0 (0%) 32
TEC-Seq 29 (41.4%) 31 (44.3%) 5 (7.1%) 5 (7.1%) 70
CancerSEEK 46 (44.7%) 26 (25.2%) 31 (30.1%) 0 (0%) 103
TRACERx 59 (61.5%) 23 (24.0%) 14 (14.6%) 0 (0%) 96
Table 1.5 NSCLC patients by stage for different studies. Data is adapted from Abbosh et
al 2018 [28]. The CancerSEEK assay is utilising both ctDNA and protein markers to achieve
a more sensitive detection.
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With regards to cancer subtype, the CAPP-Seq study had a balanced representation
of the different subtypes [36], the TRACERx and TEC-Seq study were biased towards
adenocarcinomas [19, 64] and the CancerSEEK study did not provide information on tumour
subtype [98]. These differences with respect to tumour subtype make it more challenging
to compare directly between the four studies and their respective detection rates (see Table
1.6). Due to these varieties in study design and the constellation of the respective cohorts, the
results from these four studies cannot be compared directly but rather provide an overview of
the ctDNA levels in NSCLC.
Study Stage I Stage II Stage III
TRACERx 37.29% 69.57% 57.143%
CAPP-Seq 100% 66.67% 95.24%
TEC-Seq 44.83% 74.19% 80.00%
CancerSEEK ctDNA only 4.35% 38.46% 35.48%
CancerSEEK ctDNA + proteins 43.48% 69.23% 74.19%
Table 1.6 ctDNA detection rates by stage for different NSCLC studies. Data is adapted
from Abbosh et al 2018 [28]. For the CancerSEEK assay detection is reported when just
relying on the ctDNA based assay ("ctDNA only") or when using ctDNA together with the
protein biomarker parameters ("ctDNA + proteins"), resulting in a more sensitive detection.
As part of the review, Abbosh et al analysed the maximum detected ctDNA fractions per
patient. They found an increasing maximum ctDNA fraction with increasing stage, consistent
with previous pan-cancer studies [28, 30]. The median maximum mutant allele fraction
observed across the studies for patients with stage I, II, and III disease were 0.31%, 0.48%
and 1.48%, respectively [28]. Similar to other reports [30], the detection rates of ctDNA
were lowest for stage I disease, with the exception of the CAPP-Seq assay, showing perfect
detection in the small cohort of stage I patients (n=5) [28]. The low detection rates in stage
I disease are thought to either be due to tumours not releasing ctDNA or releasing it in
such low concentrations that its detection becomes impossible given the current analysis
platforms [28].
ctDNA detection and monitoring has been used in cohorts of early stage NSCLC patients
with limited success. While detection rates look promising in patients with stage II and III
disease, detection of ctDNA in stage I patients has been inferior. It is currently unclear if this
decreased sensitivity is related to the smaller tumour size in early stage disease, resulting
in limited ctDNA release, or if additional biological factors prohibit its release. In case of
the former, development of a more sensitive ctDNA detection tool should improve detection
rates in this challenging setting.
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1.5 Limiting sample input in cfDNA analysis
As described in section 1.3.6, CNV profiles and other metrics can be used to detect ctDNA
from very low depth sequencing (usually 0.1x). If sequencing is performed to such low depth,
only a small proportion of the genetic diversity in a given sample is analysed, raising the
question if the same sensitivity could be achieved from samples with limited sample volume.
If this were possible, it could allow for even more frequent sampling of the patient as smaller
volumes are easier to obtain and the chance of successful sample collection should be higher.
In theory, a single drop of blood with a volume of 50µL should contain sufficient amounts of
cfDNA for analysis by sWGS. Given the general concentration of cfDNA (5-10ng/mL), a
single droplet of blood should contain 0.25-0.5ng of DNA. 1ng of DNA is roughly equivalent
to 300 genomic copies, meaning that a single droplet of blood could contain 75-150 genomic
copies of cfDNA, which should be more than enough to be analysed by sWGS.
The main advantage when using blood spots is the ease of sample collection and process-
ing. Without the need for specifically trained research staff, samples could even be collected
at home and sent to the lab for analysis. Real-time PCR has previously been used to carry out
fetal RHD genotyping and HIV detection using maternal dried blood spots [99, 100]. A pilot
study in breast cancer patients performed whole genome amplification on blood obtained
from a finger prick and found comparable allelic frequencies in somatic mutations between
the finger prick sample and matched venous blood [101].
Aside from the clinical utility in humans, analysis of minute amounts of blood may
facilitate longitudinal ctDNA monitoring from model organisms, such as rodents. Current
methods for longitudinal monitoring are limited to high copy-number targets only, such
as human LINE-1 sequences [102]. Potentially, sWGS of a blood spot obtained from a
xenograft model followed by separate alignment to the rodent and human genome could
permit detection of ctDNA and provide an alternative route to longitudinal monitoring from
animal models.
Generating a cfDNA sequencing library from a blood spot is challenging due to the
few cfDNA copies and abundance of long contaminating genomic DNA (gDNA) fragments
present in the sample. A new method needs to be devised that removes the contaminating
gDNA fragments while retaining the majority of the cfDNA fragments in the sample. An
additional concern will be the low levels of DNA present in the sample and it remains to be
seen if libraries can be prepared successfully from such limited inputs.
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1.6 Thesis aims
The application of cfDNA for detection of cancer has been widely described in the literature
and different methods have been developed. While these methods are great in detecting
high levels of ctDNA in patients with a higher disease burden, they start to lose sensitivity
when applied to samples with low levels of ctDNA and disease burden. Further research
has indicated a potential to improve sensitivity by utilising methodological advances (e.g.
UMIs) and biological features of cfDNA (e.g. fragment length). While some methods have
since evolved that are utilising these features, they have not led to the desired increase in
sensitivity.
Another hindrance in cfDNA analysis is the sample processing prior to analysis. The
majority of the currently available methods require a stringent sample processing, with both
skilled workers and the right equipment. Therefore, samples are mostly collected in large
clinical centres that fulfil these requirements. If sample collection and processing were
simplified, additional research centres and even general practices could participate in future
studies, increasing the number of recruitable patients.
The work presented in this thesis intends to address both of these current limitations
through:
1. The development of a tool for ctDNA detection and monitoring that utilises both
technical advances and biological features to improve overall sensitivity.
2. The application of this tool to an independent cohort to assess the generalisability of
the new method.
3. The development of a simplified method for collection and storage of blood samples,
allowing less well equipped centres to participate in research studies.
Chapter 2
Patient-specific ctDNA monitoring from
sequencing data
2.1 Attribution
This chapter is adapted from a manuscript, which was submitted to Science Translational
Medicine in June 2019 and posted on bioRxiv in September 2019:
“High-sensitivity monitoring of ctDNA by patient-specific sequencing panels and integration
of variant reads”
Jonathan C. M. Wan∗, Katrin Heider∗,..., Charles Massie†, Pippa G. Corrie†, Nitzan
Rosenfeld†,§
∗ Equally contributing authors
† CM, PGC and NR jointly supervised this work
§ Corresponding author
Together with Cancer Research Technologies Ltd we filed a patent based on the INVAR
algorithm. Please see Chapter 6 for details.
A software package for the INVAR algorithm will also be made available on bitbucket. Please
see Chapter 6 for details.
2.1.1 Author contributions
J.C.M.W., K.H. and N.R. wrote the manuscript. J.C.M.W., K.H., S.M., A.R-V., P-Y.C.,
G.R.B., C.A. and C.G.S. generated data. J.C.M.W., K.H., E.F., J.M., F.Mo., D.C. and N.R.
developed the INVAR pipeline. J.C.M.W., K.H., J.M., E.F., A.M., W.Q., F.Ma., J.M. and
D.C. analysed data and performed statistical analysis. A.B.G. and F.A.G. performed imaging
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analysis. E.B., G.Y., I.H., W.N.C. and D.G. coordinated studies and participated in design.
C.P., D.G., A.D., U.M., P.G.C. and N.R. led the MelResist study. P.C.G. and M.M. led the
AVAST-M study. C.G.S., C.M., P.G.C., N.R. supervised the project. All authors reviewed
and approved the manuscript.
Wet lab work
The wet lab work presented in this chapter was mostly performed by Jonathan Wan. Jonathan
was a PhD student (2015-2018) who was mostly working on melanoma. He received the
mutation calls for the late stage melanoma cohort which were previously called for Varela et
al. [103]. For the stage II-III melanoma cohort, Jonathan organised the extraction of tumour
tissue and buffy coats. He then prepared sequencing libraries and exome captures for these
samples for identification of tumour mutations and submitted them for sequencing. Upon
identification of tumour mutation lists for each of the patients, Jonathan designed and ordered
the custom capture sequencing panels. Additionally, Jonathan organised the extraction of
plasma samples and prepared libraries for the samples. He captured the libraries with the
custom capture baits and submitted them for sequencing.
For the application of INVAR to whole exome sequencing, Jonathan and I jointly identi-
fied suitable cases (with high enough levels of ctDNA based on custom capture data) and
split the workload for preparation and capture of the 21 samples. INVAR was also applied
to shallow whole genome sequencing data. For these samples (n=33) Jonathan identified a
subset of patients and time points from the larger cohort used for custom capture sequenc-
ing (above) and pooled remaining input libraries from the previous set of experiments for
sequencing.
Dry lab work
The first iteration of the INVAR pipeline (thereafter v1) was developed by Jonathan Wan
in our lab. Using v1 as a starting point, I developed the second iteration of the INVAR
pipeline (hereafter v2) in close collaboration with Jonathan. As the scale of the project was
such that we incorporated analysis of multiple cancer (melanoma, reported in this chapter,
and lung cancer, reported in chapter 3) and data types (custom capture, whole exome and
shallow whole genome sequencing), it was infeasible to conduct the pipeline development
and application by myself. I would like to emphasise that the INVAR project was (at least) a
two-person job as it required (often in parallel) to carry out additional experiments in the
lab, update and / or trouble shoot the pipeline, generate and update the figures and write the
paper. Hence, Jonathan and I are co-first authors on the publication presented in this chapter.
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I attempted to quantify our contribution to the INVAR pipeline by summarising the
commits per user to the tapas_pipeline Bitbucket repository which is shown in Fig. 2.1:
Fig. 2.1 Screenshot of the users working on the v2 pipeline and their commits to the
Bitbucket repository.
The initial commits through Jonathan in this repository were made when the v1 pipeline
was copied across to the new repository. Eyal Fisher was a mathematics MPhil student who
joined our lab for a 3 months rotation during the pipeline development (Spring 2018) and
was mostly responsible for the development of the underlying statistics. James Morris was a
senior bioinformatician who mentored us throughout the pipeline development and helped in
trouble shooting the code.
After data processing through the INVAR pipeline, Jonathan and I explored the output
data further. This repository (tapas_paper) was mostly used for data visualisation and figure
generation for the manuscript. In Fig. 2.2 I show the individual commits to this repository.
Fig. 2.2 Screenshot of the users working on the data exploration and visualisation and
their commits to the Bitbucket repository.
Writing of the manuscript
Jonathan and I jointly devised a general structure for the manuscript and alternated writing
the paper draft. We also jointly devised the figures to be presented for this work and took
turns in plotting and adjusting them. After an initial draft we communicated with Nitzan to
improve the appearance of both the text body and its figures. All final decisions regarding
figures and text in the manuscript presented in this chapter were discussed with Jonathan
and approved by Nitzan. I used this improved paper draft and incorporated it in this thesis,
altering and repositioning figures and text where needed.
2.1.2 Competing interests
N.R. and D.G. are co-founders, shareholders and officers or consultants of Inivata Ltd, a
cancer genomics company that commercialises ctDNA analysis. Inivata had no role in
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the conceptualisation, study design, data collection and analysis, decision to publish or
preparation of the manuscript. Cancer Research UK has filed patent applications protecting
methods described in this manuscript.
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2.2 Aims
The primary objective of this chapter was to develop a tool for ctDNA detection. Together
with Jonathan Wan we investigated:
1. Which filtering steps should be applied to reduce the background error rate in (person-
alised) sequencing data. We explored the use of UMIs and the application of locus as
well as sample specific filters to reduce the sequencing noise in a given sample.
2. Whether we can compute more accurate background error rates by analysing not only
the observed mutation class but also its trinucleotide context.
3. Whether signal can be enhanced further by utilising sequencing information on cfDNA
fragment length and allelic fraction information from the original tumour sample.
2.3 One sentence summary
Integrating tumour-derived sequences across large panels of patient-specific mutations offers
enhanced sensitivity for ctDNA detection and monitoring from both high-depth and low-depth
plasma sequencing data.
2.4 Abstract
Circulating tumour-derived DNA (ctDNA) can be used to monitor cancer dynamics noninva-
sively. Patients with small tumours have few copies of ctDNA in plasma, resulting in limited
sensitivity to detect low-volume or residual disease. We show that sampling limitations can
be overcome and sensitivity for ctDNA detection can be improved by massively parallel
sequencing when hundreds to thousands of mutations are identified by tumour genotyping.
We describe the INtegration of VAriant Reads (INVAR) analysis pipeline, which combines
patient-specific mutation lists with both custom error-suppression methods and signal en-
richment based on biological features of ctDNA. In this framework, the sensitivity can be
estimated independently for each sample based on the number of informative reads, which is
the product of the number of mutations analysed and the average depth of unique sequencing
reads. We applied INVAR to deep sequencing data generated by custom hybrid-capture pan-
els, and showed that when ∼106 informative reads were obtained INVAR allowed detection
of tumour-derived DNA fractions to parts per million (ppm). In serial samples from patients
with advanced melanoma on treatment, we detected ctDNA when imaging confirmed tumour
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volume of ∼1cm3. In patients with resected early-stage melanoma, ctDNA was detected in
40% of patients who later relapsed, with higher rates of detection when more informative
reads were obtained. We further demonstrated that INVAR can be generalised and allows
improved detection of ctDNA from whole-exome and low-depth whole-genome sequencing
data.
2.5 Introduction
Circulating tumour DNA (ctDNA) can be robustly detected in plasma when multiple copies
of mutant DNA are present; however, when ctDNA levels are low, analysis of individual
mutant loci might produce a negative result due to sampling noise even when using an
assay with perfect analytical sensitivity. Such “missed” samples can have low fractional
concentrations of ctDNA (relatively few mutant molecules in a high background), or low
absolute numbers of mutant molecules due to limited sample input (Fig. 2.3). This effect
of limited sampling reduces the sensitivity of ctDNA monitoring for patients with early-
stage cancers, or following treatment for detection of minimal residual disease [8, 30].
Studies showed, for example, that by targeting a single mutation per patient in the plasma
of early-stage breast and colorectal cancer patients post-operatively, ctDNA was detected
in approximately 50% of patients who later relapsed [104, 105]. When applied to BRAF-
or NRAS-mutant stage II-III patients with melanoma, ctDNA was detected up to 12 weeks
post-surgery in only 16.8% of patients who relapsed within 5 years [106]. To increase the
number of mutant molecules sampled, previous studies have shown that it may be possible to
analyse larger volumes of plasma from multiple blood tubes [98, 105] and/or utilise broader
sequencing panels.
Tumour-guided patient-specific analysis, which involves prior tumour genotype informa-
tion and custom panel design [19, 35, 107, 108, 65], offers the possibility to greatly increase
the sensitivity of ctDNA assays for cancer monitoring by targeting a larger number of mu-
tations [8, 109] (Fig. 2.4). Such assays have analysed up to 40 patient-specific mutations
in parallel, quantifying ctDNA to 1 mutant molecule per 25,000 copies in a patient with
non-small cell lung cancer (NSCLC) [65]. Increasingly broad tumour sequencing is being
performed both in research and clinical settings [110], which provides valuable mutation
information that may be leveraged for improved sensitivity for ctDNA. We conceptualise the
factors influencing ctDNA sensitivity as a two-dimensional space (Fig. 2.5A), highlighting
the importance of maximising the number of relevant DNA fragments analysed, by increasing
either plasma volumes or the number of (patient-specific) mutations sampled: the number of
informative reads (IR) generated is proportional to the product of these two factors.
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Fig. 2.3 Patient-specific analysis overcomes sampling error in conventional and limited
input scenarios.
When high levels of ctDNA are present, gene panels and hotspot analysis are sufficient to
detect ctDNA (top panel). However, if ctDNA concentrations are low these assays are at high
risk of false negative results due to sampling noise. Utilising a large list of patient specific
mutations allows sampling of mutant reads at multiple loci, enabling detection of ctDNA
when there are few mutant reads due to either ultra-low ctDNA levels (middle panel), or due
to limited starting material or sequencing coverage (bottom panel).
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Fig. 2.4 Targeting multiple mutations increases assay sensitivity.
A given sample contains a limited number of copies of the genome, denoted by G. For plasma
samples, the small amount of material limits the sensitivity that is attainable to one mutant
copy in G total copies. By analysing in parallel a large number of marker loci (e.g. loci that
are found to be mutated in the patient’s tumour), denoted by N, detection of tumour DNA can
be substantially enhanced to detect one or few mutant molecules per N x G copies. The same
approach can be employed for other applications which aim to detect non-background/altered
DNA, such as detection of foetal DNA or DNA from transplanted organs, in limited amounts
of material such as plasma samples or other body fluids.
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ctDNA detection methods often rely on identification of individual mutations [19, 64, 98]
which may discard mutant signal that does not pass a threshold for calling. In this study, to
improve sensitivity, we aggregated sequencing reads across 102-104 mutated loci, using prior
information from tumour genotyping to guide analysis (Fig. 2.5B). The potential sensitivity
benefit of targeting hundreds to thousands of tumour markers per patient has been previously
suggested [65, 111], though such approaches have not been applied to cancer monitoring in
plasma.
Fig. 2.5 Study outline and rationale for integration of variant reads.
(A)Illustration of the range of possible working points for ctDNA analysis using INVAR,
plotting the haploid genomes analysed vs. the number of mutations. Diagonal lines indicate
multiple ways to generate the same number of informative reads (IR, equivalent to haploid
genomes analysed (hGA) x targeted loci). Current methods often focus on analysis of ∼10
ng of DNA (300-10,000 haploid copies of the genome) across 1 to 30 mutations per patient.
This typically results in ∼10,000 IR, leading to frequently encountered detection limits
of 0.01%-0.1% [19, 64]. mL, millilitre; µL, microlitre. (B) Patient-specific mutation lists
generated by tumour genotyping were used to design hybrid-capture panels, that were applied
to DNA extracted from plasma samples and yielded high depth sequencing. In later sections,
the tumour genotyping data is used to analyse sequencing data from standard WES panels
and shallow WGS.
We suggest that a tumour-guided approach targeting a large number of patient-specific
mutations has advantages beyond simply mitigating sampling error. By virtue of generating
a large number of IR, multiple error-suppression steps may be employed to overcome
sequencing and PCR errors while retaining signal. Aside from molecular barcoding, it may
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be possible to identify artefactual signal at a given locus by comparison of the given allelic
fraction against the allele fractions at other patient-specific loci. Furthermore, greater weight
may be assigned to fragments more likely to arise from tumour cells based on their biological
characteristics such as fragment size [27], thereby enhancing the signal to noise ratio.
Here, we present a workflow for enhanced patient-specific monitoring that is optimised
for sensitive detection of ctDNA using custom hybrid-capture panels (Fig. 2.6, flowchart
in Fig. 2.7). This approach leverages custom error-suppression and signal enrichment
methods to enable sensitive monitoring and identification of residual disease. We further
demonstrate the ability to apply INVAR to plasma whole-exome sequencing (WES) and
shallow whole genome sequencing (sWGS), demonstrating improved sensitivity for detection
and quantification of ctDNA.
2.6 Tumour genotyping
First, tumour genotyping was performed to identify multiple patient-specific mutations
per patient: exome sequencing data was generated from tumour and buffy coat samples
from 47 patients with Stage II-IV melanoma (section 2.16), identifying a median of 625
mutations per patient (IQR 411-1076, Fig. 2.8 and Table 2.1). Mutations are shown by
mutation class and trinucleotide context as well as observed tumour allele fraction (Fig. 2.9,
Fig. 2.10). Interestingly, even after applying the filters suggested by Costello et al. [112],
there are remaining acrtefactual mutations in the early stage melanoma cohort as seen by
the relatively high number of C/A mutations, especially in the CCC and CCA contexts
(Fig. 2.9). Additional filtering should be applied in the future to further remove these
artefactual mutations.
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Fig. 2.6 Overview of he INtegration of VAriant Reads (INVAR) pipeline.
To overcome sampling error, signal was aggregated across hundreds to thousands of mutations.
Here we classify samples (rather than individual mutations) as significantly containing ctDNA,
or not detected. ‘Informative Reads’ (IR, shown in blue) are reads generated from a patient’s
sample that overlap loci in the same patient’s mutation list. Some of these reads may carry
the mutation variants in the loci of interest (shown in orange). Reads from plasma samples
of other patients at the same loci (‘non-patient-specific’) are used as control data to calculate
the rates of background error rates (shown in purple) that can occur due to sequencing errors,
PCR artefacts, or biological background signal. INVAR incorporates additional sequencing
information on fragment length and tumour allelic fraction to enhance detection.
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Fig. 2.7 Flowchart of analysis steps in the INVAR pipeline.
Integration of variant reads workflow. INVAR utilises plasma sequencing data and requires a
list of patient-specific mutations, which may be derived from tumour or plasma sequencing.
Filters are applied to sequencing data, then the data is split into: patient-specific (locus
belonging to that patient), non-patient-specific (locus not belonging to that patient), and
near-target (bases within 10 bp of all patient-specific loci). Patient-specific and non-patient-
specific data are annotated with features that influence the probability of observing a real
mutation. Outlier-suppression is applied to identify mutant signal inconsistent with the
overall level of patient-specific signal. Next, signal is aggregated across all loci, considering
annotated features, to generate an INVAR score per sample. Based on non-patient-specific
samples, an INVAR score threshold is determined using ROC analysis for each cohort.
Healthy control samples separately undergo the same steps to establish a specificity value for
each cohort.
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Fig. 2.8 Tumour mutation list characterisation for INVAR.
(A) Number of somatic mutations per patient, ordered by cohort. (B) Frequency of each
mutation class included in each panel design.
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Fig. 2.10 Distribution of tumour mutation allele fractions per cohort coloured by mu-
tation class.
We analysed the abundance of the commonly mutated genes in melanoma patients in
our cohort. Based on the literature, BRAF (51%), NRAS (28%), NF1 (14%), CDKN2A
(13%) and TP53 (15%) are the most commonly mutated genes in melanoma [113]. In the
present cohort we see a higher representation of BRAF mutations (61%, Fig. 2.11). This is
unsurprising as patients in this cohort are receiving BRAF-targeted therapy. Inerestingly,
we also see a higher abundance of NF1 mutations (32%). However, as described by Akbani
and colleagues, NF1 mutations are correlated to BRAF non-hot-spot mutations. We see
mutations in both BRAF and NF1 in 11 of 19 patients with NF1 mutations, likely explaining
the higher representation of NF1 mutations in this cohort (Fig. 2.11) [113]. The observed
mutation rates of CDKN2A (18%), TP54 (15%) and NRAS (15%) are overall comparable to
those seen in the literature (Fig. 2.11).
2.7 Characterising background error rates
We started by characterising background error rates in hybrid-capture sequencing data.
Approximation of error rates may potentially be achieved through grouping mutations of
similar class. We demonstrate that error rates vary between mutation class by over an order
of magnitude using raw sequencing data without using molecular barcodes (Fig. 2.12A),
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Fig. 2.11 Mutated genes in melanoma cohort.Most commonly mutated melanoma genes
were identified from [113]. Boxes are coloured if patients had a mutation in a given gene.
Blue fields indicate a patient belonging to the stage IV melanoma cohort while red boxes
indicate a patient belonging to the stage II-III melanoma cohort. White boxes indicate that
no mutation was present.
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consistent with Newman et al. [65]. To increase the resolution of background error rates
further, we grouped mutations by both mutation class and trinucleotide context, demonstrating
over two orders of magnitude difference in background error rate between the least and most
noisy trinucleotide context (Fig. 2.12B).
Using a patient-specific sequencing approach, a large number of private mutation loci
were targeted. Each locus has its own error rate, though accurate benchmarking of the
background noise rates of individual loci to levels below 10−6 would require the cfDNA
molecules from a total of 100mL of plasma in order to sample one mutant read. This assumes
a cfDNA concentration of 10ng/mL from plasma, yielding 3 million analysable molecules.
Thus, we sought to develop a background error model for patient-specific sequencing data
that could estimate the background error rate of a locus accurately using limited control
samples. In this study, 99.8% of the mutations identified by tumour sequencing were private
i.e. unique to each individual. We assessed if patients may be used to control for other
patients’ mutation lists, thereby enabling us to group patient-specific mutation lists of multiple
patients together and reduce the number of additional control samples to be run on each panel.
In this study, a mean of 5.5 patients were included on each custom hybrid-capture sequencing
panel design. There was no significant difference in background error rate whether using
healthy individuals or other patients serving as controls (‘patient-control’ samples, which
may control for other patients at private loci) (Fig. 2.12C). Thus, INVAR utilises sequencing
data from one patient to control for others with both custom and untargeted approaches such
as exome or WGS (Fig. 2.12D).
2.8 Error-suppression in patient-specific sequencing data
As part of the INVAR pipeline, we sought to develop methods to minimise artefacts in
patient-specific sequencing data. Read collapsing was performed using unique molecular
barcodes which reduced error rates across all mutation classes (Fig. 2.13A), similar to
previous studies [58]. Increasing the minimum number of duplicates required per read family
reduced error rates further, but at the expense of a greater fraction of the sequencing data
being discarded (Fig. 2.13B). To balance data loss against background error rate, a minimum
family size threshold of 2 was used.
INVAR requires any mutation signal to be represented in both the forward (F) and reverse
(R) read of the read pair. This serves to both reduce sequencing error and produces a small
size-selection effect for short fragments since only short fragments would be read completely
in both F and R with paired-end 150bp sequencing. This step retained 92.4% of mutant reads
and 84.0% of wild-type reads in a training dataset (Fig. 2.13C).
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Fig. 2.12 Characterisation of background error rates.
(A) Non-error suppressed background error rates by mutation class. Trinucleotide error rates
are grouped by mutation class. Data from 136 samples were used for this analysis. (B) Non-
error suppressed background error rates by trinucleotide context. (C) Background error rates
were calculated by mutation class for healthy control individuals (blue) and patient samples
(red) after equalising the number of read families per group. Complementary mutation classes
were combined. T-tests were performed between healthy and patient samples. Error rates
obtained from patient samples are not significantly different from the error rates in healthy
control samples. NS, not significant. (D) Overview of the usage of sequencing data by the
INVAR pipeline. Data is collected for each locus of interest in the matched patient (shown
by coloured boxes), and control data is obtained by analysing the same loci in additional
patients from the same cohort for whom the loci were not found to be mutated in the tumour
or buffy coat analysis. Such data can be generated by applying a standardised sequencing
approach, such as WES/sWGS, to all samples (Fig. 2.28) or by combining multiple patient-
specific mutation lists into a custom capture panel that is sequenced across multiple patients
(Fig. 2.21). Data from other patients in those loci (‘non-matched mutations’) are used to
determine background mutation rates and a ctDNA detection cut-off.
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Fig. 2.13 Effect of read collapsing and locus noise filter on background error.
(A) Comparison of background error rates for non-error suppressed (red) and error suppressed
(green, minimum family size of 2) data. Error rates of error suppressed data can be further
improved through bespoke INVAR filters (blue). Background error rates were calculated
by aggregating all non-reference bases across all considered bases. (B) Overall background
error rates resulting from different minimum family size requirements, and the proportion of
read families retained with each setting. (C) Effect of requiring forward and reverse reads
at a locus; a median of 84.0% of the wild-type reads and a median of 92.4% of the mutant
reads were retained with this filter. (D) Background error rates were characterised per locus
based on all reads generated from control samples, split by cohort. Loci passing the locus
noise filter are shown in blue, those not passing the filter are shown in red. The proportions
of loci blacklisted by this filter are indicated at the top right.
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When targeting a large number of patient-specific loci, it becomes increasingly likely that
technically noisy sites, or single-nucleotide polymorphism (SNP) loci are included in the list.
Newman et al. have previously utilised position specific background polishing to address this
issue [65]. In this study we blacklisted loci that showed either error-suppressed mutant signal
in >10% of the patient-control samples, or a mean background error rate of >1% mutant allele
fraction. This approach excluded 0.5% of the patient-specific loci (Fig. 2.13D). Requiring
mutant signal in both reads and applying a locus noise filter reduced noise modestly when
applied individually; however, when combined they showed a synergistic effect, reducing
background error rates to below 10−6 in some mutation classes (Fig. 2.15A and Fig. 2.14A).
The individual effects of these filters on individual trinucleotide contexts are shown in
Fig. 2.14B.
Fig. 2.14 Analysis of trinucleotide error rates and patient outlier suppression.
(A) Error rates by trinucleotide context and mutation class following data filtering but
before applying the patient specific outlier suppression. (B) For each trinucleotide context,
background error rates are plotted before and after each background error filter, highlighting
the collective benefit of each of the error filters. (C) Outlier suppression filter: Raw data-
points for both cohorts (showing patient and control samples), with the outlier-suppressed
data points indicated in red (Details in section 2.17).
2.9 Patient-specific signal enrichment 47
When targeting a large number of patient-specific sites, it becomes possible to assess the
distribution of allele fractions observed. In the residual disease setting, we expect to have a
high degree of sampling error. Therefore, signal should appear stochastically as individual
mutant molecules are distributed across patient-specific loci, with many of the loci having
zero mutant reads. In order to optimise INVAR for detection of the lowest possible levels of
ctDNA, we developed a method called patient-specific outlier suppression to exclude signal
at a locus that is not consistent with the remaining loci (Fig. 2.14C and Fig. 2.15B). This tests
each locus against the distribution of signal at all other loci with a correction for multiple
testing, excluding loci that are significantly outlying. Mutant signal was reduced 3-fold in
control samples, while retaining 96.1% of mutant signal in patient samples (Fig. 2.15C).
Overall, combining the above steps results in an average 131-fold decrease in background
error relative to raw sequencing data (Fig. 2.15A) and reduces the error rates of some
trinucleotide contexts to below 1x10−6 (Fig. 2.14A).
Fig. 2.15 Development and analytical performance of the INVAR method.
(A) Reduction of error rates following different error-suppression settings (section 2.17). (B)
Loci observed with significantly greater signal than the remainder of the loci of that patient
might be due to noise at that locus, contamination, or a mis-genotyped SNP locus (in red, see
section 2.16). (C) Summary of effect of outlier suppression on both cohorts. Mutant signal
was reduced 3-fold in control samples, while retaining 96.1% of mutant signal in patient
samples.
2.9 Patient-specific signal enrichment
To enhance detection further, INVAR is able to enrich for ctDNA signal through probability
weighting based on the tumour allele fraction of each mutation locus and ctDNA fragment
sizes. Tumour mutations with a higher tumour allelic fraction are more likely to be observed
in the plasma [108, 114], therefore, greater weight was allocated to mutant signals in plasma
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from loci with high tumour mutant allele fraction. Using a dilution series, we confirm the
relationship between the tumour allele fraction of a locus and rate of detection of ctDNA
of that locus in plasma (Fig. 2.16A). We confirm in clinical samples that patient-specific
mutation loci observed in plasma had a significantly higher tumour allele fraction compared
to those not observed in plasma (P = 2x10−16; Wilcoxon test, Fig. 2.17D).
Analysis of 144 samples showed a nucleosomal pattern of cfDNA fragmentation, with mu-
tant fragments shorter than wild-type fragments at the mono-nucleosome and di-nucleosome
peak (Fig. 2.16B). We also observed that stage IV melanoma patients had a significantly
higher median mutant fragment size compared to the stage II-III melanoma patients (163bp
vs. 154bp, P = 2x10−16, Wilcoxon test, Fig. 2.16C). Previous research has shown enrich-
ment for ctDNA when shorter fragments are selected using either in vitro or in silico size
selection [14, 15, 27]. However, at low levels of signal, such methods can cause loss of
rare mutant alleles [12]. Thus, in this study we weighted each signal based on its fragment
size in order to boost ctDNA signal, while retaining all the data (Fig. 2.17E). Based on
smoothed size profiles of mutant and wild-type fragments observed (Fig. 2.16D), patient data
were used to size-weight other patients’ data using a leave-one-out approach (section 2.17).
Following signal weighting, INVAR aggregates signal across all patient-specific mutations
(section 2.16). In order to determine whether or not ctDNA is detected in a sample, data from
non-matched mutations in other patients were used as negative controls to set the detection
threshold (Fig. 2.18). An Integrated Mutant Allele Fraction (IMAF) is determined by taking
a background-subtracted, depth-weighted mean allele fraction across the patient-specific loci
in each sample (section 2.17).
2.10 Analytical sensitivity and specificity of INVAR
To benchmark the sensitivity of INVAR, we performed custom capture sequencing of a
dilution series of plasma from one melanoma patient (stage IV disease), for whom we
identified 5,073 mutations through exome sequencing. Plasma DNA from this patient was
serially diluted into control volunteers’ plasma DNA to an expected IMAF of 3.6 x 10−7.
Without use of unique molecular barcodes, INVAR detected ctDNA down to an expected
allele fraction of 3.6 x 10−5, which was quantified to an average IMAF of 4.7 x 10−5 from
two replicates (Fig. 2.19A). Following the use of molecular barcodes and custom error-
suppression methods, the diluted ctDNA was detected to an expected IMAF of 3.6 x 10−6
(3.6 parts per million) in two replicates, with IMAF values of 4.3 and 5.2 ppm. Overall the
correlation between IMAF and the expected mutant fraction was 0.98 (Pearson’s r, p < 2.2 x
10−16, Fig. 2.18A). At an expected allele fraction of 3.6 x 10−7, ctDNA was detected in 2
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Fig. 2.16 Utilising tumour allelic fraction information and plasma DNA fragment
length to enhance ctDNA signal.
(A) Comparison of tumour and plasma mutant allele fractions. Using error-suppressed data,
tumour loci were grouped into bins of 0.01 mutant allele fraction, and the proportion of loci
observed in plasma was determined for different levels of a dilution series. The dilution level
of the spike-in dilution series is indicated by each colour. At each dilution level, there is a
positive correlation between the tumour allele fraction and proportion of loci observed in
plasma. (B) For each cohort, size profiles were generated for mutant and wild-type fragments.
(C) Comparison of mutant fragment distributions between cohorts. These were compared us-
ing a two-sided Wilcoxon rank test after downsampling the number of mutant reads to match
for both cohorts. (D) The distributions of fragment sizes for different levels of smoothing,
used to assign weights to fragment sizes (section 2.17).
50 Patient-specific ctDNA monitoring from sequencing data
Fig. 2.17 Patient-specific signal enrichment in INVAR.
(A) Tumour allele fractions were compared between loci with and without detected signal
in plasma. Loci with signal in plasma had significantly higher tumour allele fractions in
patient samples. There was no significant increase in tumour allele fraction when performing
this analysis on non-patient-specific samples (Student’s t-test, NS, not significant; *** = P <
0.0001). (B) Log2 enrichment ratios for mutant fragments from three different cohorts of
patients. Size ranges enriched for ctDNA are assigned more weight by the INVAR pipeline.
out of 3 replicates. To assess the impact on sensitivity of the number of mutations targeted
we downsampled sequencing data in silico to include subsets of patient-specific mutation
lists. This confirmed that targeting more mutations resulted in more IR and correspondingly
higher ctDNA detection rates (Fig. 2.19B, section 2.17).
The false positive rate of INVAR was measured twice, once in patient-control samples
and separately in healthy control samples. First, analytical specificity was determined through
analysis of samples from other patients (patient-control samples) at non-matched mutation
loci, giving a median specificity of 98.0% (Fig. 2.18, Table 2.4). To confirm the specificity of
INVAR in independent control samples, we ran custom capture sequencing (with the same
oligo pools) on samples from healthy individuals and analysed those by INVAR using each
of the patient-specific mutation lists. The ROC curve for the stage IV melanoma cohort
controlled against healthy individuals is shown in Fig. 2.19C. Across each of the analyses
in this study, using control cfDNA from 26 healthy individuals, a median specificity value
of 97.05% was obtained, consistent with the analytical specificity defined in non-matched
control samples from other patients (Fig. 2.20).
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Fig. 2.18 Overview of the INVAR pipeline.
INVAR leverages patients to control for one another and uses separate healthy controls. In this
study, individual mutation lists are generated from tumour and buffy coat sequencing. Each
locus of interest is sequenced in the matched patient, and in additional patients from the same
cohort for whom this locus was not found to be mutated in the tumour or buffy coat analysis.
This can be done by applying a generic panel to all samples (such as WES/WGS, Fig. 2.28),
or by combining multiple patient-specific mutation lists into a combined custom panel that
is sequenced across multiple patients (Fig. 2.21). For each patient, INVAR aggregates the
sequencing information across the loci of the patient-specific mutation list. Data from other
patients in those loci (‘non-matched mutations’) are used to determine background mutation
rates and detection cut-offs (section 2.17). Additional samples from healthy individuals are
analysed by the same panels, this data was used to assess the false positive rates in healthy
individuals.
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Fig. 2.19 Sensitivity and specificity determination of INVAR.
(A) Spike-in dilution experiment to assess the sensitivity of INVAR. Using error-suppressed
data with INVAR, ctDNA was detected in replicates for all dilutions to 3.6 ppm, and in 2
of 3 replicates at an expected ctDNA allele fraction of 3.6 x 10−7 (section 2.17). Using
error-suppressed data of 11 replicates from the same healthy individuals without spiked-in
DNA from the cancer patient, no mutant reads were observed in an aggregated 6.3 x 106
informative reads across the patient-specific mutation list. (B) The sensitivity in the spike-in
dilution series was assessed after the number of analysed loci was downsampled in silico to
between 1 and 5,000 mutations (section 2.17). (C) ROC analysis of the stage IV melanoma
cohort was performed against patient-controls (black) and healthy individuals (red).
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Fig. 2.20 ROC curves and specificity for all cohorts and data types.
(A) Analytical (based on patient control samples) and clinical specificity values (based on
healthy individuals) are provded for all cohorts. No healthy individuals were tested on the
custom capture panel of the stage II-III melanoma cohort. (B) For all cohorts, ROC analyses
were performed against patient-controls (black) and healthy individuals (red). For the stage
II-III melanoma (post-surgery) cohort, our analysis was blinded to outcome, and patients
who did not relapse within 5 years were also included in the ROC analysis; thus, the maximal
possible sensitivity for this cohort (as defined) was the fraction of relapsing patients (18/33 =
54.5%). INVAR detected 8 out of 20 patients who relapsed (ROC showing sensitivity at 9/33
= 27.3%).
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2.11 Quantification of ctDNA in patient samples
We applied INVAR to custom capture panel sequencing data from 130 plasma samples from
47 stage II-IV melanoma patients, generating up to 2.9 x 106 IR per sample (median 1.7 x
105 IR), thus analysing orders of magnitude more cfDNA fragments compared to methods
that analyse individual or few loci (Fig. 2.21A). In this study, we demonstrated a dynamic
range of 5 orders of magnitude and detection of trace levels of ctDNA in plasma samples
(Fig. 2.21B and C); this detection was obtained from a median input material of 1638 copies
of the genome (5.46 ng of DNA; Table 2.2). In a total of 13 of the 130 plasma samples
analysed with custom capture sequencing, ctDNA was detected with signal in fewer than
1% of the patient-specific loci (Fig. 2.21D). The lowest fraction of cancer genomes detected
was 1/714, equivalent to <5 femtograms of tumour DNA. Given the limited input, the low
ctDNA levels detected would be below the 95% limit of detection for a ‘perfect’ single-locus
assay in 48% of the cases (indicated with filled circles in Fig. 2.21C). The input mass vs.
IMAF of each sample is shown in Fig. 2.22A, highlighting the sensitivity benefit of a broad
sequencing approach. Thus, targeting multiple mutations can allow detection of low absolute
amounts of tumour-derived DNA.
In Stage IV melanoma patient samples, ctDNA IMAF values showed a correlation of 0.8
with tumour size assessed by CT imaging (Pearson’s r, P = 6.7 x 10−10, Fig. 2.22B, Table 2.5),
comparable to other studies [19, 31]. Similarly, ctDNA IMAF had a correlation of 0.53
with serum lactate dehydrogenase (LDH), a routinely used clinical marker for monitoring
of melanoma (Pearson’s r, P = 2.8 x 10−4, Fig. 2.23). INVAR analysis was used to monitor
ctDNA dynamics in response to treatment, in which the majority of patients received anti-
BRAF targeted therapy first line, which resulted in a rapid decline in ctDNA in those patients
(Fig. 2.24). In one patient (#59) treated with a series of targeted therapies and immunotherapy,
ctDNA was detected down to an IMAF of 2.5 ppm, corresponding to a radiological tumour
volume of 1.3 cm3 (Fig. 2.25). Following progression on vemurafenib, patient #59 progressed
on multiple other anti-BRAF targeted therapies (pazopanib, dabrafenib and trametinib) and
immunotherapy (ipilimumab), corresponding to a constant rise in ctDNA over two years of
monitoring (Fig. 2.25).
The IMAF obtained from INVAR in the late stage melanoma cohort was compared to
allelic fractions obtained from TAm-Seq [35] based amplicon sequencing of a single mutation
locus (targeting BRAF or NRAS depending on the mutation status of the patient). The two
methods correlated well down to allelic fractions of 1 x 10−2 (Pearson’s r = 0.85, P = 1.9
x 10−15, Fig. 2.26). However, the single mutation amplicon approach is unable to detect
ctDNA below 1 x 10−2 while INVAR detects ctDNA down to 1 x 10−6, highlighting the
advantage of INVAR over a single locus assay (Fig. 2.26).
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Fig. 2.21 ctDNA detection by INVAR in early and advanced disease.
(A) Number of haploid genomes analysed (hGA) and the number of mutations targeted in 130
plasma samples from 47 cancer patients across two cohorts. Dashed diagonal lines indicate
the number of targeted loci x hGA that yield the indicated IR. Shaded regions highlight
the working point of current methods (green), the working point of INVAR from custom
capture (red) and sWGS plasma data (blue) (B) Two-dimensional representation of detected
ctDNA fractions are plotted against the IR for each sample. Samples falling above the dashed
line, which is plotted at 1/IR were detected. In some samples, >106 IR were obtained, and
ctDNA was detected down to fractions of few ppm (orange shaded region). We used a
sensitivity threshold of 20,000 IR (left-most dotted line), such that samples with undetected
ctDNA with fewer than 20,000 IR (detection level 0.01%) were called “unclassified” and
excluded from the analysis (total of 4 of 130 samples; dark blue shaded region). Using an
alternative threshold, for example 66,666 IR (indicated by the second dotted line and the
light blue shaded region), will increase the overall detection rates in the cohorts. (C) ctDNA
fractional levels (IMAF) detected in this study, shown in ascending order for the two cohorts.
Filled circles indicate samples where the number of hGA would fall below the 95% limit of
detection for a perfect single-locus assay given the measured IMAF (section 2.17). Empty
circles indicate unclassified samples. (D) Copies of the cancer genome detected for each of
the samples (same order as above in part (C)), calculated as the number of mutant fragments
divided by the number of loci queried (Table 2.2).
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Fig. 2.22 Characterisation of ctDNA levels in advanced melanoma.
(A) Comparison of input mass and IMAF observed. For each library with detected ctDNA,
the DNA input mass for library preparation is plotted against IMAF. The black line indicates
the threshold below which a perfect single-locus assay would have <95% sensitivity. In this
study, 48% of samples would not be detectable using a perfect single-locus assay with the
plasma DNA input amounts used. (B) Comparison between ctDNA and tumour volume in
our study (Pearson’s r = 0.67, P = 0.003) and in previous publications measuring multiple
mutations per patient in NSCLC, using CAPP-Seq (Pearson’s r = 0.72, P = 0.003) [31], and
multiplexed PCR in the TRACERx cohort (Pearson’s r = 0.5, P = 4.3 x 10−4) [19].
Fig. 2.23 Relationship between serum lactate dehydrogenase and IMAF in advanced
stage melanoma patients.
Pearson’s r = 0.46, P = 0.0058. The dashed line at 250IU/L indicates the upper limit of
normal for LDH.
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Fig. 2.24 Longitudinal ctDNA profiles for advanced melanoma patients.
IMAF values are plotted over time per patient, using error-suppressed individualised sequenc-
ing data. Vertical dashed lines indicate time of radiological progression.
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Fig. 2.25 Longitudinal monitoring in late stage melanoma patient.
ctDNA IMAF and tumour volume plotted over time for one patient with metastatic melanoma
over the course of several treatment lines (indicated by shaded boxes). ctDNA was detected
to 2.5 ppm during treatment with anti-BRAF targeted therapy, when disease volume was
approximately 1.3 cm3.
Fig. 2.26 Comparison of INVAR and single locus assay.
IMAF obtained from INVAR was compared to the allelic fraction obtained from a single
locus TAm-Seq assay, showing good correlation down to 1 x 10−2 (Pearson’s r = 0.85, P
= 1.9 x 10−15). INVAR continues to detect ctDNA down to 1 x 10−6, while these samples
remain undetected with the single locus assay. ND, not detected.
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2.12 ctDNA detection post-surgery
To test INVAR in the residual disease setting, we applied INVAR to post-operative samples
from 38 patients with resected Stage II-III melanoma recruited in the UK AVAST-M trial.
Patient samples were collected up to 6 months after surgery with curative intent. The clinical
details of this cohort are given in Fig. 2.27A. We interrogated a median of 3.6 x 105 IR (IQR
0.64 x 105 to 4.03 x 105) and detected ctDNA to a minimum IMAF of 2.85 ppm, indicated
in Fig. 2.21C. The specificity of this analysis was >0.98 (Fig. 2.20). In total, ctDNA was
detected in samples from 11 of 38 patients (28.9%). ctDNA was detected at higher rates
when higher numbers of informative reads were obtained, with ctDNA detected in 10 of 28
(35.7%) cases with >66,666 informative reads (sensitivity of detection of 30 ppm), 9 of 18
(50%) cases with >250,000 informative reads (sensitivity of detection below 10 ppm) and
in 5 of 6 (83%) cases with >106 informative reads (Fig. 2.21B). Samples with no ctDNA
detected and few informative reads may indicate limited resolution and would benefit from
additional information (more informative reads, obtainable from deeper sequencing or more
mutations). A similar approach was previously described in the relative haplotype dosage
method by Lo et al. [9]. In our case, excluding 3 samples where ctDNA was undetected
and had fewer than 20,000 informative reads (sensitivity of detection of 0.01% not reached),
ctDNA was detected in 8 of 20 (40%) patients who later recurred and was associated with
a strong trend for shorter disease-free interval (6.3 months vs. median not reached with 5
years’ follow-up; Hazard ratio (HR) = 2.08; 95% CI 0.85-5.13, P = 0.11) and overall survival
(2.6 years vs. median not reached, P = 0.08). In comparison, a previous analysis of ctDNA
detection at 12 weeks after surgery in 161 patients with resected BRAF or NRAS mutant
melanoma detected ctDNA in 16.8% of patients who later relapsed [106].
2.13 Sensitive ctDNA monitoring using WES and sWGS
Patient-specific capture panels allow highly sensitive detection of ctDNA, but require prior
design of patient specific capture panels. Therefore, we assessed whether INVAR could be
applied to standardised workflows such as WES or WGS. This allows the panel design step
to be omitted and requires only the patient-specific mutation list from tumour sequencing,
which may be performed in parallel with plasma sequencing to save time (Fig. 2.28A).
To test the generalisability of INVAR, we selected samples with IMAF values quantified
as being between 4.5 x 10−5 and 0.16 using custom-capture sequencing and utilised com-
mercially available exome capture kits to sequence plasma DNA to a median raw depth of
238x. Despite the modest depth of sequencing, we obtained between 1,565 and 473,300 IR
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Fig. 2.27 Characterisation of IMAF values in the early-stage melanoma cohort.
(A) Summary table of patient characteristics for the stage II-III resected melanoma cohort (n
= 38). (B) We estimated the detection rates of ctDNA for different levels of IR (section 2.17).
We observe a linear relationship (R2 = 0.95) between the number of IR and detection rate
in the baseline samples of the stage IV melanoma cohort. ctDNA was detected in 100% of
baseline samples with 105 IR (red), whereas following the initiation of treatment, 106-107 IR
are needed to detect all longitudinal samples (blue), reflecting the lower levels of ctDNA.
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Fig. 2.28 Application of INVAR to WES/WGS data.
(A) schematic overview of a generalised INVAR approach. Tumour (and buffy coat) and
plasma samples are sequenced in parallel using whole exome or genome sequencing, and
INVAR can be applied to the plasma WES/WGS data using mutation lists inferred from the
tumour sequencing. (B) INVAR was applied to WES data from 21 plasma samples (238x
raw depth), and to WGS data from 33 plasma samples (0.6x raw depth). For each sample
IMAF values are plotted against the number of unique IR and compared to the application
of custom capture sequencing. Both sWGS and WES applications of INVAR can detect
ctDNA but show a lower number of IR compared to custom capture data. Dotted vertical
line: 20,000 IR threshold, dashed diagonal line: 1/IR.
using WES (Fig. 2.28B). We detected ctDNA in all 20 samples tested down to IMAFs as
low as 4.34 x 10−5 (Fig. 2.30A), demonstrating that ctDNA can be sensitively detected by
INVAR from WES data using patient-specific mutation lists. These IMAF values showed a
correlation of 0.97 with custom capture data from the same samples (Pearson’s r, P = 1.5 x
10−13, Fig. 2.30B). Therefore, INVAR is not only highly sensitive when applied to custom
capture panels that redundantly sequence up to 102-103 haploid genomes, but also when
applied to WES data with a de-duplicated coverage between 10-100x (Fig. 2.30C).
We hypothesised that ctDNA could be detected and quantified with INVAR from even
smaller amounts of input data. Therefore, we performed WGS on libraries from cfDNA
of longitudinal plasma samples from a subset of six patients with Stage IV melanoma, to
a mean depth of 0.6x (indicated in black in Fig. 2.28B). For each of those patients we
identified >500 patient-specific mutations using WES from each patient’s tumour and buffy
coat DNA, generating between 226 and 7,696 IR per sample (median 861, IQR 471-1,559;
Fig. 2.28B) with a “minimum family size” requirement of 1 (i.e. duplicate removal). Despite
not leveraging unique molecular barcodes, error rates per trinucleotide were still sufficiently
low, with many trinucleotide contexts showing error rates below 1 x 10−5 (Fig. 2.29). Using
INVAR on sWGS data, IMAF values as low as 1.1 x 10−3 were quantified (Fig. 2.30D).
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Compared to custom capture data from the same samples we observed a correlation of 0.93
(Pearson’s r, P = 9 x 10−10, Fig. 2.30B). In samples where ctDNA was not detected, it was
possible to estimate the maximum likely IMAF of that sample from the known number of
informative reads for each sample, which is indicated by the grey bars in Fig. 2.30D. Using
less than 1x coverage, INVAR can boost the sensitivity utilising patient-specific mutation
lists by up to an order of magnitude compared to copy-number analyses [27, 75].
Fig. 2.29 Application of INVAR to whole genome sequencing data.
Background error rates per trinucleotide context for sWGS data. Data was analysed with
INVAR using a minimum family size of 1 when performing read collapsing.
These analyses suggest that with a sufficiently large number of tumour -specific mutations,
INVAR may yield high sensitivity for ctDNA detection from untargeted sequencing data that
can be limited in depth and thus input material.
2.14 Extrapolation to higher IR and sensitivity
The sensitivity of INVAR depends on the number of patient-specific mutations identified, and
so its effectiveness may be limited in samples with fewer identified mutations, or in cancers
with lower mutation rates. Fig. 2.31A shows the distribution of IR for all the samples in this
study, highlighting those with limited sensitivity (<20,000 IR) and those with sensitivity to
ppm. Samples with limited sensitivity could be re-analysed with larger amounts of DNA
input/more sequencing, or by designing larger capture panels by identifying additional
patient specific mutations through broader-scale sequencing such as WGS of the tumour and
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Fig. 2.30 Sensitive detection of ctDNA from WES/WGS data using INVAR.
(A) IMAF observed for the 21 samples analysed with WES ordered from low to high. ND, not
detected. (B) IMAFs obtained from plasma WES (gold) and sWGS (black) were compared
to the IMAF obtained from the custom capture approach of matched samples, showing
correlations of 0.97 and 0.93 (Pearson’s r, P = 1.5 x 10−13 and P = 9 x 10−10). (C) Number
of hGA (indicating depth of unique coverage after read collapsing) and mutations targeted
by plasma WES and sWGS. Compared to the custom capture approach, both the WES and
sWGS samples had fewer hGA and occupy a space further to the left in the two-dimensional
space. (D) sWGS longitudinal monitoring of ctDNA levels in plasma. All six patients
had >500 mutations based on WES tumour profiling. Filled circles indicate detection at a
specificity level of >0.99. For other samples, the 95% confidence intervals of the ctDNA
level are shown, based on the number of informative reads for each sample (empty circles
and bars). ND, not detected.
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buffy coat DNA from that patient. Analyses involving greater IR would render the current
background error rates limiting and would therefore require greater error-suppression, such
as duplex molecular barcodes [115]. However, when increasing the sensitivity of ctDNA
beyond the ppm range, sequencing output may become the limiting factor.
We studied the ctDNA levels in the samples analysed with custom capture in order to
estimate the levels of sensitivity that would be required for different clinical applications. We
used IMAF values from the clinical samples and plotted the detection rates while varying
the numbers of IR and the levels of sensitivity (Fig. 2.31B). In Stage IV melanoma patients
at pre-treatment baseline time points, ctDNA was detected in 100% of cases using 105 IR,
whereas up to two orders of magnitude greater sensitivity may be needed to detect ctDNA at
high rates following treatment initiation (Fig. 2.27B). For the population we studied of Stage
II-III melanoma patients who underwent surgery, we suggest that even analysis of 107 IR
might not be sufficient to detect all patients who ultimately relapse.
2.15 Discussion
In this study, we developed a method for sensitive patient-specific monitoring of ctDNA
that leverages the properties of patient-specific sequencing data. This approach mitigates
sampling error through aggregation of mutant signal, which is first weighted based on the
features of each read and mutation locus, and uses features of cfDNA aside from specific
sequence alterations, such as fragment sizes and tumour allele fractions of each mutation.
By aggregating signal across 102-104 mutated loci it is possible to detect <0.01 copies of a
cancer genome, even when this represents few parts per million of the cfDNA in plasma, 1-2
orders of magnitude lower than previous studies [65, 98].
We show that INVAR can be applied not only to patient-specific capture panel data to
quantify ctDNA to parts per million (Fig. 2.21), but also to exome sequencing and sWGS
data (Fig. 2.28 and Fig. 2.30). Although these latter methods generated fewer informative
reads, INVAR detected ctDNA to 50 ppm using WES, and to 0.1% mutant allele fraction
using sWGS, over an order of magnitude more sensitive compared to previous methods based
on copy-number analysis of sWGS [75, 76]. This level of sensitivity can only be achieved by
targeting a sufficiently large number of patient-specific mutations, as increasing input mass
alone would not be feasible to this extent (Fig. 2.5A). Therefore, we assessed whether INVAR
would still retain sufficient sensitivity when applied to sWGS data from other cancer types
with lower mutation rates than melanoma. We estimated the potential sensitivity for INVAR
using sWGS on other cancer types based on their known whole-genome mutation rates [116]
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Fig. 2.31 Current limitations and future applications of INVAR.
(A) The number of informative reads that would be obtainable with different numbers
of mutations analysed, across the cases in these three cohorts. Increasing sensitivity is
directly correlated to IR, with the minimal detected ctDNA fraction being 2/IR in the current
implementation of INVAR (section 2.16). The red line shows the distribution of IR obtained
with the custom panels covering all mutations identified by tumour WES. Light/dark green
lines show the IR generated if 1 or 20 mutations were analysed for each sample (calculated
based on the mean IR per locus). IR could be increased further by using whole genome
sequencing (WGS) to guide the design of custom panels (orange curve, extrapolated based
on our observed mutation rates in WES). Using mutation lists from WES, samples exceeding
106 IR are shaded in orange, and samples with fewer than 2x104 IR are shaded in blue. (B)
Detection rates of ctDNA for different numbers of IR sequenced were estimated. There was a
linear relationship between IR and detection (R2 = 0.95) in the baseline samples of the stage
IV melanoma cohort (blue). In stage II-III melanoma post-surgery (red), a linear relationship
was observed between IR and detection rate, and the predicted rates of detection of ctDNA
was extrapolated. ND, not detected. (C) Predicted sensitivities for sWGS plasma analysis of
patients with different cancer types, using an average of 0.1x or 10x coverage (equivalent to
0.1 and 10 hGA) and the known mutation rates per Mbp of the genome for different patients
and cancer types obtained from Lawrence et al. [116]. The limit of detection for ctDNA
based on copy number alterations is shown at 3% [75].
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(Fig. 2.31C). Using 0.1x WGS coverage, INVAR may yield sensitivities of 10−1–10−3 for
these cancer types, with the potential for higher sensitivity with deeper sequencing.
In summary, patient-specific mutation lists provide an opportunity for highly sensitive
monitoring from a range of sequencing data types using methods for signal aggregation,
weighting and error-suppression. As tumour sequencing becomes increasingly performed in
personalised oncology, patient-specific mutation lists may be leveraged for individualised
monitoring using INVAR-like tools.
2.16 Methods
2.16.1 Patient cohort
Samples were collected from patients enrolled on the MelResist (REC 11/NE/0312) and
AVAST-M studies (REC 07/Q1606/15, ISRCTN81261306) [117, 118]. Consent to enter the
studies was taken by a research/specialist nurse or clinician who was fully trained regarding
the research. MelResist is a translational study of response and resistance mechanisms to
systemic therapies of melanoma, including BRAF targeted therapy and immunotherapy, in
patients with stage IV melanoma. AVAST-M is a randomised control trial which assessed
the efficacy of bevacizumab in patients with stage IIB-III melanoma at risk of relapse
following surgery; only patients from the observation arm were selected for this analysis. The
Cambridge Cancer Trials Unit-Cancer Theme coordinated both studies, and demographics
and clinical outcomes were collected prospectively. Baseline characteristics for all cohorts
are summarised in Table 2.6.
2.16.2 Sample collection and processing
Fresh frozen tumour biopsies prior to treatment were collected from patients with Stage
IV cutaneous melanoma. Formalin-fixed paraffin-embedded (FFPE) tumour tissue was
obtained for the AVAST-M trial. For patients on the AVAST-M study, plasma samples were
collected within 12 weeks of tumour resection, with a subsequent sample after 3 months,
where available. Longitudinal samples were collected during treatment of patients with stage
IV melanoma as part of the MelResist study. Peripheral blood samples were collected at
each clinic visit in S-Monovette 9mL EDTA tubes. For plasma collection, samples were
centrifuged at 1,600 g for 10 minutes within an hour of the blood draw, and then an additional
centrifugation of 20,000 g for 10 minutes was carried out. All aliquots were stored at -80°C.
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2.16.3 Tissue and plasma extraction and quantification
FFPE samples were sectioned into up to 8 µm sections, and one H&E stained slide was
generated, which was outlined for tumour regions by a histopathologist. Marked tumour
regions were macrodissected, and DNA extraction was performed using the QIAamp DNA
FFPE Tissue Kit using the standard protocol, except with incubation at 56°C overnight and
500 rpm agitation on a heat block. DNA was eluted twice using 20 µL ATE buffer each time
with centrifugation at full speed. Following extraction, DNA repair was performed using
the NEBNext® FFPE DNA Repair Mix as per the manufacturer’s protocol. Fresh frozen
tissue biopsies were first homogenised prior to DNA extraction, which was performed as
follows: up to 30 mg of each fresh frozen tissue biopsy sample was combined with 600 µL
RLT buffer, then placed in a Precellys CD14 tube (Bertin Technologies) and homogenised at
6,500 rpm for two bursts of 20 seconds separated by 5 seconds. Subsequently, the Qiagen
AllPrep extraction kit as per the manufacturer’s protocol.
Genomic DNA was extracted from up to 1 mL whole blood or buffy coat using the Gentra
Puregene Blood Kit (Qiagen) as per the manufacturer’s protocol. Samples were eluted in
two rounds of 70 µL buffer AE and incubated for 3 minutes before centrifugation. Up to
4mL of plasma was extracted using the QIAsymphony (Qiagen) with a QIAamp protocol.
DNA was eluted in 90 µL elution buffer and stored at -80°C. Plasma samples were extracted
using the QIAsymphony instrument (Qiagen) using the 2-4mL QIAamp protocol. For each
QIAsymphony batch, 24 samples were extracted, which included a positive and negative
control.
Following extraction of fresh frozen, FFPE and genomic DNA, eluted DNA concentration
was quantified using a Qubit fluorimeter with a dsDNA broad range assay (ThermoFisher
Scientific). To quantify cell-free DNA concentration of plasma DNA eluates, digital PCR was
carried out using a Biomark HD (Fluidigm) with a 65bp TaqMan assay for the housekeeping
gene RPP30 (Sigma Aldrich) [35]. 55 PCR cycles were used. The estimated number of
RPP30 DNA copies per µL of eluate was used to determine the cell-free DNA concentration
in the original sample.
2.16.4 Tumour library preparation
FFPE tumour tissue DNA samples (up to 150 ng) and buffy coat DNA samples (75 ng) were
sheared to a length of 150bp, using the Covaris LE 220 (Covaris, Massachusetts, USA).
The standard Covaris protocol for a final fragment length of 150bp and an input volume of
15µL using the 8 microTUBE-15 AFA Beads Strip V2 was used. After the shearing, the
fragmentation pattern was verified using a Bioanalyser (Agilent).
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Sequencing libraries were prepared using the ThruPLEX DNA-seq kit (Rubicon). 100 ng
and 50 ng sheared tumour and buffy coat DNA, respectively, were used and the protocol was
carried out according to the manufacturer’s instructions. The number of amplification cycles
was varied during library preparation according to the manufacturer’s recommendations.
Library concentration was determined using qPCR with the Illumina/ROX low Library
Quantification kit (Roche). Library fragment sizes were determined using a Bioanalyser
(Agilent). After library preparation, exome capture was performed with the TruSeq Exome
Library Kit (Illumina), using a 45Mbp exome baitset. Three libraries were multiplexed
in one capture reaction and 250 ng of each library was used as input. For compatibility
with ThruPLEX libraries, the protocol was altered by adding 1µL of i5 and i7 TruSeq HT
xGen universal blocking oligos (IDT) during each hybridisation step. To compensate for the
increased hybridisation volume, the volume of CT3 buffer was adjusted to 51 µL. Two rounds
of hybridisations were carried out, each lasting for 24 hours. Library QC was performed
using qPCR and Bioanalyser, as above. Samples were multiplexed and sequenced with a
HiSeq 4000 (Illumina).
Fresh frozen tumour biopsies and matched buffy coat library preparation was performed
as described by Varela et al. [103] using the SureSelectXT Human All Exon 50 Mb (Agilent)
bait set. Samples were multiplexed and sequenced with a HiSeq 2000 (Illumina).
2.16.5 Tumour mutation calling
For fresh frozen tumour biopsies, mutation calling was performed as described by Varela
et al. [103]. For FFPE tumour biopsies, mutation calling was performed with Mutect2 with
the default settings: –cosmic v77/cosmic.vcf and –dbsnp v147/dbsnp.vcf. To maximize the
number of mutations retained, variants achieving Mutect2 pass OR tumour LOD > 5.3 were
retained. Mutation calls were filtered as follows:
1. Buffy coat mutant allele fraction equals zero
2. Mutation not in homologous region
3. Mutation not at a multiallelic locus
4. 1000 Genomes ALL and EUR frequency equals zero
5. A minimum unique tumour depth of 5.
In addition, for FFPE based tissue data in the melanoma cohort, the filter for C/A errors
proposed by Costello et al. [112] was applied to suppress C/A artefacts. The remaining
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mutations are shown in Fig. 2.9. The remaining signal in the C/A class, especially within
the trinucleotide contexts CCC and CCA indicate that artefactual mutations still remain in
the data. Additonal filtering in these contexts, for example by allelic fraction, should be
conducted to remove further artefactual mutations [112]. As a result, we generated patient-
specific mutation lists for 47 patients with stage II-IV melanoma. A median of 625 (IQR
411 -1076) patient-specific mutations were identified per patient (Fig. 2.8, Table 2.1). These
mutation lists were used both to design custom capture sequencing panels, and as input for
the INVAR method.
2.16.6 Plasma library preparation
Cell-free DNA samples were vacuum concentrated at 30°C using a SpeedVac (ThemoFisher)
prior to library preparation where required. The median input into the library was 1652 hap-
loid genomes (IQR 900 – 3013). Whole genome library preparation for plasma cell-free DNA
was performed using the Rubicon ThruPLEX Tag-Seq kit. The number of PCR amplification
cycles during the ThruPLEX protocol was varied between 7-15 cycles, as recommended by
the manufacturer. Following amplification and sample barcoding, libraries were purified
using AMPure XP beads (Beckman Coulter) at a 1:1 ratio. Library concentration was de-
termined using the Illumina/ROX low Library Quantification kit (Roche). Library fragment
sizes were determined using a Bioanalyser (Agilent).
For the stage IV melanoma cohort, library preparation and sequencing were run in
duplicate to assess the technical reproducibility of the experimental and computational
method, showing a correlation between IMAF values generated by the INVAR pipeline of
0.97 (Pearson’s r, p-value < 2.2 x 10−16). For the early-stage cohorts, input cell-free DNA
material was not split and was instead prepared and sequenced as a single sample per time
point.
2.16.7 Custom hybrid-capture panel design and plasma sequencing
Following mutation calling, custom hybrid-capture sequencing panels were designed using
the Agilent SureDesign software. Between 5 and 9 patients were grouped together per panel
in this implementation. Baits were designed with 4-5x density and balanced boosting. 95.5%
of the variants had baits successfully designed; bait design was not reattempted for loci that
had failed. Custom panels ranged in size between 1.26-2.14 Mb with 120 bp RNA baits. For
each panel, mutation classes and tumour allele fractions are shown in Fig. 2.9, Fig. 2.10 and
Table 2.1.
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Libraries were captured either in single or 3-plex (to a total of 1000 ng capture input)
using the Agilent SureSelectXT protocol, with the addition of i5 and i7 blocking oligos
(IDT) as recommended by the manufacturer for compatibility with ThruPLEX libraries [119].
Custom Agilent SureSelectXT baits were used, with 13 cycles of post-capture amplification.
Post-capture libraries were purified with AMPure XP beads at a 1:1.8 ratio, then were
quantified and library fragment size was determined using a Bioanalyser (Agilent).
2.16.8 Exome capture sequencing of plasma
For exome sequencing of plasma, the Illumina TruSeq Exome capture protocol was followed.
Libraries generated using the Rubicon ThruPLEX protocol (as above) were pooled in 3-plex,
with 250 ng input for each library. Libraries underwent two rounds of hybridisation and
capture in accordance with the protocol, with the addition of i5 and i7 blocking oligos (IDT)
as recommended by the manufacturer for compatibility with ThruPLEX libraries. Following
target enrichment, products were amplified with 8 rounds of PCR and purified using AMPure
XP beads prior to QC.
2.16.9 Plasma sequencing data processing
Cutadapt v1.9.1 was used to remove known 5’ and 3’ adaptor sequences specified in a
separate FASTA of adaptor sequences. Trimmed FASTQ files were aligned to the UCSC
hg19 genome using BWA-mem v0.7.13 with a seed length of 19. Error-suppression was
carried out on ThruPLEX Tag-seq library BAM files using CONNOR [67]. The consensus
frequency threshold -f was set as 0.9 (90%), and the minimum family size threshold -s was
varied between 2 and 5 for characterisation of error rates. For custom capture and exome
sequencing data, a minimum family size of 2 was used. For sWGS a minimum family size of
1 was used, i.e. not using molecular barcodes except for where duplicates are present.
To leverage signal across multiple time points, error-suppressed BAM files could be
combined using ‘samtools view -ubS - | samtools sort -‘ prior to further data processing. In
the early-stage melanoma cohort (AVAST-M), where multiple samples were available for the
same patient before 6 months post-surgery, sequencing data for each of the samples were
merged.
2.16.10 Low-depth whole-genome sequencing of plasma
For sWGS, 30 libraries were sequenced per lane of HiSeq 4000, achieving a median of
0.6x deduplicated coverage per sample. For these libraries, since the number of informative
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reads (IR) would limit sensitivity before background errors would become limiting, we used
error-suppression with family size 1 for this particular setting. Error rates per trinucleotide
were compared between WGS and custom hybrid-capture sequencing data for family size 1,
showing a Pearson r of 0.91. WGS data underwent data processing (section 2.17) except the
minimum depth at a locus was set to 1, and patient-specific outlier-suppression (section 2.17)
was not used because loci with signal vs. loci without signal would only give allele fractions
of 0 or 1 given a depth of 0.6x.
2.16.11 INVAR pipeline
The INVAR pipeline takes BAM files (+/- error-suppression with molecular barcodes), a
BED file of patient-specific loci, and a CSV file indicating the tumour allele fraction of each
mutation and which patient it belongs to. The pipeline is shown in Fig. 2.7 and full details
are given in the section 2.17. See ‘Data and materials availability’ for code access.
2.16.12 Imaging
CT imaging was acquired as part of the standard of care from each patient of the stage IV
melanoma cohort and was examined retrospectively. Slice thickness was 5 mm in all cases.
All lesions with a diameter greater than 5 mm were outlined slice by slice on CT images by
an experienced operator, under the guidance of a radiologist, using custom software written
in MATLAB (Mathworks, Natick, MA). The outlines were subsequently imported into the
LIFEx software [120] in NifTI format for processing. Tumour volume was then reported by
LIFEx as an output parameter from its texture-based processing module (Table 2.5).
2.16.13 Data and materials availability
Raw sequencing data will be made available at the European Genome-phenome archive,
accession number EGAS00001002959. The INVAR pipeline will be made publicly accessible
at http://www.bitbucket.org/nrlab/invar.
2.17 Supplementary methods
2.17.1 INVAR data processing
SAMtools mpileup 1.3.1 was used at patient-specific loci based on a BED file of mutations,
with the following settings: –ff UNMAP, –q 40 (mapping quality), –Q 20 (base quality), –x,
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–d 10,000, then multiallelic calls were split using BCFtools 1.3.1. Next, all TSV files were
annotated with 1,000 Genomes SNP data, COSMIC data, and trinucleotide context using a
custom Python script. Output files were then concatenated, compressed, and read into R. First,
based on prior knowledge from tumour sequencing data, all loci were annotated per patient
with being either: patient-specific (present in patient’s tumour) or non-patient-specific (not
present in patient’s tumour, or individual does not have cancer). Data points were excluded
if MQSB < 0.01 (mapping quality / strand bias). Since each non-patient-specific sample
contains the loci from multiple patients, every non-patient-specific sample may control for
all other patients analysed with the same sequencing panel or method (excluding loci that are
shared between individuals).
2.17.2 INVAR data filters I
The following filters were applied to INVAR data:
1. Loci that showed mutant signal in >10% of the non-patient-specific (patient-control)
samples were blacklisted. For custom capture and exome sequencing data, we required
the mean background error rate in each locus to be <1% mutant allele fraction, other-
wise the locus was classed as noisy. The proportion of loci that were blacklisted with
these filters ranged from 0.21%-3.53% (Fig. 2.13D). Patient samples may be used to
characterise the noise per locus (at loci that did not belong to them), since 99.8% of
mutations were private to each patient. Control sample QC data are shown in Table 2.3.
2. Mutation signal had to be represented in both the F and R read of that read pair
(Fig. 2.13C). The resulting error-suppression is analogous to tools that merge paired-
end reads [121].
2.17.3 INVAR data annotation
After data filtering, data was annotated with both locus noise filter and trinucleotide error
rate. Since the locus noise filter is limited by the number of control samples and cfDNA
molecules at that locus, we also assessed trinucleotide error rate. Trinucleotide error rates
were determined from the region up to 10bp either side of every patient-specific locus
(excluding patient-specific locus itself), and data was pooled by trinucleotide context. After
pooling data in this manner, a median of 3.0 x 108 informative reads (or deduplicated
reads) per trinucleotide context were analysed. Trinucleotide error rate was calculated as a
mismatch rate for each specific mutation context. If a trinucleotide context had zero mutant
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deduplicated reads, the error rate was set to the reciprocal of the number of IR/deduplicated
reads in that context.
In addition, each data point was annotated with the cfDNA fragment size of that read
using a custom Python script. Then, to eliminate outlier signal that was not consistent
with the remainder of that patient’s loci, we performed patient-specific outlier suppression
(Fig. 2.15B and C, Fig. 2.14C). The data is now error-suppressed (both by read-collapsing
and bespoke methods for patient-specific sequencing data) and annotated with parameters
required for signal-enrichment (by features of ctDNA sequencing) for the INVAR method.
2.17.4 INVAR data filters II - patient-specific outlier-suppression
Patient-specific sequencing data consists of informative reads at multiple known patient-
specific loci, providing the opportunity to compare mutant allele fractions across loci as a
means of error-suppression. The distribution of signal across loci potentially allows for the
identification of noisy loci not consistent with the overall signal distribution. Each locus was
tested for the probability of having observed mutant reads given the average signal across
all loci (Fig. 2.15B and C, Fig. 2.14C). A locus observed with significantly greater signal
than the remainder of the loci might be attributed to noise at that locus, contamination, or a
mis-genotyped SNP locus. The possibility of a mis-genotyped SNP becomes increasingly
likely when a large number of mutated loci are targeted by INVAR.
For each sample, the IMAF was determined across all loci passing pre-INVAR data
processing filters with mutant allele fraction at that locus of <0.25, similar to that outlined
by Phallen et al. [64], who used a similar threshold, and Abbosh et al. [19], who used a
threshold of 0.20. Loci with signal >0.25 mutant allele fraction were not included in the
calculation because (i) in the residual disease setting, loci would not be expected to have
such high mutant allele fractions (unless they were mis-genotyped SNPs), and (ii) if the
true IMAF of a sample is >0.25, when a large number of loci are tested, they will show a
distribution of allele fractions such that detection is supported by having many low allele
fraction loci with signal.
Based on the ctDNA level of the sample, the binomial probability of observing each
individual locus given the IMAF of that sample was calculated. Loci with a Bonferroni
corrected P-value <0.05 (corrected for the number of loci interrogated) were excluded in that
sample, thereby suppressing outliers. As a result of outlier-suppression, background noise
was reduced to 33% in control samples, while retaining 96.1% of signal in patient samples
(Fig. 2.15C). By correcting the P-value threshold for the number of loci tested, this filter can
be applied to data with a variable number of mutations targeted per patient, enabling analysis
of samples from patients with cancer types with both high and low mutation rates.
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2.17.5 Statistical detection method for INVAR
We developed a statistical method to model the number of mutant reads at multiple patient-
specific loci, incorporating prior information available from patient-specific sequencing,
such as the background error of the trinucleotide context, the tumour allele fraction at the
locus, and fragment length. This approach aggregates signal across multiple patient-specific
mutations following error-suppression. For each locus, we test the significance of the number
of mutant reads given the trinucleotide error rate of that context. Trinucleotide error rates were
used instead of locus-specific error rates in order to determine a more accurate estimation of
background error rates to 10−7 (Fig.2.14A).
Tumour allele fractions and trinucleotide error rates were considered as follows: Denote
AFi as the tumour mutant allele fraction at locus i, ei as the background error in the context of
locus i, and let p be an estimate of ctDNA content in that sample for the INVAR pipeline. A
random read at locus i can be observed to be mutant either if it arose from a mutant molecule,
or an incorrectly sequenced wild type DNA molecule. This occurs with probability qi:
qi = AFi · (1− ei) · p+(1−AFi) · ei · p+ ei · (1− p)
(1)
Testing for the presence of ctDNA is now equivalent to testing the statistical hypothesis
H0: p = 0. Assuming the number of observed mutant reads is independent between loci, the
following likelihood function can be produced:
L(p;M,AF,e) =
n
∏
i=1
Ri
∏
j=1
qMi ji (1−qi)1−Mi j
(2)
where Mi j is the indicator for a mutation in read j of locus i, and Ri is the number of
reads in locus i. The above method allows weighting of signal by tumour allele fraction,
which we confirm influences plasma mutation representation in patient samples with early
stage and advanced disease (Fig. 2.17A), and in the spike-in dilution series from one patient
(Fig. 2.16A).
Each sequencing read provides fragment size information (Fig. 2.16B), which may be
used to separate mutant from wild-type molecules and produce an enrichment in ctDNA
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(Fig. 2.17B). Probability weighing was preferred over size selection to avoid allelic loss at
ultra-low allele fractions, suggested by Fan et al. [12] in the non-invasive prenatal testing
setting. Therefore, read length information can also be incorporated into the likelihood. The
method for read length distribution of mutant and wild-type fragments estimation is given
in section 2.17.9. This approach is in contrast to size-selection and may be considered as a
size-weighting step alongside tumour AF weighting that was performed above. Fragment
sizes for each sequencing read may be incorporated to the INVAR method. To do so, let L ji
be the length of read j at locus i. The likelihood can be written as:
L(p;M,L,AF,e) =
n
∏
i=1
Ri
∏
j=1
P(mi j, li j|e,AF, p)
(3)
Assuming that given the read length and mutation status are independent given the source
of the read (mutant or wild-type DNA), we can factor the likelihood as follows:
L(p;M,L,AF,e) =
n
∏
i=1
Ri
∏
j=1
P(mi j, li j|zi j = 0) ·P(zi j = 0)+P(mi j, li j|zi j = 1) ·P(zi j = 1) =
n
∏
i=1
Ri
∏
j=1
P(mi j|zi j = 0) · p0(li j) · (1− p)+P(mi j|zi j = 1) · p1(li j) · p =
n
∏
i=1
Ri
∏
j=1
emi ji · (1− ei)1−mi j · p0(li j) · (1− p)+g
mi j
i · (1−gi)1−mi j · p1(li j) · p
(4)
where zi j is the indicator that read j of locus i came from ctDNA, pk(li j) = P(li j | zi j = k),
and gi = AFi · (1− ei)+(1−AFi) · ei. The above method weights the signal based on both
fragment length of mutant and wild-type reads, though in this implementation of INVAR, we
set the weight of all wild-type size bins to be equal, thereby neglecting size information from
wild-type reads.
76 Patient-specific ctDNA monitoring from sequencing data
Lastly, a score is generated for each sample through aggregation of signal across all
patient-specific loci in that sample using the Generalised Likelihood Ratio test (GLRT). The
GLRT directly compares the likelihood under the null hypothesis against the likelihood under
the maximum likelihood estimate of p:
λ (p0) =
L(p0;M,L,AF,e)
L(pˆ;M,L,AF,e)
(5)
The higher the value of the likelihood ratio, the greater evidence for ctDNA presence in a
sample. Classification of samples was performed based on comparison of likelihood ratios
between patient and control samples.
2.17.6 Likelihood ratio threshold determination
Other patients were used to control for one another at non-shared loci (Fig. 2.12D). Only
samples run on the same sequencing panel (i.e. same custom sequencing panel design), with
the same error-suppression setting and targeting the same mutation list were used to control
for one another.
In order to determine an accurate threshold for the likelihood ratio (LR) based on controls,
reads from each control sample were iteratively resampled with replacement 10 times, and the
GLRT script was run. To minimise the risk of any patient-specific contamination of signal at
non-patient-specific control loci (through de novo mutations overlapping with patient-specific
sites), only samples with patient-specific IMAF <1% were used as controls for determination
of the cut-point. Control samples were required to have at least as many IR as the patient
sample with the fewest IR in that cohort, otherwise they were excluded.
Based on the LR distribution in patient controls and patient samples, the cut-off for LR
was determined for each cohort using the ‘OptimalCutpoints’ package in R [122], maximising
sensitivity and specificity using the ‘MaxSnSp’ setting. Based on the LRs per cohort, an
analytical specificity was determined for each cohort (Fig. 2.20, Table 2.4).
2.17.7 Assessment of specificity in healthy individuals
26 healthy individuals’ cfDNA from plasma were analysed using the stage IV melanoma
cohort. These samples were treated as ‘patient’ samples, and so had no influence on the
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filters in the pipeline and were not used for the determination of LR thresholds. After deter-
mination of the LR thresholds (described above), the LRs from healthy individuals’ samples
were assessed for false positive detection of ctDNA. For each of the INVAR applications
(custom capture, WES and sWGS), the clinical specificity values in healthy individuals were
determined (Fig. 2.20, Table 2.4).
2.17.8 Estimation of ctDNA content per sample for likelihood ratio de-
termination
In this section we derive an Expectation Maximisation (EM) algorithm to estimate p as part
of the INVAR method. If we treat the tumour of origin zi j as a latent variable, and assume
that it is known, the joint likelihood of Z, M (mi j is the indicator for a mutation in read j of
locus i), L (li j is the length of read j of locus i), AF (AFi is the tumour allele fraction at locus
i), e (ei is the background error in the context of locus i) can be written as:
L(p;Z,M,L,AF,e)
=
n
∏
i=1
Ri
∏
j=1
[eimi j] · p0(li j) · (1− p)]1−zi j
·[gmi ji · (1−AFi) · p1(li j) · p]zi j
Where gi = AFi · (1− ei)+(1−AFi) · ei. The log-likelihood is linear in zi j, so taking the
expectation of the likelihood amounts simply to replacing the zi j with their expectation at
stage l, zli j = E(zi j | mi j, li j, pl), where pl is the best estimate of p at iteration l. We can thus
use EM to find a maximum likelihood estimate for p, by iteratively maximising the likelihood
with respect to p, and taking the expectation of the likelihood with respect to zi j. An estimate
for pl is obtained by taking the derivative with respect to pl and equating it to zero:
pl =
∑ni=1∑
Ri
j=1 z
l
i j
∑ni=1 Ri
The above is simply the expected proportion of reads from ctDNA at stage l. Bayes’
theorem can be used to compute zli j:
zli j = P(zi j = 1|mi j, li j, pl)
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=
P(mi j|zi j = 1) · p1(li j) · p
P(mi j|zi j = 1) · p1(li j) · p+P(mi j|zi j = 0) · p0(li j) · (1− p)) .
By substituting the respective probabilities we obtain:
zli j =
gmi ji (1−gi)1−mi j p1(li j)p
gmi ji (1−gi)1−mi j p1(li j)p+ e
mi j
i (1− ei)1−mi j p0(li j)(1− p)
The algorithm proceeds by alternating the maximisation of p, and the expectation of the
zi j.
2.17.9 Estimation of read length distribution for INVAR
Size-weighting with INVAR depends on first having a known distribution of sizes of mutant
and wild-type reads against which to perform weighting. In order to estimate the read length
distribution with the greatest accuracy, we used all wild type and mutant reads from all
samples in that panel, leaving out the sample being tested (i.e. leave-one-out approach), and
we used kernel density estimation to smooth the respective probabilities.
The size distributions from each of the studied cohorts are shown in Fig. 2.16, and the
enrichment ratios for each size range are shown in Fig. 2.17B. We demonstrated that the
early stage melanoma cohort had a significantly different size profile from the advanced
stage melanoma cohort, which had a significantly greater proportion of di-nucleosomal
fragments despite downsampling of data to a similar number of reads (Fig. 2.16C). Thus, the
fragment length distribution of mutant and wildtype fragments was assessed separately in the
two cohorts, and data was smoothed with a Gaussian kernel with a default setting of 0.25
(Fig. 2.16D).
To estimate the probability that a read is of length l, given that the cell of origin is wild
type, P(L = l | z = 0), we used all of the wild-type reads from each pooled dataset. For both
of the data sets, we used the R function “density”, with a Gaussian kernel, to smooth the
estimated probabilities, and obtained a density estimate fˆ (l | Z = z). Finally, to estimate
P(L = l | z = z), we integrated the respective density:
P(L = l | Z = z) =
∫ l+0.5
l−0.5
fˆ (t | Z = z)dt
Smoothing the size distribution estimates is important in datasets where data is sparse to
avoid assigning too large a weight to any given mutant fragment.
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2.17.10 Calculation of informative reads (IR)
The number of informative reads (IR) for a sample is the product of the number of mutations
targeted (i.e. length of the mutation list) and the number of haploid genomes analysed by
sequencing (hGA, equivalent to the deduplicated coverage following read-collapsing). Thus,
the limit of detection for every sample can be calculated based on 1/IR (with adjustment
for sampling mutant molecules based on binomial probabilities). For non-detected samples,
the 1/IR value provides an estimate for the upper limit of ctDNA in that sample; this allows
quantification of samples even if no mutant molecules are present, and is utilised in Fig. 2.30D
to define the upper confidence limits to ∼10−4 using sWGS data. Also, samples with limited
sensitivity can be identified and classified as a ‘low-sensitivity’ or ‘non-evaluable’ group,
where the INVAR method is limited by the number of IR (Fig. 2.31A). In this study, we
aimed to quantify ctDNA with sensitivity greater than other methods, and classified samples
with non-detected ctDNA with <20,000 IR as low-sensitivity and thus non-evaluable. Across
the cohorts in this study, 4 patients were non-evaluable with these criteria.
2.17.11 Calculation of integrated mutant allele fraction (IMAF)
To quantify ctDNA across multiple mutated loci, we calculated an ‘integrated mutant allele
fraction’, as follows:
• For each trinucleotide context in a sample, the deduplicated depth-weighted mean
allele fraction across all patient-specific loci was calculated
• The background error rate per trinucleotide context in control data was subtracted from
the mean allele fraction calculated in (a). Trinucleotide contexts with negative mutant
allele fraction after subtraction were set to zero.
• The mean background-subtracted allele fraction was taken across the trinucleotide
contexts, weighted by the deduplicated depth in each trinucleotide context.
2.17.12 Experimental spike-in dilution series
Plasma DNA from one patient with a total of 5,073 patient-specific variants was serially
diluted 10-fold each step in a pool of plasma cfDNA from 11 healthy individuals (Seralab) to
give a dilution series spanning 1-100,000x. Library preparation was performed, as described
above, with 50 ng input per dilution. In order to interrogate a sufficiently large number
of molecules in the dilution series to assess sensitivity, the lowest dilution (100,000x) was
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generated in triplicate. The healthy control cfDNA pools were included as control samples for
the determination of locus error rate to identify and exclude potential SNP loci (Fig. 2.19A).
Given the relationship between tumour allele fraction and plasma mutation representation
(Fig. 2.16A), any smaller panel for INVAR should be based on clonal mutations with highest
priority, with lower allele fractions included only if plasma sequencing data is sufficiently
broad. Thus, we iteratively sampled the data with replacement from each of the dilution series
sequencing libraries (with 50 iterations), and then selected the top N mutations (spanning 1
to 5,000 mutations). The locus with the highest mutant allele fraction was the BRAF V600E
mutation. After downsampling the number of loci, outlier-suppression was repeated on all
samples except for the single BRAF V600E locus data (Fig. 2.19B).
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84 Patient-specific ctDNA monitoring from sequencing data
study LR_threshold analytical_specificity specificity fam_size
WES_samples 3.19 96.18% 95.79% 2
MELR 6.62E-07 95.41% 96.74% 2
AVASTM_MERGED 4.43E-01 98.37% NA 2
sWGS_samples 5.96 100% 97.60% 1
Table 2.4 INVAR score thresholds
This table gives details on each of the cohorts, the experimental method performed to generate
data, and the INVAR score threshold used (determined by ROC analysis). LR_threshold,
likelihood ratio threshold used for detection; analytical_specificity, determined using other
patients as control samples; specificity, determined using healthy individuals on the same
panel; fam_size, minimum family size setting used in read-collapsing.
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patient days volume_mL n_lesions TP evaluable
58 0 23.89 1 1 TRUE
58 63 11.37 1 3 TRUE
59 0 4.61 5 1 TRUE
59 75 1.02 5 3 TRUE
59 187 1.30 5 7 TRUE
59 300 5.49 5 11 TRUE
59 406 28.28 7 16 TRUE
59 609 157.49 7 18 TRUE
59 720 307.58 5 22 TRUE
62 0 991.04 4 1 TRUE
62 57 135.87 4 3 TRUE
62 114 120.06 4 6 TRUE
62 169 186.26 4 7 TRUE
62 224 499.19 4 9 TRUE
63 0 0.96 1 1 FALSE
Table 2.5 Tumour volumes for stage IV melanoma cohort (selected indicative rows out
of 34 rows)
This table shows the CT imaging data for stage IV melanoma patients. Patient, number of
patient in the study; days, days since start of treatment; volume_mL, tumour volume in mL;
n_lesions, number of lesions in the patient; TP, timepoint the sample was taken; evaluable,
denotes evaluability of lesion through CT imaging.
Characteristic Stage IV melanoma Stage II-III melanoma
Median age in years (range) 66 (38-66) 58 (23-79)
Gender - male (%) 6 (67%) 17 (45%)
Gender - female (%) 3 (33%) 21 (55%)
Total patients 9 38
Table 2.6 Patient baseline characteristics
Baseline characteristics for each of the patient cohorts in this study are shown.

Chapter 3
Detection of early-stage non-small cell
lung cancers using personalised ctDNA
analysis
3.1 Attribution
This chapter will be written up as a manuscript after handing in the thesis.
3.1.1 Author contributions
Wet lab work
I have carried out all the INVAR related lab work for this chapter, which also included
organising the initial shipment of tissue, plasma and buffy coat samples from Papworth
and Addenbrookes hospital to our lab. I extracted DNA from a total of 125 tissue samples,
each comprising of 10 tissue slides which I macrodissected before extraction. After DNA
extraction I performed DNA repair on samples with sufficient material. I then sonicated all
tissue samples before preparing sequencing libraries from them. Upon successful library
preparation I submitted the majority of tissue libraries for shallow whole genome sequencing
(data not shown here) and captured all tissue libraries with exome bait sets. In parallel,
I performed buffy coat extraction on a subset of the cohort (n=20) and organised for the
remaining samples (n=80) to be extracted by an external collaborator. I sheared the 90 buffy
coat samples of patients who had tissue available and prepared libraries followed by exome
capture. I submitted all tumour and buffy coat captures for whole exome sequencing to
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identify patient specific mutation lists which I then used to design custom capture panels for
the plasma samples.
I organised the extraction of the plasma samples (n=90, coming from 360 aliquots)
through an external collaborator. Upon return of extracted samples I quantified the DNA
with dPCR before preparing libraries for these plasma samples. All samples were captured
with the customised bait sets I designed based on the tumour and buffy coat sequencing.
For the collaboration with Inivata I facilitated the communication with the company
and prepared the required information for the project. I also identified the plasma samples
required for analysis that had to be sent to Inivata and organised their shipment.
Dry lab work
With help from Dineika Chandrananda and James Morries I performed mutation calling on
the tissue and buffy coat whole exome sequencing data. I devised additional filters to remove
remaining artefactual mutations from the original calling set before using the final mutation
lists for the design of custom capture bait sets. Upon return of custom capture sequencing
data from the plasma samples I aligned and collapsed the sequencing data before running the
INVAR pipeline (chapter 2). For the subcohort of samples that was sent to Inivata I analysed
the data returned to us further and compared it to the data I had generated with INVAR.
Writing of the chapter
I wrote the first draft of this chapter and generated all the figures presented here. I received
comments and edits from Jonathan Wan, Irena Hudecova and Mareike Thompson to improve
the chapter.
3.1.2 Funding
I would like to acknowledge the support of The University of Cambridge and Cancer Research
UK (grant numbers A11906, A20240, C2195/A8466, and C9545/A29580). The research
leading to these results has received funding from the European Research Council under the
European Union’s Seventh Framework Programme (FP/2007-2013) / ERC Grant Agreement
n.337905.
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3.2 Aims
The primary objective of this chapter was to apply the tool developed in chapter 2 to an
independent cohort to assess its generalisability. In this chapter I investigate:
1. Whether INVAR can be applied to an independent cohort without major tweaking of
individual parameters.
2. The detection rates in this cohort of samples with low levels of ctDNA and whether
the new method proves advantageous to currently published methods.
3.3 Abstract
Although liquid biopsies have shown sensitive detection of cancer patients with early-stage
disease across a variety of cancer types, detection in lung cancer has proven difficult and was
only assessed in small cohorts. In this paper, we assess ctDNA levels in a large cohort of 100
patients with early-stage non-small cell lung cancer (NSCLC) prior to treatment with curative
intent. The cohort contained 60 patients with stage I disease, allowing us to focus on patients
where ctDNA detection has been challenging previously. Using custom capture sequencing
panels, followed by an Integration of Variant Reads approach, we detected ctDNA in 62%
of all patients, including 47% detection of patients with stage I disease and 81% and 89%
detection for patients with stage II and III disease. ctDNA mutant allele fractions varied
from 1.7x10−5 to 6x10−2 across this cohort, highlighting both the low levels of ctDNA and
the variability in ctDNA fraction in this cancer type. Additionally, detection was superior
in squamous cell carcinoma patients compared to adenocarcinoma patients (75% vs. 53%
detection rate, respectively). To validate our results, we assessed the concordance between
patient-specific mutation analysis and a generic sequencing panel, identifying concordance
in 71% of cases (14 out of 17). Overall, the patient-specific approach was more sensitive on
this subset of patients (detection of 82% vs. 65% for the untargeted approach). Our study
characterises ctDNA in early-stage NSCLC patients using both patient specific and non-
patient specific analysis platforms. Despite using a highly sensitive patient-specific analysis,
still over 50% of early-stage cancers remain undetected, highlighting that ctDNA-based
approaches on its own may not be sufficient in this setting and that using a multi-analyte
analysis may provide a way forward.
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3.4 Introduction
Despite the numerous advances in the field of liquid biopsy over the past decade [8], liquid
biopsies have had limited success in circulating tumour DNA (ctDNA) detection in early-
stage lung cancer. In the published literature, detection rates vary from 37% to 45% in stage
I disease [19, 64, 98] with the exception of one study showing a 100% detection rate for a
small cohort of stage IB non-small cell lung cancer patients (NSCLC) [36]. These studies
use ctDNA to assess patients based on either small panels with patient-specific mutation
information [19] or larger panels utilising cancer-specific mutation information based on
public data sets [36, 64, 98]. In case of the CancerSEEK assay, additional tumour markers
were used to further enhance cancer detection [98].
It is not clear why detection rates for ctDNA are low in early-stage NSCLC. It has
been suggested that this might be due to low disease burden in early-stage, leading to
limited release of ctDNA in the circulation which is not detected given the current sensitivity
limitations of analytical platforms [19, 31]. Alternatively, it is possible that the reduced
detection rates are due to differences in tumour biology in the early stages, whereby only
more aggressive tumour forms are releasing sufficient amounts of DNA to be detected in the
plasma [28].
In this study we assess the detection of ctDNA in 100 early-stage, treatment-naïve NSCLC
patients. Where tumour tissue was available (n=90), we utilised patient-specific sequencing
panels in combination with our previously published INVAR analysis pipeline (Chapter 2).
INVAR utilises large, patient-specific mutation lists in combination with noise reduction
methods, signal-weighting and signal integration in order to detect ctDNA. We also applied
a commercial targeted sequencing assay [123] to samples from 27 patients who underwent
chemo-/radiotherapy treatment, including those patients without tissue (n = 10, Fig. 3.1A).
For both of these methods, ctDNA detection rates were analysed with regards to cancer stage
and histological subtype.
3.5 Main text
A total of 100 treatment naïve patients with stage I – IIIB NSCLC undergoing surgery or
chemo-/radiotherapy were recruited to the LUCID study (REC 14/WM/1072). The cohort
predominantly consisted of stage IA and IB patients (n=60), recruiting only 19 patients with
stage III disease (Fig. 3.1B). The median age of the cohort was 72 years (range: 44–88
years) and 89 (89%) of the recruited patients were current or previous smokers. Tumour
subtype information was available for 82 patients and consisted of 34% (28 out of 82)
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Fig. 3.1 LUCID study design.
(A) Patients were recruited to the LUCID study. Where tumour tissue was available, patient
specific sequencing panels were designed and applied to baseline plasma samples (n=90).
Custom capture sequencing data was analysed using the INVAR pipeline. Where tumour
tissue was unavailable, patients were analysed using the InVisonSeq™ assay (n=10). 17
samples were analysed with both platforms. (B) Stage distribution in the LUCID cohort.
60% of the patients presented with stage I disease. (C) Subtype distribution in the LUCID
cohort.
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squamous cell carcinoma, 57% (47 out of 82) adenocarcinoma and 9% (7 out of 82) other
subtypes (Fig. 3.1C). Patients either underwent surgery (71 out of 100) or radiotherapy ±
chemotherapy (29 out of 100, supplementary table 3.2). For 90 patients, we obtained a tissue
sample (either from surgery or remaining material from the diagnostic biopsy) and used it
to guide our analysis. Plasma samples were obtained before the initiation of treatment, at
each treatment visit (for patients undergoing radiotherapy ± chemotherapy), and during a
nine-month follow up window.
For our tumour-guided analysis of this cohort we used the plasma samples that were
collected at baseline before the initiation of treatment, and analysed them using our previ-
ously published INVAR pipeline (Chapter 2). Additionally, we applied the InVisionSeq™
assay [123] to cases where no tumour tissue was available and a subset of patients analysed
with INVAR.
3.5.1 Mutational landscape in NSCLC
For patients with available tissue we analysed the abundance of commonly mutated lung
cancer genes and mutation signatures. We identified commonly mutated lung cancer genes
from the literature [88, 124] and compared their abundance to the present cohort. The results
are shown in the heatmap in Fig. 3.2. For the two main subtypes of NSCLC in this cohort
(adenocarcinoma and squamous cell carcinoma) TP53 is the most commonly mutated gene
(46%), which agrees with the literature [88, 124]. Compared to the literature we see a
surprisingly large number of KRAS mutations (32%). This can partially be explained by the
subtype distribution in this cohort, which is biased towards adenocarcinomas (table 3.2) [88].
Mutation rates found in NF1 (23%), EGFR (16%), CDKN2A (12%) and BRAF (11%)
are mostly comparable to those indicated in the literature (Fig. 3.2) [88, 124]. As the
landscape of the two main tumour subtypes is quite different, it will be interesting to
associate the observed tumour mutations with the respective subtypes once more detailed
patient information becomes available. For example, KRAS and EGFR seemed more
indicative of adenocarcinoma while CDKN2A is more commonly seen in squamous cell
carcinoma [88, 124].
We also analysed the mutation signatures of the present cohort [125]. Using the decon-
structSigs package [126] and the 26 signatures of mutation processes identified by Alexandrov
and colleagues in 2013 [125], we computed the mutation signatures present in the 90 patients
with available tissue data (Fig. 3.3). Signature 1A was most abundant in this cohort (82%). As
described by Alexandrov and others, signature 1 is seen across all cancer types and is thought
to be associated with ageing [125]. Given that the patients in this study were diagnosed at
a median age of 72 (table 3.1), the high abundance of signature 1 is not surprising. The
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second most frequently observed mutation signature is signature 4 (76%, Fig. 3.3), which is
associated with the smoking of tobacco [125]. In this lung cancer cohort 90% of patients
are current or previous smokers (table 3.1), which is a common observation in lung cancer
cohorts and explains the abundance of signature 4. Apart from these two common signatures,
the remaining signatures are observed in only few patients in this cohort and have not been
previously associated with lung cancer [125].
3.5.2 Detection using the patient-specific INVAR pipeline
Whole exome sequencing information from the tumour and matched buffy coat was available
for 90 of the 100 patients and yielded a median of 345.5 mutations per patient (IQR 213
to 515), which were used to design a total of three patient-specific hybrid-capture panels
to cover all 90 patients. Sequencing panels were applied to baseline plasma samples from
these 90 patients, and INVAR analysis was performed (Chapter 2). In this cohort, 99.8%
of mutations were private, allowing patient samples to serve as controls for one another
(Chapter 2). Signal was error suppressed on a cohort and sample basis and additionally
weighted by both fragment length and corresponding tumour allelic fraction (Fig. 3.4A and B,
Chapter 2). As tumour allelic fraction always also depends on tumour purity, one could think
about adding an additional tumour purity feature to the INVAR pipeline or rely on cancer
cell fractions instead of tumour allele fractions. For the present cohort this information was
only available for just over 50% of samples and could, therefore, not be implemented. For
samples with available information, a median of 20% estimated tumour purity was observed
(IQR 0.1 - 0.3).
Detection limits were determined using receiver operating characteristic (ROC) curves
and a sensitivity threshold of at least 95% was set (median=96.15%) on each of the three
sequencing panels (Fig. 3.5A), detecting 62.2% (56 out of 90) of patients (see Supplementary
table 3.7). Applying the same detection thresholds to sets of healthy controls that were run
on the same panels, we observed a mean specificity of 95.84% (Fig. 3.5A). The patients
with detectable levels of ctDNA had signal in a median of 2.6% of the initially targeted
patient specific mutations (IQR 0.7% - 24.7%). As the majority of identified mutations
were private to each patient, this minimal signal would have likely been missed with a
generic panel or hotspot assay. Using the INVAR pipeline, we generated a median of 80,460
informative sequencing reads (IR) at patient-specific loci (IQR 42,030- 149,000). The number
of IR guide in the estimation of the sensitivity limit in each sample (roughly 1/IR). In this
cohort, 4 samples yielded less than 20,000 IR, limiting our ability to detect ctDNA below
levels of 5x10−5 (Fig. 3.5B). Additionally, the INVAR pipeline can infer the total cancer
genomes in the circulation at the time of blood draw by dividing the total number of unique
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Fig. 3.2 Commonly mutated lung cancer genes.
Commonly mutated lung cancer genes were identified from Collisson et al. and Hammerman
et al. [88, 124]. Abundance of mutations in these genes was determined in the present cohort
where tumour tissue was available (n=90 patients). Boxes are highlighted in green for the
presence of mutations in a given gene and patient.
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Fig. 3.3 Mutation signatures in lung cancer.
Mutation signatures were obtained using deconstructSigs [126] and are shown for the 90
patients in this study where tissue data was available. Boxes are highlighted in green for
signatures present in the mutation data of a given patient.
96 Detection of early-stage non-small cell lung cancers using personalised ctDNA analysis
Fig. 3.4 INVAR feature analysis in NSCLC.
(A) Fragment length enrichment ratios in cohort. Enrichment ratios were used to weight
mutant fragments by their fragment length. (B) Comparison of tumour allelic fractions of
observed and not observed plasma mutations. In patient specific samples, mutations seen in
the plasma come from tumour mutations with a higher allelic fraction. This was not observed
in control samples (Wilcox-test, p<2x10−16 vs 1).
mutated molecules with the total unique number of cfDNA molecules (Chapter 2). For the
56 samples with detected ctDNA from INVAR we observe a median cancer genome fraction
of 0.074 (IQR 0.016 to 0.99) (Fig. 3.5C), highlighting the low levels of disease burden in the
circulation in our early-stage cohort.
3.5.3 Detection of ctDNA using the InVisionSeq™ assay
Next, we applied the Inivata InVisionSeq™ assay [123] to 27 of the 100 patients, which were
part of the chemo-/radiotherapy cohort. Ten of these had no tumour tissue available, rendering
them ineligible for a patient-specific approach. The remaining 17 patients were chosen to
compare ctDNA detection between INVAR and the InVisionSeq™ assay. The InVisionSeq™
assay analyses single nucleotide variants, copy number variants and insertions and deletions
in regions from 36 selected cancer related genes, covering 10.61kb in total [127]. Based
on the original TAm-Seq method [35], this enhanced TAm-Seq (eTAm-Seq™) technology
uses 72bp-154bp long amplicons in a two-step multiplex PCR amplification to prepare
sequencing libraries [127]. In a validation study across two laboratories Inivata could show
94% sensitivity and 99.99% specificity for mutations with allelic fractions ranging from
0.25% to 0.33% and could detect AFs as low as 0.02%[127].
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Fig. 3.5 INVAR pipeline analysis in NSCLC.
(A) Specificities for the three custom capture sequencing panels in this study. Specificities
were assessed twice. Once using the other patients as controls and once using an independent
set of healthy controls. (B) Informative Reads (IR) are plotted against Integrated Mutant
Allele Fraction (IMAF). Sensitivity of the INVAR pipeline increases with increasing IR and
can be roughly estimated as 1/IR (indicated by dashed diagonal line). Samples with less
than 20,000IR (dark grey box) allow only for limited detection while samples with more
than 1,000,000 IR (indicated by orange box) would allow for highly sensitive detection of
ctDNA. Samples that pass the sensitivity threshold are shown in green. (C) Cancer genomes
in the circulation. The total proportion of cancer genomes in the circulation was estimated
for patients with detected levels of ctDNA.
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Using a median input of 3.7mL of plasma (3.2mL – 4mL) and a median of 7,240 DNA
copies (2,720 – 16,000), this non-patient-specific approach initially detected ctDNA in 17
of 27 patients in the present study. For 12 of these 17 patients matching tumour and buffy
coat data was available. In one case this led to the reclassification of a mutation to a SNP
(signal observed in the buffy coat), yielding a false positive rate of 8.3%. No tumour tissue
was available for the other five detected patients. Overall, the InVisionSeq™ assay detected
ctDNA in 16 of 27 patients (59%) with a mean of 1.67 alterations per patient and a total of
27 mutations across the cohort (Supplementary tables 3.3, 3.4, 3.5, and 3.7). 18 of these
calls (66.7%) were below an allelic fraction of 0.01 and 12 (44.4%) were below an allelic
fraction of 0.005, highlighting again the low levels of ctDNA in the early-stage setting. The
majority of patients had alterations in TP53 (37%), followed by alterations in KRAS (22%),
STK11 (11%), CDKN2A (11%), PTEN (4%), NFE2L2 (4%), KIT (4%) and PIK3CA (4%)
(Fig. 3.6A). The performance of the InVisionSeq™ assay was best for stage III patients,
reaching a detection of 73% (11 out of 15) (Supplementary tables 3.3, 3.4, 3.5). Detection
decreases to 50% (3 out of 6) in stage II patients and 33% (2 out of 6) in stage I patients.
17 out of the 27 patients analysed with the InVisionSeq™ assay were also analysed with
the INVAR pipeline as they had tumour tissue available and qualified for a patient specific
analysis approach. 10 of the 17 cases (59%) were detected and two cases (12%) were not
detected with both platforms, leading to a concordance between the two platforms of 71%
(Fig. 3.6B). When comparing the ctDNA fractions of the detected cases between the two
methods we observe a correlation of 0.87 (Pearson’s r, p = 0.001, Fig. 3.6C). Out of the
remaining discordant samples (n=5), four were only detected with the patient-specific INVAR
pipeline but missed with the untargeted InVisionSeq™ assay (Fig. 3.6B). Interestingly, there
was one case detected with the InVisionSeq™ assay but missed by the INVAR pipeline
(Fig. 3.6B). This case had only 43 patient-specific mutations identified by whole exome
sequencing, limiting the potential sensitivity of INVAR which was developed to target
hundreds to thousands of mutations, thereby maximising the overall sensitivity in a given
sample. This highlights that if only few patient specific mutations are available, a patient
specific amplicon-based or even untargeted analysis approach might be preferred based on
assay cost and time constraints.
3.5.4 Overall detection rates in NSCLC
62 of the 100 patients were detected positive at baseline (62%). When split up by stage, we
observe detection rates of 47% for stage I, 81% for stage II and 89% for stage III patients
(Fig. 3.6D). Similar to previous reports on ctDNA detection in NSCLC, we see the highest
detection rates for the advanced stage patients and observe similar or higher detection rates
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Fig. 3.6 InVisionSeq™ assay analysis in NSCLC.
(A) A total of 27 mutations were identified; most alterations were identified in TP53 (37%
of samples, after removing the false positive call), followed by KRAS (22%). Matched
tissue data confirmed 70% (14/20) of these calls. (B) Comparison between INVAR and
InVisionSeq™. Sensitivity of INVAR alone was 62% (56/90) and InVisionSeq™ detected
ctDNA in 59% (16/27). 17 samples were analysed with both platforms with a concordance
in ctDNA detection of 71% (12/17, 10 samples detected and two samples undetected with
both platforms). (C) ctDNA correlation between INVAR and InVisionSeq™. 10 samples
were detected with both platforms; yielding a correlation in ctDNA AF of 0.87 (Pearson’s
r, p = 0.001). (D) In total, ctDNA was detected in 62 of 100 samples. Detection rates are
reported by stage in the inserted table.
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compared to other reports [19, 36, 64, 98]. In this cohort, we quantified ctDNA down to a
mutant allele fraction of 1.7x10−5. Overall, the median detected allelic fraction across all
stages was 3.9x10−4 (IQR 7.2x10−5 to 3.7x10−3, Fig. 3.6D, Supplementary table 3.7).
Histological subtype information was available for 82 of the 100 patients. Similar to a
previous report [19], we also observed higher detection rates in squamous cell carcinoma
than in adenocarcinoma, with detection of 75% (21 out of 28), and 53% (25 out of 47), re-
spectively. We also detected 71% (5 out of 7) of patients with other subtypes (Supplementary
table 3.6). We observed a lower mean ctDNA fraction in adenocarcinoma patients (0.003)
compared to squamous cell carcinoma patients (0.006) and patients with other subtypes
(0.011, Supplementary table 3.6).
3.6 Discussion
Characterisation of the present cohort of early stage NSCLC patients revealed the presence of
previously identified commonly mutated genes and signatures for lung cancer. TP53, KRAS
and NF1 were the most commonly mutated genes in this cohort, concordant with previous
findings [88, 124]. Similar to previously published literature we observe an abundance of
the ageing related signature 1 and smoking related signature 4 in this cohort [125]. Once
unblinded to patient demographics, these can be correlated with patient age and smoking
status. For some of the patients in this cohort samples from multiple tumour regions were
available. This could allow for analysis of tumour clonality, which in turn could be developed
as an additional feature of signal weighting for the INVAR piepline. Unfortunately, no
information on the location of the regions and their respective distances to each other were
available for this cohort, prohibiting such an analysis.
We and others have shown that the use of patient-specific mutation assays can improve
sensitivity and yield improved ctDNA detection [19, 35, 36]. In this study, we have applied
both, patient-specific and targeted mutation assays to members of a cohort of 100 stage I –
IIIB NSCLC patients. The INVAR pipeline, utilising large lists of patient-specific mutation
lists combined with signal weighting and integration to detect ctDNA, detected 62.2% (56
out of 90) of patients, reaching over 85% (34 out of 40) detection levels for patients with
stage II disease and above. For patients with stage I disease INVAR detected 45% of patients.
Part of this cohort was analysed using the targeted InVisionSeq™ assay where detection
levels by stage were lower. When comparing the two platforms, 23% (4 out of 17) of patients
were only detected by INVAR and one patient was only detected with the InVisionSeq™.
Taken together, the two platforms would have detected 88% (15 out of 17) of all patients,
highlighting the power of multiple testing approaches to improve overall detection.
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However, there are still cases being missed, requiring an even more sensitive platform.
INVAR could achieve greater sensitivity by targeting more patient specific mutations (for
example identified by whole genome sequencing of the tumour) or analysing larger plasma
volumes. Recent reports have indicated the use of either a combination of multiple tumour
markers or patient-specific platforms to increase the overall detection in a cohort compared to
targeted or untargeted mutation assay approaches [8, 128, 129]. One example of combining
multiple markers is the CancerSEEK assay. Using just the ctDNA assay, detection was at 22%
but was increased to 59% (more than 2.5-fold increase) when considering other blood-based
tumour markers [98]. Especially for patients with stage I disease, detection rates changed
10-fold from 4.3% to 43% when adding additional markers [98]. The CancerSEEK assay is
one example highlighting how combining multiple cancer markers can substantially increase
the chances of cancer detection and might set the standard for future ctDNA based assays.
3.7 Methods
3.7.1 Patient cohort
Samples were collected from patients enrolled on the LUCID (REC 14/WM/1072) study, a
prospective and observational study on patients with stage I – IIIB non-small cell lung cancer
(NSCLC) undergoing treatment (either surgery or radio- +/- chemotherapy) with curative
intent. The primary endpoint of the study investigates the detection rates and levels of ctDNA
at baseline in early-stage NSCLC. Patients were consented by a research/specialist nurse or
clinician. The study was coordinated by the Cambridge Cancer Trials Unit-Cancer Theme,
which also prospectively collected patient demographics and clinical outcomes. An overview
of all patient demographics is given in supplementary tables 3.1 and 3.2.
3.7.2 Sample collection and processing
Tissue samples were obtained either from surgical specimens or diagnostic biopsies and
processed as FFPE tissue. The tissue was sectioned in 8 µm sections with one slide set aside
for H&E staining to guide tumour extraction. Plasma samples were collected before treatment
initiation (at baseline). Additional plasma samples were collected to be analysed in the future.
These included samples during treatment (for chemo-/radiotherapy cohort), after surgery
(for surgical cohort), in three-month intervals for nine months following the completion
of treatment and, if possible, at relapse. For all plasma time-points, peripheral blood was
collected in S-Monovette 9mL EDTA tubes. Within an hour of blood draw, samples were
centrifuged at 1,600g for 10 minutes before undergoing another centrifugation at 20,000g
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for 10 minutes. Plasma was then stored at -80°C. A buffy coat sample was collected at the
beginning of treatment.
3.7.3 Sample extraction
For FFPE samples, the stained H&E slide was used to identify regions of high tumour cellu-
larity, which were then macro dissected from the other tissue slides. Samples were extracted
using the QIAmp FFPE Tissue Kit (Qiagen) according to manufacturer’s instructions with
the following modifications: DNA was incubated at 56°C and 500rpm over-night and elution
was carried out by applying 20 µL to the membrane twice. FFPE repair was carried out for
samples containing more than 800 ng of DNA using the NEBNext® FFPE DNA Repair Mix
(New England Biolabs) according to the manufacturer’s instructions.
Buffy coat samples were extracted from up to 1 mL either manually or using the QI-
Asymphony platform (Qiagen). Samples were eluted in 70 µL (manual extraction) or up to
200 µL (QIAsymphony). For plasma extraction, 2-4 mL of the sample were extracted using
the QIAsymphony platform with the QIAmp protocol. 24 samples were extracted in each
batch, including a positive and negative control to monitor extraction efficiency. FFPE and
genomic DNA were quantified using a dsDNA broad range assay on the Qubit fluorimeter
(ThermoFisher Scientific). Plasma samples were quantified using a digital PCR with 55
cycles on a Biomark HD (Fluidigm) with a Taq-man probe against a 65bp region of the
RPP30 gene (Sigma Aldrich) [35].
3.7.4 Library preparation
Using the Covaris LE220 (Covaris) according to manufacturer’s instructions, tumour and
buffy coat DNA were first sheared to a fragment length of 200 bp.15 µL volumes and the 8
microTUBE-15 AFA Beads Strip V2 were used and fragmentation patterns were randomly
validated using a Bioanalyser (Agilent). A total of 100 ng (tumour) and 50 ng (buffy coat) of
sheared DNA were used for library preparation with the ThruPLEX DNA-seq kit (Rubicon).
The number of library cycles was adjusted to the sample input based on the manufacturer’s
recommendations.
Up to 15 ng of plasma DNA were used for library preparation with the ThruPLEX
Tag-seq (Rubicon) or SureSelect XTHS kit (Agilent). Depending on the input the number of
amplification cycles was varied according to the recommendations from the manufacturers.
After all library preparations, qPCR (NEBNext® Library Quant Kit for Illumina® in the ROX
low setting, New England Biolabs) and Bioanalyser or TapeStation (both Agilent) were used
to determine library concentration and size.
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3.7.5 Exome capture of tumour and buffy coat samples
The Illumina TruSeq kit with a 45 Mbp bait set (Illumina) was used for the exome capture
of tumour and buffy coat samples after library preparation. Keeping tumour and buffy coat
DNA separate, 250 ng of each library were multiplexed in three-plex reactions. To ensure
compatibility with the ThruPLEX libraries, 1µL of i5 and i7 TruSeq HT xGen universal
blocking oligos (IDT) were added at the hybridisation step and the volume of CT3 buffer
was adjusted to 51 µL. Samples underwent two rounds of hybridisation, each lasting for 24
hours. After exome capture, sample QC was performed as described above and sequencing
was carried out using a HiSeq4000 (Illumina).
3.7.6 Mutation calling in tumour tissue
Tumour mutation calling was carried out in two batches. For the first batch of FFPE tumour
biopsies, mutation calling was performed with Mutect2 with the default settings: –cosmic
v77/cosmic.vcf and –dbsnp v147/dbsnp.vcf. To maximise the number of mutations retained,
all variants achieving Mutect2 pass were retained. Mutation calls were then filtered as
follows:
1. Buffy coat mutant allele fraction equals zero
2. Mutation not in homologous region
3. Mutation not at a multiallelic locus
4. 1000 Genomes ALL and EUR frequency equals zero
5. A minimum unique tumour depth of 5.
For the second batch, mutations were identified using MuTect2, VarDict and Freebayes.
The same filters as described above were applied to this cohort. In addition to retaining
mutations passing MuTect2, mutations identified by both Freebayes and VarDict were also
retained, thereby increasing our total number of targetable mutations. In some cases, multiple
tumour regions were available for the same patient so mutation calling was carried out on the
individual tumour regions as well as from the merged bam files of both regions.
3.7.7 Design of hybrid-custom capture panel and plasma capture
Following mutation calling, custom capture panels were designed using the SureDesign
software (Agilent). Mutation lists of 19 to 35 patients were combined per capture panel and
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a 1x tiling density and balanced boosting were used. 120 bp RNA baits were used for the
panels, which varied in size from 2.138Mbp to 2.987Mbp. Mutation lists for each panel are
shown in Supplementary table 3.8.
Plasma libraries were captured in singleplex or two-plex using 1000 ng of total input.
SureSelect XT and SureSelect XTHS captures were carried out according to the manufac-
turer’s instructions. For ThruPLEX Tag-Seq libraries, i5 and i7 blocking oligos (IDT) were
added based on the manufacturer’s recommendations [130]. Captures underwent 13 cycles
of post-capture amplification and underwent the same QC as described above. Samples were
sequenced on the HiSeq4000 platform (Illumina).
3.7.8 Read collapsing on plasma sequencing data
Known 5’ and 3’ adapter sequences were specified in a separate FASTA file and removed
using Cutadapt v1.9.1. Using BWA-mem v0.7.13 with a seed length of 19, the trimmed
FASTQ files were aligned to the UCSC hg19 genome. For ThruPLEX Tag-Seq libraries, read
collapsing was carried out using CONNOR [67] with a consensus threshold of 90% (-f flag
of 0.9) and a minimum family size of 2 (-s flag of 2). SureSelect XTHS libraries underwent
read collapsing using the Agilent Genomics NextGen Toolkit (AGeNT) with a minimum
family size of 2 [69].
3.7.9 Plasma analysis using INVAR pipeline
Plasma custom-capture sequencing data was analysed using the INVAR pipeline, which was
developed previously (Chapter 2).
3.7.10 Plasma analysis using the InVisionSeq™ assay
Up to 4mL of plasma were sent to Inivata, where samples were extracted and analysed using
the InVisionSeq™ assay [123]. The essay utilises the eTAm-Seq™ technology, which is
based on the previously developed TAm-Seq method[35]. Sequencing libraries are prepared
using a two-step PCR amplification with amplicons (72bp-154bp in length) covering 10.61kb
across 36 cancer related genes. Upon analysis, data was returned to us for further exploration.
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Variable: n/N(%) Total
Age
Total patients 100
Mean (Standard deviation) 71 (8)
Median (Minimum, Maximum) 72 (44, 88)
Inter-quartile range 66, 76
Age group
<50 2/100(2)
50-59 years 8/100(8)
60-69 years 31/100(31)
70-74 years 20/100(20)
75 plus years 39/100(39)
Sex
Female 49/100(49)
Male 51/100(51)
Smoking status
Never smoked 10/99(10.1)
Ex-smoker 67/99(67.7)
Current smoker 22/99(22.2)
Number of years smoked
(for ex-and-current smokers)
Number 88
Mean (Standard deviation) 38 (16)
Median (Minimum, Maximum) 40 (1, 71)
Inter-quartile range 25, 50
Number of years quit smoking
(ex-smokers only)
Number 67
Mean (Standard deviation) 18 (15)
Median (Minimum, Maximum) 14 (0, 51)
Inter-quartile range 3, 32
Table 3.1 Summary of demographic variables and smoking history. n-Number of pa-
tients; N-Total number of patients; %-Percentage of patients; SD-Standard deviation; Min-
Minimum; Max-Maximum.
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Variable n/N (%)
Disease stage at diagnosis
IA 33/100(33)
IB 27/100(27)
IIA 11/100(11)
IIB 10/100(10)
IIIA 16/100(16)
IIIB 3/100(3)
Treatment plan for patients
Surgical 71/100(71)
Non-surgical 29/100(29)
Tumour subtype
Squamous cell carcinoma 28/82(34.1)
Adenocarcinoma 47/82(57.3)
Large cell carcinoma 0
Other 7/82(8.5)
Table 3.2 Summary of radiological/pathological history. n-Number of patients; N-Total
number of patients; %-Percentage of patients.
Variable Numbern/N
ctDNA detection rate
(95% CI)†
Disease stage at diagnosis
IA 15/33 0.45 (0.28 to 0.64)
IB 13/27 0.48 (0.29 to 0.68)
IIA 9/11 0.82 (0.48 to 0.98)
IIB 8/10 0.80 (0.44 to 0.97)
IIIA 14/16 0.88 (0.62 to 0.98)
IIIB 3/3 1.00 (0.29 to 1.00)
Tumour subtype
Squamous cell carcinoma 21/28 0.75 (0.55 to 0.89)
Adenocarcinoma 25/47 0.53 (0.38 to 0.68)
Large cell carcinoma 0 0
Other 5/7 0.71 (0.29 to 0.96)
Summary Overall 62/100 0.62 (0.52 to 0.72)
Table 3.3 ctDNA detection summary full LUCID cohort. CI – Confidence Interval; † -
Clopper-Pearson confidence interval.
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Variable Numbern/N
ctDNA detection rate
(95% CI)†
Disease stage at diagnosis
IA 1/3 0.33 (0.01 to 0.91)
IB 1/3 0.33 (0.01 to 0.91)
IIA 2/4 0.50 (0.07 to 0.93)
IIB 1/2 0.50 (0.01 to 0.99)
IIIA 8/12 0.67 (0.35 to 0.90)
IIIB 3/3 1.00 (0.29 to 1.00)
Tumour subtype
Squamous cell carcinoma 3/6 0.50 (0.12 to 0.88)
Adenocarcinoma 5/10 0.50 (0.19 to 0.81)
Large cell carcinoma 0 0
Other 4/4 1.00 (0.40 to 1.00)
Summary Overall 16/27 0.59 (0.39 to 0.78)
Table 3.6 ctDNA detection summary LUCID sub-cohort analysed with the InVision-
Seq™ assay. CI – Confidence Interval; † - Clopper-Pearson confidence interval.
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Chr Position Ref Alt Gene Depth AF Patient Mut class
chr17 72341041 G C KIF19 140 0.07 1032 G/C
chr2 166747053 G C TTC21B 125 0.19 1022 G/C
chr3 100949948 A G IMPG2 138 0.20 1024 A/G
chr2 141665427 C A LRP1B 39 0.05 1023 C/A
chr7 140287448 T C DENND2A 57 0.32 1026 T/C
chr1 80916992 C A HNRNPA1P64 142 0.07 1023 C/A
chr2 179412560 A T TTN 107 0.38 1026 A/T
chr1 157737268 C A FCRL2 184 0.24 1012 C/A
chr2 24261216 T C C2orf44 118 0.10 1032 T/C
chr22 25053485 G A POM121L10P 64 0.25 1017 G/A
chr8 100821666 A G VPS13B 258 0.09 1026 A/G
chr2 189917652 C G COL5A2 58 0.40 1012 C/G
chr3 62306099 G A C3orf14 98 0.11 1026 G/A
Table 3.8 LUCID patient-specific mutation lists (selected indicative rows out of 38853
rows)
This table contains all patient-specific mutation lists for patients in the LUCID study. Muta-
tion positions are given using the hg19 genome build. For each mutation the chromosome,
position and reference and alternate allele are given. Additionally, the gene name, tumour
depth and allelic fraction, patient name and mutation class are also listed.
Chapter 4
Detection of ctDNA from dried blood
spots after DNA size selection
4.1 Attribution
This chapter is adapted from a manuscript, which was submitted to bioRxiv in September
2019:
“Detection of ctDNA from dried blood spots after DNA size selection”
Katrin Heider∗, Jonathan C. M. Wan∗,..., Nitzan Rosenfeld§
∗ Equally contributing authors
§ Corresponding author
4.1.1 Author contributions
K.H., J.C.M.W. and N.R. wrote the manuscript. K.H. and J.C.M.W. carried out the experi-
ments and data analysis. J.H. and S.B. generated and prepared the animal model. I.H. and
W.N.C. helped in designing the study. P.G.C., N.R. and D.G. led and coordinated work on
the MelResist study from which the human blood spot was used. C.G.S., J.D.B. and N.R.
supervised the project.
Wet lab work
Jonathan and I jointly developed the concept for blood spot collection, extraction and size
selection. The preparation of each blood spot sample requires four steps: the blood spot has
to be generated, extracted, size selected with magnetic beads and a library has to be prepared
before submission for sequencing. After the extraction and bead selection we would also
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perform a bioanalyser to confirm the removal of contaminating genomic DNA. The initial
experiments to optimise the protocol (n = 10 blood spots) were carried out together. The
later experiments to generate the data presented here were carried out by myself (n = 2 blood
spots). The plasma and tumour shallow whole genome sequencing data of the melanoma
patient presented in this chapter were prepared by Jonathan as part of chapter 2. The data of
the ascites and engrafted tumour of the xenograft sample were generated by the Brenton lab.
Dry lab work
I devised the analysis pipeline for both, the xenograft and human blood spot data. For the
xenograft data I identified Xenomapper [131] as a suitable package to differentiate between
human and mouse reads and wrote a wrapper around it. For both the human and xenograft
data I identified ichorCNA [75] as a tool to visualise copy number changes as a means to
report the presence of ctDNA and wrote a wrapper around the publicly available code. I
also analysed the plasma and tissue data (generated by Jonathan and the Brenton lab) with
ichorCNA. Furthermore, I analysed and plotted the fragment patterns for the human blood
spot as well as the copy number similarities between blood spot and matched plasma data
presented in this chapter.
Writing of the manuscript
The first draft of the manuscript was written by me and I prepared all the figures presented in
this chapter. After an initial draft, Jonathan and I worked jointly on improving the manuscript
and communicated with Nitzan for further guidance. I then converted the manuscript into the
chapter presented here, altering the figures and text where needed.
4.1.2 Acknowledgements
The authors would like to thank Catherine Thorbinson, Emily Barker and Alex Azevedo
from the MelResist study group and the Cambridge Cancer Trials Centre, Addenbrookes
Hospital, Cambridge. We also thank Carolin Sauer for acquisition of mouse samples and
preparation of sequencing data.
4.1.3 Competing interests
N.R., J.D.B. and D.G. are co-founders, shareholders and officers or consultants of Inivata
Ltd, a cancer genomics company that commercialises ctDNA analysis. Inivata had no role
in the conceptualisation, study design, data collection and analysis, decision to publish or
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preparation of the manuscript. Cancer Research UK has filed patent applications protecting
methods described in this manuscript.
4.1.4 Funding
We would like to acknowledge the support of The University of Cambridge and Cancer
Research UK (grant numbers A11906, A20240, C2195/A8466, and C9545/A29580). The
research leading to these results has received funding from the European Research Council
under the European Union’s Seventh Framework Programme (FP/2007-2013) / ERC Grant
Agreement n.337905.
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4.2 Aims
The primary objective of this chapter was to develop a method for easier collection and
storage of blood samples to allow less well equipped centres to participate in research studies.
Together with Jonathan Wan I established a method:
1. Which allows blood samples to be stored longer term without hampering the quality of
cfDNA for downstream analysis.
2. Which can process whole blood samples by removing the genomic DNA proportion
and retaining the cfDNA proportion of interest.
3. For the analysis of ctDNA from as little as a single drop of blood by analysing changes
in copy number in both human and xenograft samples.
4. To analyse the similarities between blood spot and plasma or tumour based sequencing
data.
4.3 Abstract
Recent advances in the research and clinical applications of circulating tumour DNA (ctDNA)
is limited by practical considerations of sample collection. Whole genome sequencing (WGS)
is increasingly used for analysis of ctDNA, identifying copy-number alterations, fragment
size patterns, and other genomic features. We hypothesised that low-depth WGS data may be
generated from minute amounts of cfDNA, and that fragment-size selection may be effective
to remove contaminating genomic DNA (gDNA) from small volumes of blood. There are
practical advantages to using dried blood spots as these are easier to collect, facilitate serial
sampling, and support novel study designs. Novel designs include the utilisation of archival
samples by the removal of gDNA in small volumes, prospective human studies and studies
based on animal models. We therefore developed a protocol for the isolation and analysis of
cell-free DNA from dried blood spots. Analysing a dried blood spot of 50 µL frozen whole
blood from a patient with melanoma, we identified ctDNA based on tumour-specific somatic
copy-number alterations, and found a fragment size profile similar to that observed in plasma
DNA processed by traditional methods. We extended this approach to detect tumour-derived
cell-free DNA in a dried blood spot from a mouse xenograft model and were able to identify
ctDNA from the originally grafted ascites. Together, our data suggests that ctDNA can be
detected and monitored in dried blood spots. This will enable new approaches for sample
collection from patients and in vivo models.
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4.4 Introduction
Circulating tumour DNA (ctDNA) can be used to sensitively detect and quantify disease
burden using a variety of sequencing based approaches [8]. For example, using shallow
whole genome sequencing (sWGS), ctDNA can be detected down to mutant allele fractions
of ∼3% through analysis of somatic copy-number alterations (SCNAs)[75, 77]. Alterna-
tively, leveraging differences in fragment size between tumour-derived and non-tumour
cell-free DNA molecules (cfDNA) can enhance the detection of genomic alterations and
the identification of plasma samples from patients with cancer compared to healthy indi-
viduals [27, 132]. Although sWGS generates data on only a fraction of a single genome
(0.3 genome equivalents correspond to ∼1 pg DNA), sequencing libraries for sWGS have
traditionally been generated from larger amounts of cfDNA extracted from millilitre volumes
of plasma from a venous blood samples [77]. Established protocols for collection of plasma
for ctDNA analysis require prompt spinning of EDTA-containing tubes or delayed spinning
of tubes containing cell preservatives/fixatives [133]. However, this processing restriction
poses practical limitations on possible clinical study designs, especially in the context of
serial sampling.
The use of limited blood volumes and dried blood spots for analysis of cfDNA may
facilitate new trial designs, widen clinical applications, and enable point-of-care testing
and self-collection of samples. Additionally, analysis of minute amounts of blood may
facilitate longitudinal ctDNA monitoring from animal models with limited circulating blood
volume. In prenatal diagnostics, polymerase chain reaction (PCR) has been used to carry
out fetal RHD genotyping and HIV detection using maternal dried blood spots [99, 100]. In
applications to cancer, ctDNA from a limited plasma volume was previously analysed in a
study of a mouse xenograft model, where quantitative PCR was used to measure the human
long interspersed nuclear element-1 (hLINE-1) as a measure of tumour burden [102]. In
another pilot study in breast cancer patients, whole genome amplification was performed on
blood obtained from a finger prick. They found comparable allelic frequencies in somatic
mutations between the finger prick sample and matched venous blood [101]. Sensitive
detection of ctDNA from limited volumes or blood spots represents a technical challenge
due to the limited total number of mutant molecules. Whole blood samples are considered
inferior to carefully-collected plasma samples due to the presence of contaminating genomic
DNA (gDNA) from lysed white cells in whole blood [8, 134], which dilutes tumour-derived
ctDNA signal. In this study, we present methods for cfDNA extraction from dried blood
spots and the subsequent analysis and detection of ctDNA.
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4.5 Results
We sought to assess the number of cfDNA genome copies that can be sequenced from a
single blood drop or dried blood spot. Based on previous reports, the median concentration of
cfDNA is approximately 1600 amplifiable copies per mL of blood for patients with advanced
cancer [64, 135]. This translates to approximately 80 copies of the genome as cfDNA in a
blood drop/spot of 50 µL. Assuming a yield in the range of ∼60%-80% in DNA extraction
and efficiency of ∼15%-40% in generating a sequencing library, this is estimated to result in
approximately 7x-25x representation of the genome in sequencing libraries prepared from
cfDNA from a single blood drop. We therefore hypothesised that low-depth WGS of cfDNA
can be attainable from a dried blood spot after removal of genomic DNA.
To test this hypothesis, we thawed frozen whole blood from a patient with Stage IV
melanoma, and transferred 50 µL to a Whatman FTA filter paper card. After drying the card
for 15 minutes, we performed DNA extraction and library preparation from the dried blood
spot. An overview of the workflow is shown in Fig. 4.1A. Quality control using capillary
electrophoresis revealed contaminating gDNA, as indicated by an excess of large DNA
fragments (Fig. 4.1B). cfDNA fragments typically display a characteristic fragmentation
profile with a prominent peak at 166bp [15, 27]. This peak was not observed, likely due to
the low mass of cfDNA in the blood spot and the larger amounts of gDNA. We attempted
a library preparation from the extracted blood spot but were unsuccessful, likely due to
the inability of the longer fragments to undergo successful amplification. To remove these
contaminating gDNA fragments (> 500bp in length), we applied a right-side size-selection
using AMPure beads, at a bead-to-sample ratio of 1:1 (Section 4.7). For this selection, beads
are added to the sample and initially the DNA bound to the beads (carrying high molecular
weight DNA) is removed while the supernatant containing low molecular DNA is retained.
In a second step, additional AMPure beads are added (in a bead-to-sample ratio of 7:1) to
capture all the remaining small-size fragments in the supernatant [136]. We generated a
sequencing library from the size-selected DNA using the Thruplex Tag-Seq kit, and obtained
a total of 232,107,928 sequencing reads (PE150; Illumina HiSeq4000; Fig. 4.1A).
In our data, we achieved a unique sequencing depth of 6x from sWGS following collaps-
ing with a minimum family size of 1 [67]. Using a diversity estimator (SPECIES [137]), we
inferred that, based on the distribution of the number of duplicate reads per molecule, up to
10x unique coverage are likely to be achieved from this blood spot library (Section 4.7).
Sequencing data obtained from the blood spot was analysed for somatic copy-number
alterations using ichorCNA [75].The generated copy number plot is shown in Fig. 4.2A. The
alterations observed were consistent with those identified in a matched plasma sample from
the same patient, isolated by standard plasma DNA-based methods (Fig. 4.2A). The extent of
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Fig. 4.1 Schematic representation of experimental workflow.
(A) Overview of the analysis of dried blood spots: DNA extraction, followed by size selection,
and low-depth WGS. (B) Bioanalyser trace of DNA extracted from a 50 µL dried blood spot
from blood of a patient with advanced melanoma, showing a high level of genomic DNA
contamination (> 1kbp) and no clear cfDNA peak (∼166bp).
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SCNAs between the two samples was significantly correlated (Pearson’s r = 0.75, p < 2.2 x
10−16, Fig. 4.2B) and similar to that found in the initial tumour biopsy copy number profile
(Fig. 4.2A).
Using sWGS, we show that the overall fragment size distribution of the human blood spot
cfDNA was comparable to that of cfDNA derived from plasma (Fig. 4.2C) [8, 14, 27]. We
then independently analysed the size distribution of mutant and wild-type reads, leveraging
mutation calls from exome sequencing of matched tumour tissue in order to accurately
distinguish true mutations from sequencing noise. This confirmed that the tumour-derived
fragments were shorter in size compared to wild-type fragments, with modal sizes of 150
bp and 170 bp, respectively (Fig. 4.2D). These data recapitulate size profiles derived from
plasma samples of cancer patients [8, 14, 27].
We applied INVAR to the blood spot data and were able to detect ctDNA and could
compare the obtained IMAF to that of the time-matched plasma. INVAR was applied to
custom capture data of technical replicates of the plasma sample as well as WES and sWGS
data. Informative reads (IR), the total count of observed mutant reads and IMAF of these
samples are compared in table 4.1 below. As to be expected, the largest number of IR were
observed for the technical replicates of the custom capture data where input material and
sequencing saturation are the highest. We observe five times more IR in the blood spot sWGS
data compared to the sWGS of the matched plasma, likely due to the difference in sequencing
depth between the two data-sets. When comparing the obtained IMAF, a good concordance
is observed between the different INVAR applications to the plasma sample. Interestingly,
the blood spot sample has a lower IMAF, potentially indicating remaining contaminating
DNA fragments diluting down the ctDNA.
sample type data type Informative reads mut sum IMAF
plasma custom capture 940,770 72,359 0.070
plasma custom capture 1,233,542 107,006 0.079
plasma WES 124,920 8,889 0.060
plasma sWGS 5,529 383 0.069
blood spot sWGS 26,867 1,110 0.039
Table 4.1 INVAR application to blood spot data. INVAR was applied to the blood spot
data of the melanoma patient and the time-matched plasma sample. Informative reads, total
count of mutant reads (mut sum) and the obtained integrated mutant allele fraction (IMAF)
are shown.
We next considered whether blood spot analysis may have applications in the longitudinal
analysis of disease burden in live murine patient derived xenograft (PDX) models. At
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Fig. 4.2 Detection of ctDNA in a dried blood spot from a cancer patient.
(A) Copy-number profiles from sWGS of a sequencing library generated from the same dried
blood spot as in Fig. 4.1B after size selection, from a matched plasma sample from the same
individual and time point and the matched tumour tissue. Blue=neutral, red=gain, green=loss.
(B) Correlation of log2 ratios for each copy-number bin using ichorCNA [75], comparing
bins between matched blood spot and plasma data. The correlation in log2 ratios for all bins
between the two samples was 0.75 (Pearson’s r, p < 2.2 x 10−16). (C) Size profile of the
sequencing reads generated from the size selected blood spot DNA library (data shown in
panel A). The overall size profile is comparable to that of cfDNA, i.e. with a peak at ∼170
bp. (D) Length of the sequencing reads (data from panel C) carrying known patient-specific
mutations (light blue), and reads carrying reference alleles at the same loci (dark blue).
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present, analysis of cfDNA is challenging in small rodents as the volumes of blood required
for most traditional ctDNA analysis can only be obtained through terminal bleeding. To
assess the feasibility of dried blood spot analysis in animal models, we sampled 50 µL of
whole blood onto a dried blood spot card from an orthotopically implanted ovarian tumour
PDX model. DNA was extracted and sequenced (Section 4.7). Following alignment of
sequencing reads, both human genome (tumour-derived) and mouse genome (wild-type)
reads were observed, again showing characteristic fragmentation patterns of mutant and
wild-type cfDNA (Fig. 4.3A) [27]. Copy-number alterations were observed when analysing
the human sequencing reads and mirrored the profile observed in both the original patient
ascites sample and the matched PDX tumour in the mouse (Fig. 4.3B). This confirms that
blood spots can indeed be used to monitor disease progression and burden in animal models.
4.6 Discussion
In this study, we demonstrate a new method to detect ctDNA in blood drops/spots using sWGS
from both human and PDX samples. Our analysis mirrors observations previously made in
cfDNA plasma analysis. This approach relies on the use of size-selection to remove genomic
DNA, combined with ctDNA measurement approaches such as sWGS which leverage signal
from across the entire genome. Only highly multiplexed approaches leveraging signals from
multiple loci are suitable for blood spot analysis. The analysis of any individual locus would
have limited sensitivity due to the small number of genome copies of cfDNA that may be
obtained from a single blood spot (in the order of 5-50 copies).
We analysed a dried blood spot from a patient with melanoma and observed a good
correlation in the copy-number profiles obtained from the blood spot and a time-matched
plasma and tumour sample. We see similar cfDNA and ctDNA size profiles as observed
from standard plasma DNA-based methods. Further work on larger cohorts with fresh finger
prick blood is warranted before progressing towards broader use of blood spots for ctDNA
monitoring. This work should compare the ctDNA allele fractions between blood spot
and matched plasma, as the extent of gDNA contamination of blood spot DNA might vary.
Additionally, the sensitivity limit for ctDNA analysis in blood spots should be determined
with both sWGS and targeted sequencing approaches. If single nucleotide variants were to
be targeted, a larger number of patient-specific mutations must be identified and interrogated
in order to adequately mitigate the effect of sampling error from the limited copies of cfDNA
in small volumes of blood. In future, the potential application of personalised sequencing
panels to sequencing data could facilitate highly sensitive monitoring of disease from even
small volumes.
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Fig. 4.3 ctDNA detection from a dried blood spot in a xenograft model.
(A) sWGS analysis of whole blood taken from a mouse xenograft model of ovarian cancer
(illustrated in the left panel). The fragment lengths of reads aligning to the human genome
(red, representing tumour ctDNA) were shorter than those aligning to the mouse genome (blue,
representing non-tumour cfDNA). (B) Copy-number profiles were successfully generated
from a dried blood spot from the mouse ovarian xenograft model (Section 4.7). The copy-
number profiles of the original human ascites sample and the engrafted tumour are also
shown. Segments coloured in blue, red and green indicate regions of copy-number neutrality,
gain and loss, respectively.
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In addition, we demonstrate the value of this approach in animal models, allowing the
detection of SCNAs and the characteristic ctDNA fragmentation pattern from dried blood
spots of PDX models. In the monitoring of ctDNA in small animal models, overcoming low
circulating blood volumes is a major challenge. Although tail vein blood sampling in rodents
has already been used for longitudinal cancer monitoring from small blood samples, analysis
was limited to high copy-number markers such as hLINE repeat sequences [102]. Here, we
highlight the possibility of next generation sequencing of blood spot cfDNA, enabling both,
shallow and up to 10x WGS.
From a practical standpoint, the application of dried blood spots could enable high-
frequency ctDNA monitoring of patients and animal models. Sampling and pre-analytical
processing can be further simplified, potentially supporting new study designs incorporating
wider populations and more frequent collection of smaller sample volumes. We hope that
detection of ctDNA from limited blood volumes will enable novel approaches for cancer
monitoring, such as self-collection of samples at home followed by shipping and centralised
analysis.
4.7 Methods
4.7.1 Cell-free DNA extraction from dried blood spots
The human sample was collected from a patient enrolled on the MelResist study (REC
11/NE/0312). Written consent to enter the study was taken by a research/specialist nurse or
clinician who was fully trained regarding the research. MelResist is a translational study of
response and resistance mechanisms to systemic therapies of melanoma, including BRAF
targeted therapy and immunotherapy, in patients with stage IV melanoma. Thawed whole
blood (50 µL) was transferred to Whatman FTA™ Classic Cards (Merck) and allowed to
air dry for 15 minutes before DNA extraction. A single fresh blood spot was obtained from
an ovarian cancer xenograft mouse model immediately after culling, and similarly applied
to Whatman FTA™ Classic Cards, and allowed to air dry. Blood spot card samples were
stored at room temperature inside a re-sealable plastic bag. DNA was extracted from the card
using the QIAamp DNA Investigator kit (Qiagen), using the manufacturer’s recommended
extraction protocol for FTA and Guthrie cards, which are conventionally used for assessment
of inherited genetic conditions in neonates from gDNA. The protocol was followed with the
following modifications. 1) three 3mm punches were made from the blood spot, and carrier
RNA was added to Buffer AL as per the manufacturer’s recommendation. 2) blood spot
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DNA (which we hypothesised contained both cfDNA and gDNA) was eluted in two rounds
of 25 µL elution buffer.
4.7.2 Size-selection and library preparation of blood spot cfDNA
Blood spot DNA eluates contain a low concentration of cfDNA, among a large background
of gDNA (Fig. 4.1B). cfDNA library preparation cannot be effectively performed from such a
sample since the abundance of long fragments reduces the likelihood of any cfDNA fragments
successfully being ligated with adaptor molecules for subsequent amplification. Based on our
characterisation of gDNA length of >1-10kb (Fig. 4.1B), and previous work demonstrating
that cfDNA in vitro ranges from ∼70-300bp in length with a peak at 166bp [7], we opted
to perform size-selection in order to remove contaminating long gDNA fragments. Thus, a
right-side size-selection was performed on DNA eluates using AMPure XP beads (Beckman
Coulter) in order to remove long gDNA fragments. For this purpose, we adapted a published
protocol for a right-side size selection that is conventionally used for DNA library size-
selection prior to next generation sequencing [136]. Following optimisation of bead:sample
ratios for cfDNA fragment sizes, we used a bead:sample ratio of 1:1 to remove contaminating
gDNA. The supernatant was retained as part of the right-side size-selection protocol. A
second size-selection step used a 7:1 bead:sample ratio to capture all remaining fragments,
and the size-selected DNA was eluted in 25 µL water. Blood spot eluates were concentrated
to 10 µL volume using a vacuum concentrator (SpeedVac), since this volume is the maximum
recommended for downstream library preparation using the Thruplex Tag-Seq kit (Takara).
16 cycles of library amplification were carried out. Libraries underwent QC using Bioanalyser
2100 (Agilent) and qPCR with the Illumina/ROX low Library Quantification kit (Roche) on a
QuantStudio 6 (Life Technologies). Libraries were submitted for whole-genome sequencing
on a HiSeq4000 (Illumina) with paired end 150bp/cycles.
4.7.3 Plasma library preparation
Plasma cfDNA libraries were prepared for the matched time point where the blood spot
was collected as well as a cohort of 49 healthy controls. The DNA was extracted using
the QIAsymphony (Qiagen) with the QIAamp protocol and quantified by digital PCR on
a Biomark HD (Fluidigm) using a 65bp TaqMan assay for the housekeeping gene RPP30
(Sigma Aldrich) [35] and 55 cycles of amplification. Using the estimated number of RPP30
DNA copies per µL eluate, the cfDNA concentration in the original sample was estimated.
Up to 9.9ng were used for the library preparation. The ThruPLEX Tag-Seq kit (Takara)
was used according to the manufacturer’s instructions and 7 cycles of amplification were
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carried out. After barcoding and sample amplification, the library underwent bead clean-up
and underwent QC as described above. The sample was submitted for sequencing on a
HiSeq4000 with paired end 150bp/cycles.
4.7.4 Tumour library preparation
For the human blood spot, a time-matched tumour sample was available. Tumour DNA was
extracted as described by Varela et al. [103] and sheared to 200bp fragment length using the
COVARIS LE220 Focused-ultrasonicator according to manufacturer’s instructions. 50ng of
material were prepared for sWGS using the ThruPLEX Plasma-Seq kit (Takara) according
to the manufacturer’s instructions and 7 cycles of amplification were carried out. After
barcoding and sample amplification, the library underwent bead clean-up and underwent
QC as described above. The sample was submitted for sequencing on a HiSeq4000 with
150bp/cycles.
For the xenograft sample, material from the engrafted tumour as well as the human
ascites sample used for grafting were available for analysis. The sample was extracted using
the Qiagen allprep kit (Qiagen) and the DNA was sheared to 200bp fragment as described
above. 50ng of DNA were prepared with the Thruplex DNA-Seq kit (Takara) according
to the manufacturer’s instructions and followed by a bead clean-up (1:1 ratio, as described
above). The sample was quantified using TapeStation (Agilent) and submitted for sequencing
on a HiSeq4000 with single end 50bp/cycles.
4.7.5 Sequencing data analysis
All samples were sequenced on a HiSeq4000. FASTQ files were aligned to the UCSC
hg19 genome using BWA-mem v0.7.13 with a seed length of 19, then deduplicated with
MarkDuplicates. For sWGS detection of ctDNA, ichorCNA was run as described [75],
utilising a panel of normal derived from a set of plasma cfDNA samples from 49 healthy
individuals (SeraLabs).
For xenograft sequencing analyses, BAM files underwent alignment to the mouse and
human genomes in parallel using Xenomapper [131]. Fragment lengths were determined for
both files using Picard CollectInsertSizeMetrics [138]. Additionally, ichorCNA [75] was run
on the subset of reads aligning to the human genome to confirm the presence of CNA.
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4.7.6 Library diversity estimation
In order to estimate the total number of cfDNA genome copies present in a blood spot library,
we used CONNOR [67] to perform deduplication of the blood spot sequencing library based
on endogenous barcodes [58] with minimum family sizes ranging between 1 and 5 (data
not shown). For each family size setting, the mean deduplicated coverage was calculated
using Samtools mPileup. Deduplicated coverage values for each family size setting were
used as input for diversity estimation using a statistical method, SPECIES [137], best known
for estimating the diversity of ecological populations based on the frequency of members
observed through a random sample. A minimum family size of 1 was used for the data
analysis.

Chapter 5
Discussion
The two main goals of my PhD were to improve the detection of ctDNA and to detect ctDNA
from limited sample volumes or input copies of DNA. The development of the INVAR
pipeline provides a means to detect ctDNA more sensitively down to levels of parts per
million (chapter 2) and was applied to a large cohort of early-stage NSCLC patients to assess
ctDNA levels (chapter 3). In chapter 4 I explored the possibility for a simpler method of
liquid biopsy sampling by collecting blood spots, and showed ctDNA detection from minimal
volumes of blood.
5.1 Improving the sensitivity of ctDNA detection
ctDNA is widely used in the cancer field and detection methods have evolved over time.
Currently, the most sensitive methods in the ctDNA field focus on the detection of SNVs.
Assays can be tumour guided, requiring a priori knowledge of tumour specific alterations.
They may also focus on cancer (subtype) specific mutations (identified through public
datasets). Finally, when ctDNA levels are sufficiently high, de novo mutation calling from
the blood sample itself can be carried out by e.g. whole exome sequencing.
The most sensitive detection is achieved when tumour information is available and can
help to detect low levels of ctDNA, which is why INVAR utilises patient specific tumour
information for the detection of ctDNA (see chapter 2). Detection is improved further by
a reduction in background error and an enrichment of ctDNA specific signal. Background
errors are reduced by using UMIs and a sample specific suppression of outlier signal while
signal enrichment is accomplished by utilising locus specific information on fragment length
and tumour allelic fraction. Combined, INVAR reliably detected ctDNA down to parts
per million when applied to a dilution series of plasma DNA obtained from a patient with
melanoma. As INVAR requires prior tumour information, its application is limited to the
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availability of a tumour sample. Therefore, INVAR is most suited to the detection of minimal
residual disease after surgery when a tumour sample is readily available. The early detection
of minimal residual disease can expedite treatment of disease relapse and improve the
patient’s prognosis. Similarly, cases with undetected MRD can provide a confidence of cure
for the patient, reducing overtreatment.
In chapter 3, I applied INVAR to a cohort of early-stage NSCLC patients (from the
LUCID study) to study the levels of ctDNA detectable in early-stage cancer. While ctDNA
detection has yielded promising results in detecting cancer in patients with advanced disease
and larger tumour burden, the detection rates in early-stage cancer have been low for many
cancer types. By applying the INVAR assay to this cohort, I aimed to improve the detection
of ctDNA and better understand the distribution of ctDNA levels in early-stage NSCLC.
While the observed detection rates were similar to those observed in other smaller lung
cancer studies (Section 1.4.1), the LUCID cohort contained patients at lower levels of ctDNA
compared to the other studies [19, 36, 64, 98]. The demographic details with regards to
stage and subtype distribution vary substantially between the different studies, making
a direct comparison challenging. Nonetheless, the application of INVAR to the LUCID
cohort provided additional information on the ctDNA levels that can reliably be detected in
early-stage cancer.
For any assay the limit of sensitivity will depend on both assay specific limitations and
sample specific restrictions. For example, the sensitivity of a SNV based assay will not only
depend on its background error rate and the assay chemistry but also on the copies of DNA
available for analysis and the number of mutations that can be targeted. The number of
targetable mutations will depend on the cancer type: cancer types with a high mutation burden,
such as melanoma and lung cancer, will allow for greater sensitivity compared to cancers
that are more driven by copy number changes such as ovarian and breast cancer [84, 116].
As described in the introduction, these sample specific sensitivity considerations can be
simplified to a two-dimensional matrix (Fig. 5.1).
The sensitivity can be improved by increasing the DNA material available for analysis
or increasing the total number of targeted mutations. The DNA input can be increased
by sampling a larger volume of blood or (depending on the assay) reducing sample loss
by optimising the protocols. While PCR based methods usually retain the majority of the
input molecules, library preparation based methods often lose >50% of the initial molecules.
An improved library preparation approach that retains more molecules would immediately
increase the total number of molecules, and therefore sensitivity, of a given assay. Simul-
taneously, sensitivity can be improved by increasing the number of targeted mutations. In
the present INVAR application, mutation identification was based on prior whole exome
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Fig. 5.1 Two-dimensional representation of assay sensitivity for ctDNA detection.
ctDNA sensitivity can be viewed as a two-dimensional matrix where the product of DNA
input and the number of targeted mutations determines the overall sensitivity of the assay.
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sequencing of matched tumour tissue. Calling mutations from the entire genome would
substantially increase the number of mutations identified in a given patient’s tumour and
also result in a greater sensitivity for ctDNA detection. However, given the current cost of
sequencing, this approach is not feasible on a large scale. In future, tumour whole genome
sequencing is expected to be performed more routinely, both in the research setting as well
as in the clinic, and would provide the necessary sequencing data to perform more sensitive
ctDNA detection.
5.2 Towards a simplified sample collection
Another major hurdle in the liquid biopsy field has been appropriate sample collection
and processing. Samples are either collected in EDTA-containing tubes, requiring prompt
spinning after collection or in more costly tubes with added preservatives/fixatives which
allow for a more lenient processing [133]. If the sample is not processed correctly, any
ctDNA signal will be diluted by genomic DNA, which is broken down and can hamper
downstream analysis. Sample collection facilities have to ensure that they have trained staff
and the required equipment to adhere to these standards. Samples are therefore usually
only collected in large clinical centres with the required expertise and facilities to ensure
appropriate processing. However, this may become restrictive to the frequency of sample
collection. A simplified sample collection method could enable new trial designs and widen
clinical applications.
In this PhD I explored the possibility of collecting samples in a way that could be
universally applied to most clinical centres. By collecting blood spots one can avoid the
immediate sample processing requirements described above. Furthermore, sample storage
requirements are reduced considerably. One can envision a general practitioner collecting a
blood spot from a patient, letting it dry for a few minutes and sending it by regular post to the
nearest research facility, where the sample will be further processed. In the future, it could
become possible for the patient to collect their own sample at home. Additionally, due to the
minimal sampling volume and ease of collection, it becomes feasible to obtain multiple time
points from the same patient, facilitating the exploration of additional research questions.
My research on minimal sampling volume forms a proof of concept study, highlighting the
detection of ctDNA from a blood spot in a sample from a patient with melanoma. I also
applied the same method to a sample from an ovarian PDX model. Most traditional ctDNA
analysis requires volumes that are only obtainable from small rodents through terminal
bleeding of the animal, prohibiting longitudinal sampling. I was able to detect both cancerous
ctDNA (coming from the engrafted tumour and aligning to the human genome) and non-
5.3 The future of circulating tumour DNA 135
cancerous cfDNA (aligning to the mouse genome) from a PDX blood spot sample. As a tail
vain blood spot can be obtained without culling the animal, this application could provide a
novel means for the analysis of samples from small rodents. Further research and additional
samples will have to be analysed to determine the robustness and sensitivity of this method.
In the future I hope to apply INVAR to blood spot data. If patient-specific tumour
mutations are known, INVAR could be run straight from whole genome sequencing data as
demonstrated in section 2.13. In that instance, ctDNA was detected at a sequencing depth of
just 0.6x. In chapter 4 I obtain a sequencing depth of 6x for the blood spot, which would
(given the same number of patient-specific mutations) result in a ten-fold greater sensitivity
based on the sensitivity matrix in Fig. 5.1. As mentioned above, sensitivity can be increased
even further by obtaining patient-specific mutations from whole genome sequencing of the
matched tumour tissue: for example, maintaining a sequencing depth of 6x and analysing
10,000 patient specific mutations (realistic in whole genome sequencing of high mutation
burden cancers), one would obtain a sensitivity of 1.7x10−5 when analysing a single drop of
blood.
5.3 The future of circulating tumour DNA
One of the current areas of focus in the ctDNA field lies in the detection of minimal volumes
of disease, either to diagnose cancer in early-stage such as undiagnosed or treatment naïve
patients or to discover minimal residual disease in patients after completing treatment, aiming
to identify relapse sooner.
By combining multiple cancer markers or utilising machine learning some assays have
shown promising results in the detection of very low levels of disease. For example, the
ctDNA based part of the CancerSeek assay showed only limited sensitivity in the cohort.
Once eight additional protein markers were added, the detection rate of the assay increased
between two- and ten-fold and resulted in detection of stage I disease in 43% of cases [98].
Similarly, two recent approaches utilise machine learning on sWGS data from plasma
samples to detect cancer more sensitively. Machine learning enables the exploration of
large datasets with manifold features and provides tools to reveal hidden structures and
patterns in these data. Such patterns can then be leveraged to build a more robust method for
discrimination of samples containing cancer from healthy control samples. Mouliere and
colleagues show that using CNVs and fragmentation features in a machine learning approach
improves the identification of cancerous samples compared to using the two parameters
individually [27]. The second approach by Cristiano and colleagues train a model based
on genome wide fragmentation features from sWGS data and distinguish cancer samples
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from healthy controls [132]. All three approaches yield promising results in the detection
of cancer without previous information on the tumour mutations and may pave the way for
future detection assays that are being developed in this space.
While the field has improved in the detection of minimal residual disease, it is lacking
large scale studies to identify cancer in the general population to generate a catalogue of
potential markers for the early detection of cancer. GRAIL, a spin out company from Illumina,
set up the Circulating Cell-free Genome Atlas Study (CCGA) in 2016 to characterise cancer
signals in the blood from a population of 15,000 healthy and cancerous patients. In 2017 they
launched the STRIVE study, which has recruited 100,000 women after taking a mammogram
to study the detection of breast and other cancers using a blood-based methylation test that
was developed as part of the CCGA effort. In 2019 the SUMMIT study was launched,
a prospective observational study of 50,000 patients, some of which have a higher risk
of developing lung and other cancers. Using the same methylation-based blood test, the
population will be screened for the presence of cancer and the identification of the cancer
type. Similarly, Guardant Health, a precision oncology company, has developed the LUNAR
assay, which detects cancer using genomic alterations and epigenetic signatures. Currently,
the assay has only been applied in the minimal residual disease setting but Guardant Health
plans to apply the test for detection of early-stage cancer from the general population as well.
Both GRAIL and Guardant Health are setting the path for the future of liquid biopsy and
its potential use to detect cancer in the general population. The data they generate will be
crucial to the development of a future population wide screening tool.
It should be noted that other than analysing components in the blood, direct sampling
for cancer has also proven advantageous in its early detection and may provide yet another
avenue to detect cancer population-wide in the future. The main drawback for direct sampling
approaches is that they are only applicable to cancers with an accessible sample for analysis.
Examples are urine for urological cancers, saliva for cancers of the oral cavity, cerebrospinal
fluid for brain tumours, stool for colorectal cancers, cervical sampling for cervical cancer
and cell sampling for oesophageal cancer. Some studies have compared direct sampling
to ctDNA analysis from plasma and saw discordant detection in the cohort, indicating that
information can be gained by analysing both the blood and direct samples where possible.
In the future, accepting cost and practical considerations, any test should try and analyse a
multitude of sample types and biomarkers within each sample to try and maximise overall
detection.
While many of the methods discussed in this chapter are currently only used in the
research setting, they nonetheless point towards the potential of future cancer diagnosis
and monitoring. Together with the large scale efforts of GRAIL and Guardant Health, it
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could become possible to identify seemingly healthy early-stage cancer patients amongst
the total population, thereby increasing their chances of survival. Additionally, patients
who underwent successful treatment will enter a longitudinal follow up where sensitive
(patient-specific) methods (either based on liquid biopsies or direct sampling) are utilised to
monitor the patient closely and minimally invasively to detect a potential relapse as early as
possible, thereby increasing the chances of survival for the patient. Combined, these advances
in cancer diagnosis and monitoring of minimally residual disease can substantially enhance
the overall survival chances of the patients and become the future of cancer monitoring.

Chapter 6
Publications
6.1 Manuscripts
J. C. M. Wan∗, K. Heider∗, D. Gale, S. Murphy, E. Fischer, J. Morris, F. Mouliere, D.
Chandrananda, A. Marshall, A. B. Gill, P. Y. Chan, E. Barker, G. Young, W. N. Cooper, I.
Hudecova, F. Marass, G. R. Bignell, C. Alifrangis, M. R. Middleton, F. A. Gallagher, C.
Parkinson, A. Durrani, U. McDermott, C. G. Smith, C. Massie, P. G. Corrie, N. Rosenfeld,
High-sensitivity monitoring of ctDNA by patient-specific sequencing panels and integration
of variant reads, bioRxiv (2019); [Available online: https://doi.org/10.1101/759399]
∗ Joint first authors
K. Heider, F. Mouliere, C. G. Smith, Overview of selected approaches for cell free DNA
library preparation and sequencing, as part of the book “Circulating Tumour DNA – Purifica-
tion and Analysis Techniques”, World Scientific Publishing - to be published.
K. Heider∗, J. C. M. Wan∗, J. Hall, S. Boyle, I. Hudecova, D. Gale, W. N. Cooper, P. G.
Corrie, J. D. Brenton, C. G. Smith, N. Rosenfeld, Detection of ctDNA from dried blood spots
after DNA size selection, bioRxiv (2019); [Available online: https://doi.org/10.1101/759365]
∗ Joint first authors
J. C. M. Wan∗, K. Heider∗, D. Gale, S. Murphy, E. Fischer, F. Mouliere, A. Ruiz-Valdepenas,
A. Santonja, J. Morris, D. Chandrananda, A. Marshall, A. B. Gill, P. Y. Chan, E. Barker, G.
Young, W. N. Cooper, I. Hudecova, F. Marass, R. Mair, K. M. Brindle, G. D. Stewart, J. Abra-
ham, C. Caldas, D. M. Rassl, R. C. Rintoul, G. R. Bignell, C. Alifrangis, M. R. Middleton, F.
A. Gallagher, C. Parkinson, A. Durrani, U. McDermott, C. G. Smith, C. Massie, P. G. Corrie,
N. Rosenfeld, ctDNA monitoring to parts per million using patient-specific sequencing and
140 Publications
integration of variant reads, in preparation
F. Mouliere, A. M. Piskorz, D. Chandrananda, E. Moore, J. Morris, C. G. Smith, T. Goranova,
K. Heider, R. Mair, A. Supernat, I. Gounaris, S. Ros, J. C. M. Wan, M. Jimenez-Linan, D.
Gale, K. Brindle, C. E. Massie, C. A. Parkinson, J. D. Brenton, N. Rosenfeld, Selecting
Short DNA Fragments In Plasma Improves Detection Of Circulating Tumour DNA, bioRxiv
(2017); [Available online: https://doi.org/10.1101/134437]
F. Mouliere, D. Chandrananda, A. M. Piskorz, E. K. Moore, J. Morris, L. B. Ahlborn,
R. Mair, T. Goranova, F. Marass, K. Heider, J. C. M. Wan, A. Supernat, I. Hudecova, I.
Gounaris, S. Ros, M. Jimenez-Linan, J. Garcia-Corbacho, K. Patel, O. Østrup, S. Murphy,
M. D. Eldridge, D. Gale, G. D. Stewart, J. Burge, W. N. Cooper, M. S. van der Heijden, C.
E. Massie, C. Watts, P. Corrie, S. Pacey, K. M. Brindle, R. D. Baird, M. Mau-Sørensen, C.
A. Parkinson, C. G. Smith, J. D. Brenton, N. Rosenfeld, Enhanced detection of circulating
tumor DNA by fragment size analysis, Sci. Transl. Med. 10, eaat4921 (2018)
F. Mouliere, K. Heider, C. G. Smith, J. Su, M. Thompson, J. Morris, J. C. M. Wan, D.
Chandrananda, J. Hadfield, M. Grezlak, I. Hudecova, W. Cooper, D. Gale, M. Eldridge,
C. Watts, K. Brindle, N. Rosenfeld, R. Mair, Integrated clonal analysis reveals circulating
tumor DNA in urine and plasma of glioma patients, bioRxiv (2019); [Available online:
https://doi.org/10.1101/758441]
C. G. Smith, T. Moser, J. Burge, M. Eldridge, A. L. Riediger, F. Mouliere, D. Chandrananda,
K. Heider, J. C. M. Wan, A. Y. Warren, J. Morris, I. Hudecova, W. N. Cooper, T. J. Mitchell,
D. Gale, A. Ruiz-Valdepenas, T. Klatte, S. Ursprung, E. Sala, A. C. P. Riddick, T. F. Aho,
J. N. Armitage, S. Perakis, M. Pichler, M. Seles, G. Wcislo, S. J. Welsh, A. Matakidou, T.
Eisen, C. E. Massie, N. Rosenfeld, E. Heitzer, G. D. Stewart, Comprehensive characterisation
of cell-free tumour DNA in plasma and urine of patients with renal tumours, bioRxiv (2019);
[Available online: https://doi.org/10.1101/758003]
6.2 Abstracts
K. Heider, J. C. M. Wan, D. Gale, A. Ruiz-Valdepenas, F. Mouliere, J. Morris, W. Qian,
J. Wulff, N. Demiris, A. Williams, T. Eisen, C. G. Smith, D. M. Rass, S. Harden, R. C.
Rintoul, C. Massie, N. Rosenfeld, Improved ctDNA detection in early stage non-small cell
lung cancer, 11th CNAPS Symposium in Jerusalem
6.3 Patents 141
K. Heider, J. C. M. Wan, D. Gale, F. Mouliere, W. Qian, A. Kateb, G. Doughton, N.
Ramenatte, R. Tysoe, C. G. Smith, D. M. Rassl, S. Harden, R. C. Rintoul, C. Massie, N.
Rosenfeld, Improved ctDNA detection in early stage non-small-cell lung cancer, AACR 2019
conference in Atlanta
K. Heider, A. Ruiz-Valdepenas, G. Doughton, W. Qian, D. Chandrananda, C. G. Smith, E.
Mosseley, T. Young, C. Castedo, A. Stone, T. Green, A. Walker, C. Thorbinson, M. Griffiths,
D. Gale, C. E. Massie, T. Eisen, D. M. Rassl, S. Harden, R. C. Rintoul, N. Rosenfeld, ctDNA
in early stage NSCLC (LUCID study): high sensitivity analysis in low burden disease, 10th
CNAPS Symposium in Montpellier
A. Ruiz-Valdepenas, K. Heider, G. Doughton, W. Qian, C. Massie, D. Chandrananda,
C. Smith, D. Gale, E. Moseley, C. Castedo, A. Stone, C. Thorbinson, T. Eisen, D. Rassl,
S. Harden, R. Rintoul, N. Rosenfeld, MA 11.02 Circulating Tumor DNA in Early Stage
NSCLC: High Sensitivity Analysis in Low Burden Disease. LUCID Study Update, J. Thorac.
Oncol. 12, S1843–S1844 (2017).
6.3 Patents
Patent application 1819134.6: Improvements in Variant Detection.
Application filed in 2018 by Cancer Research Technologies Ltd.
6.4 Software packages
INVAR (not yet published) - https://bitbucket.org/nrlab/invar/wiki/Home
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